Prediction of Findings from the Ongoing COBRRA-AF Trial Using Healthcare Database Analyses

DUPLICATE – COBRRA AF

March 7<sup>th</sup>, 2022

#### 1. RCT Details

This section provides a high-level overview of an **ongoing** RCT that the described real-world evidence study is trying to replicate as closely as possible given the limitations inherent in the healthcare databases.

#### 1.1 <u>Title</u>

# Comparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients with Atrial Fibrillation (COBRRA - AF)

#### 1.2 Intended aim(s)

To compare the incidence of major and clinically relevant non-major bleeding events in patients with non-valvular atrial fibrillation diagnosed by an ECG.

#### 1.3 Primary endpoint for replication

Time from randomization to the first confirmed, adjudicated occurrence of a major bleeding or clinically relevant non-major bleeding event up to 365 days after initiating anticoagulation treatment.

#### 1.4 Required power for primary endpoint and noninferiority margin (if applicable)

The hazard ratio for the clinical trial is unknown because the trial is ongoing. Based upon Proietti et al., a systematic review of observational studies of apixaban safety in atrial fibrillation patients, we calculated power based on an array of potential effect sizes.<sup>1,2</sup>

#### 1.5 <u>Secondary endpoint for replication (assay sensitivity) and RCT finding</u> Secondary cardiovascular objectives:

- To assess the frequency of major bleeding events and non-major clinically relevant bleeding events as separate outcomes
- Stroke
- All-cause mortality

#### 1.6 Trial estimate

The trial is ongoing and scheduled to complete in December of 2025.

#### 2. Person responsible for implementation of replication in Aetion

Luke Zabotka, BA and Mufaddal Mahesri, MD, MPH, implemented the study design in the Aetion Evidence Platform. They are not responsible for the validity of the design and analytic choices. All implementation steps are recorded, and the implementation history is archived in the platform.

#### 3. Data Source(s)

Optum CDM, IBM® MarketScan®, CMS NOAC

#### 4. Study Design Diagram

The study design diagram visualizes key aspects of the longitudinal study design for expedited review.

Figure 1.



#### 5. Cohort Identification

#### 5.1 Cohort Summary

An active-comparator, new-user design, propensity score matched, cohort study will be applied to compare patients that received apixaban vs. rivaroxaban. Patients will enter the cohort upon initiation of apixaban or rivaroxaban after a 180 day washout without anticoagulant exposure. They will be required to have a diagnosis code indicating non-valvular atrial fibrillation in the prior 180 days, and be age 18 or older on the date of initiation of therapy. Subjects will be excluded if they have had any indication of stage IV or V CKD, ESRD, an active bleeding episode, cancer, obesity, liver disease, or another indication for long-term anticoagulation, such as hospitalization for DVT or PE, in the prior 180 days. Patients will also be excluded if they have used any contraindicated medications in the prior 180 days or had an indication for atrial fibrillation that was not non-valvular. All patients were required to have continuous enrollment for 180 days prior to cohort entry to ensure incident use of the study drugs.

#### 5.2 Important steps for cohort formation

New use of the exposure (apixaban or rivaroxaban) is defined as no use of either drug in the 180 days prior to cohort entry. The first eligible cohort entry date will be selected after applying all inclusion-exclusion criteria.

#### 5.2.1 Eligible cohort entry dates

The apixaban indication for prevention of stroke or systemic embolism in patients with atrial fibrillation was approved by the FDA on December 28<sup>th</sup>, 2012. Rivaroxaban was initially approved for the same indication on November 4<sup>th</sup>, 2011.

- IBM® MarketScan®: Dec 28, 2012 December 31, 2019 (end of available data)
- Optum CDM: Dec 28, 2012 June 30, 2020 (end of available data)
- CMS NOAC: Dec 28, 2012 Dec 31, 2017 (end of available data)

#### 5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date

Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided in **Appendix** and are summarized in the flowcharts below.

#### 5.3 <u>Flowchart of the study cohort assembly</u> For Apixaban vs. Rivaroxaban

	0	ptum CDM	IBM® M	arketScan®	CMS - NOAC	
	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients
All patients in our database		81,796,156		205,537,714		6,886,908
Patients with Apixaban/Rivaroxaban [measured between Dec 28, 2012 and June 30, 2020.]		856,974		685,749		2,232,416
Excluded due to insufficient enrollment [-180, 0]	-118,628 (14%)	738,346	-54,038 (8%)	631,711	-373,136 (17%)	1,859,280
After wash-out for prior use of reference (Rivaroxaban) [-180, -1]	-206,560 (28%)	531,786	-211,703 (34%)	420,008	-601,148 (32%)	1,258,132
After wash-out for prior use of exposure (Apixaban) [-180, -1]	-278,943 (52%)	252,843	-170,997 (41%)	249,011	-549,695 (44%)	708,437
Excluded because patient qualified in >1 exposure category	-13 (<1%)	252,830	-24 (<1%)	248,987	-54 (<1%)	708,383
Exclusion of Missing Age [-180, 0]	-7 (<1%)	252,823	-0 (<1%)	248,987	-151 (<1%)	708,232
Exclusion of Gender (Exclude Missing Values) [start of all available data, 0]	-17 (<1%)	252,806	-0 (<1%)	248,987		
Inclusion of Age >= 18 [0,0]	-170 (<1%)	252,636	-415 (<1%)	248,572		
Inclusion of Non-Valvular A-fib [- 180,0]	-104,252 (41%)	148,384	-132,025 (53%)	116,547	-264,650 (37%)	443,581
Exclusion of Anticoagulant Use [- 180, 0]	-7,414 (5%)	140,970	-6,140 (5%)	110,407	-34,042 (8%)	409,539
Exclusion of CKD Stage 4/5 or ESRD [-180,0]	-2,876 (2%)	138,094	-994 (<1%)	109,413	-7,617 (2%)	401,922
Exclusion of Dialysis or Renal Transplant) [-180, 0]	-158 (<1%)	137,936	-119 (<1%)	109,294	-421 (<1%)	401,501

Exclusion of Bleeding History [-180, 0]	-2,721 (2%)	135,215	-3,332 (3%)	105,962	-23,500 (6%)	378,001
Exclusion of Cancer [-180,0]	-5,556 (4%)	129,659	-3,177 (3%)	102,785	-14,538 (4%)	363,463
Exclusion of Weight > 120 kg [-180, 0]	-6,963 (5%)	122,696	-3,322 (3%)	99,463	-10,521 (3%)	352,942
Exclusion of Significant Liver Disease [-180, 0]	-1,781 (1%)	120,915	-892 (<1%)	98,571	-3,233 (<1%)	349,709
Exclusion of Use of Contraindicated Medications [-180, 0]	-693 (<1%)	120,222	-596 (<1%)	97,975	-2,762 (<1%)	346,947
Exclusion of Dual Antiplatelet Therapy [-180,0]	-3,219 (3%)	117,003	-2,642 (3%)	95,333	-9,829 (3%)	337,118
Exclusion of Other Heart Conditions [-180,0]	-3,603 (3%)	113,400	-3,056 (3%)	92,277	-7,962 (2%)	329,156
Exclusion of Other Indication of Long-Term Anticoagulation [-180, 0]	-489 (<1%)	112,911	-293 (<1%)	91,984	-1,447 (<1%)	327,709
Exclusion of Pregnancy [-180,0]	-3 (<1%)	112,908	-4 (<1%)	91,980		
Exclusion of Coagulopathy [-180,0]	-958 (<1%)	111,950	-320 (<1%)	91,660		
Final cohort		111,950		91,660		325,926

 $^{\ast}\text{CMS}$  cell suppression policies may result in omitted data

#### 6. Variables

#### 6.1 Exposure-related variables:

#### Study drug:

The study exposure of interest is defined by a prescription drug claim indicating apixaban dispensation. New initiation will be defined by no such records of apixaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study eligibility criteria.

#### Comparator agent:

The comparator is defined by a prescription drug claim indicating rivaroxaban dispensation. New initiation will be defined by no such records of rivaroxaban in the prior 180 days before treatment initiation (washout period) and fulfillment of study eligibility criteria.

#### 6.2 <u>Preliminary Covariates:</u>

- Age
- Gender
- CCI score

The covariate listed above represents only a small subset of the covariate vector that will ultimately be controlled for in the design and analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility analysis and the initial power assessment and are listed in Table 1 (**Appendix B**).

#### 6.3 Outcome variables and study follow-up:

6.3.1 Outcome variables

Safety outcome variables of interest (definitions provided in **Appendix**):

- Primary outcome: Major bleeding and clinically relevant non-major bleeding through 365 days of treatment with apixaban or rivaroxaban.
- Secondary outcomes:
  - To assess the frequency of major bleeding events and clinically relevant non-major bleeding individually
  - $\circ$   $\,$  To assess the frequency of intracranial and extracranial bleeding events
  - o Stroke
  - $\circ$  All-cause mortality

6.3.2 Study follow-up

Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on day of cohort entry. The **as-treated** will be the primary analysis. An allowable gap of 10 days between records indicating each treatment will qualify as "continuous therapy" with respect to follow-up in the as-treated analysis.

The follow-up will start the day after drug initiation (i.e., cohort entry date), and will continue until the earliest date of the following events:

- The first occurrence of the outcome of interest
- The date of end of continuous registration in the database
- End of the study period at 365 days
- Measured death event occurs
- Switch
- Discontinuation (10-day allowable grace period and risk window)
- Nursing home admission
- Initiation of another anticoagulant (dabigatran, heparin, warfarin, etc.)

In the secondary ITT analysis, we will not censor for discontinuation, switching among study drugs, or addition of other anticoagulants

#### 7. Initial Feasibility Analysis

#### Aetion report name:

For apixaban vs. rivaroxaban Optum CDM - <u>https://bwh-dope.aetion.com/projects/details/1813/rwrs/78411</u> IBM® MarketScan®- <u>https://bwh-dope.aetion.com/projects/details/1814/rwrs/78632</u> CMS NOAC - <u>https://bwh-dope.aetion.com/projects/details/1814/rwrs/78632</u>

Date conducted: 01/28/2022

Complete Action feasibility analysis using age, gender, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the outcome. No measures of association will be computed, nor will incidence rates be stratified by treatment group.

• Report patient characteristics by treatment group

### Apixaban vs Rivaroxaban

		Optum CDM			IBM® MarketScan® CMS - NOAC				
Variable	Rivaroxaban - Comparator	Apixaban - Exposure	Difference	Rivaroxaban - Comparator	Apixaban - Exposure	Difference	Rivaroxaban - Comparator	Apixaban - Exposure	Difference
Number of patients	39,628	72,322		41,932	49,503		148,933	176,546	
Age									
mean (sd)	71.62 (10.97)	74.33 (10.15)	-2.71 (-2.84, -2.58)	66.38 (12.81)	68.13 (13.18)	-1.75 (-1.92, -1.58)	76.19 (8.31)	77.68 (8.32)	-1.49 (-1.55, -1.44)
median [IQR]	73.00 [66.00, 80.00]	75.00 [68.00, 82.00]		65.00 [58.00, 76.00]	67.00 [59.00, 79.00]		76.00 [70.00, 82.00]	77.00 [72.00, 84.00]	
Gender									
М	22,048 (55.6%)	35,362 (48.9%)	6.7% (6.1%, 7.4%)	25,981 (62.0%)	28,450 (57.5%)	4.5% (3.8%, 5.1%)	69,102 (46.4%)	74,655 (42.3%)	4.1% (3.8%, 4.5%)
F	17,580 (44.4%)	36,960 (51.1%)	-6.7% (- 7.4%, -6.1%)	15,951 (38.0%)	21,053 (42.5%)	-4.5% (- 5.1%, -3.8%)	79,831 (53.6%)	101,891 (57.7%)	-4.1% (- 4.5%, -3.8%)
U									
CCI (180 Days									
mean (sd)	2.18 (2.11)	2.63 (2.37)	-0.45 (-0.48, -0.42)	1.53 (1.58)	1.80 (1.80)	-0.27 (-0.29, -0.24)	1.83 (1.81)	2.04 (1.95)	-0.21 (-0.22, -0.20)
median [IQR]	2.00 [1.00, 3.00]	2.00 [1.00, 4.00]		1.00 [0.00, 2.00]	1.00 [0.00, 3.00]		1.00 [0.00, 3.00]	2.00 [1.00, 3.00]	

#### • Report summary parameters of study population **FEASIBILITY- FOR STUDY OUTCOME**

For Apixaban vs Rivaroxaban

FEASIBILITY FOR STUDY OUTCOME								
	Optum CDM	IBM® MarketScan®	CMS - NOAC					
Number of patients in full cohort	111,950	91,660	325,926					
Number of patients dropped as incomplete cases	0	0	0					
Number of patients that did not begin follow-up	115	225	447					
Number of patients in analytic cohort	111,835	91,435	325,489					
Number of events	2,226	2,570	17,135					
Number of person-years	44,062.25	35,513.75	126,012.26					
Number of patients in group: Rivaroxaban - Comparator	39,574	41,932	148,933					
Number of patients in group: Apixaban - Exposure	72,261	49,503	176,546					
Risk per 1,000 patients	19.9	28.11	52.65					
Rate per 1,000 person-years	50.52	72.37	135.98					

- Report median follow-up time by treatment group
  - For Apixaban vs Rivaroxaban

FOLLOW-UP TIME FOR STUDY OUTCOME Median Follow-Up Time (Days) [IQR] – At 10 days gap								
Patient Group Optum CDM IBM® MarketScan® CMS - No								
<b>Overall Patient Population</b>	98 [38, 235]	98 [38, 222]	98 [38, 222]					
Referent - Rivaroxaban	98 [38, 222]	98 [38, 219]	98 [38, 219]					
Exposure - Apixaban	98 [38, 243]	98 [38, 225]	98 [38, 226]					

• Report reasons for censoring in the overall study population

#### For Apixaban vs Rivaroxaban

CENSORING REASONS FOR STUDY OUTCOME								
Reasons	Optum CDM	IBM® MarketScan®	CMS - NOAC					
Outcome	2,226 (2.0%)	2,570 (2.8%)	17,135 (5.3%)					
Death	852 (0.8%)	38 (0.0%)	3,744 (1.2%)					
Start of an additional exposure	1,423 (1.3%)	1,250 (1.4%)	5,584 (1.7%)					
End of index exposure	71,747 (64.2%)	55,668 (60.9%)	189,840 (58.3%)					
Maximum follow-up time reached	16,894 (15.1%)	12,797 (14.0%)	42,722 (13.1%)					
End of patient data	18 (0.0%)	5,277 (5.8%)	38,454 (11.8%)					
End of patient enrollment	5,827 (5.2%)	11,391 (12.5%)	4,681 (1.4%)					
Other Anticoagulant Use + Nursing Home Admission	12,848 (11.5%)	2,444 (2.7%)	23,319 (7.2%)					

#### • Report overall risk of the primary outcome.

	Optum CDM	IBM® MarketScan®	CMS - NOAC	Pooled
Risk per 1,000 patients	20.2089659	27.7425893	53.4783969	41.4990646

#### 8. Initial Power Assessment

#### Aetion report name:

- For Apixaban vs Rivaroxaban
  - Optum CDM <u>https://bwh-dope.aetion.com/projects/details/1813/rwrs/78412</u>
  - IBM® MarketScan®- https://bwh-dope.aetion.com/projects/details/1814/rwrs/78633
  - CMS NOAC <u>https://bwh-dope.aetion.com/projects/details/1831/rwrs/78415</u>

#### Date conducted: 01/21/2022 and 01/28/2022

In order to complete the initial power analysis, a dummy outcome indicating a 90-day gap in database enrollment will be used. This

outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. A 1:1 PS-matched comparative analysis was performed, including age, gender, and CCI score as the only covariates. Power calculations are based on the formulas from Chow et al. (2008).

• Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and reported in the subsequent sections, after incorporating feedback and refining the protocol.

This emulation is of a trial that is not yet completed. The trial investigators have not published their power calculations. Therefore, we present a range of power calculations for different effect sizes given the feasibility counts and an alpha of 0.05. The range in potential hazard rations comes from a meta- analysis of safety and efficacy studies of apixaban in patients with atrial fibrillation (Proietti et al. 2017). The target enrollment for the trial is 3,028 participants. We anticipate a pooled analytic cohort of 529,536 subjects.

1. Pooled

Superiority Analysis - Pooled					
Number of patients matched	454,312	454,312	454,312	454,312	454,312
Reference	227,156	227,156	227,156	227,156	227,156
Exposure	227,156	227,156	227,156	227,156	227,156
Risk per 1,000 patients	41.4155034	41.4155034	41.4155034	41.4155034	41.4155034
Alpha (2-sided	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	18815.5602	18815.5602	18815.5602	18815.5602	18815.5602
Power	1	1	1	1	1

2. Optum CDM

Superiority Analysis - Optum					
Number of patients matched	78,962	78,962	78,962	78,962	78,962
Reference	39,481	39,481	39,481	39,481	39,481
Exposure	39,481	39,481	39,481	39,481	39,481
Risk per 1,000 patients	19.8838767	19.8838767	19.8838767	19.8838767	19.8838767
Alpha (2-sided	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	1570.07067	1570.07067	1570.07067	1570.07067	1570.07067
Power	0.99307189	0.99999984	1	1	1

#### 3. IBM® MarketScan®

Superiority Analysis - MarketScan					
Number of patients matched	82,730	82,730	82,730	82,730	82,730
Reference	41,365	41,365	41,365	41,365	41,365
Exposure	41,365	41,365	41,365	41,365	41,365
Risk per 1,000 patients	28.0384028	28.0384028	28.0384028	28.0384028	28.0384028
Alpha (2-sided	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	2319.61706	2319.61706	2319.61706	2319.61706	2319.61706
Power	0.99967945	1	1	1	1

#### 4. <u>CMS – NOAC</u>

Superiority Analysis – CMS NOAC					
Number of patients matched	292,620	292,620	292,620	292,620	292,620

Effectiveness research with Real World Data to support FDA's regulatory decision making

Reference	146,310	146,310	146,310	146,310	146,310
Exposure	146,310	146,310	146,310	146,310	146,310
Risk per 1,000 patients	52.5732835	52.5732835	52.5732835	52.5732835	52.5732835
Alpha (2-sided	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	23075.9913	15383.9942	15383.9942	15383.9942	15383.9942
Power	1	1	1	1	1

**5.** Stop analyses until feasibility and power are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:	Date reviewed:	
Reviewed by FDA:	Date reviewed:	
Reasons for stopping		
analysis (if required):		

#### 9. Balance Assessment

#### Aetion report name:

- Rivaroxaban versus Apixaban
  - o Optum https://bwh-dope.aetion.com/projects/details/1813/rwrs/79770
  - o MarketScan https://bwh-dope.aetion.com/projects/details/1814/rwrs/79771
  - o CMS NOAC https://bwh-dope.aetion.com/projects/details/1831/rwrs/79772

#### Date conducted: 02/25/2022

After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using the

dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete list of covariates.

6. Provide plot of PS distributions stratified by treatment group.

#### a. See Appendix B

- 7. Report covariate balance after matching.
  - a. See Appendix B
    - i. CMS cell suppression policy may result in omitted data

#### 8. Report reasons for censoring by treatment group.

Censoring Reasons for Study Outcome					
Reasons	Overall	Referent	Exposure		
Death	0 (0.0%)	0 (0.0%)	0 (0.0%)		
Start of an additional exposure	5,906 (1.1%)	2,416 (1.0%)	3,490 (1.2%)		
End of index exposure	8,557 (1.6%)	4,649 (2.0%)	3,908 (1.3%)		
Maximum follow-up time	328,427 (62.1%)	147,012 (63.8%)	181,415 (60.8%)		
End of patient data	74,371 (14.1%)	31,658 (13.7%)	42,713 (14.3%)		
End of patient enrollment	44,450 (8.4%)	16,025 (7.0%)	28,425 (9.5%)		
Other Anticoagulant Therapy + Nursing Home Admission	22,230 (4.2%)	9,772 (4.2%)	12,458 (4.2%)		

#### 9. Report follow-up time by treatment group.

FOLLOW-UP TIME FOR STUDY OUTCOME Median Follow-Up Time (Days) [IQR] – At 10 days gap						
Patient Group	Optum CDM	IBM® MarketScan®	CMS - NOAC			
<b>Overall Patient Population</b>	98 [38, 238]	98 [38, 227]	98 [38, 228]			
Referent - Rivaroxaban	98 [38, 225]	98 [38, 224]	98 [38, 225]			
Exposure - Apixaban	98 [38, 245]	98 [38, 231]	98 [38, 231]			

#### **10. Final Power Assessment**

#### Date conducted: 02/09/2022

- 10. Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. All other parameters in the table should be the same as in Section 8.
- 1. Pooled

Superiority Analysis - Pooled					
Number of patients matched	368,214	368,214	368,214	368,214	368,214
Reference	184,107	184,107	184,107	184,107	184,107
Exposure	184,107	184,107	184,107	184,107	184,107
Risk per 1,000 patients	41.4155034	41.4155034	41.4155034	41.4155034	41.4155034
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	15249.7682	15249.7682	15249.7682	15249.7682	15249.7682
Power	1	1	1	1	1

#### 2. Optum CDM

Superiority Analysis - Optum					
Number of patients matched	68,134	68,134	68,134	68,134	68,134
Reference	34,067	34,067	34,067	34,067	34,067
Exposure	34,067	34,067	34,067	34,067	34,067
Risk per 1,000 patients	19.8838767	19.8838767	19.8838767	19.8838767	19.8838767
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4

Number of events expected	1354.76806	1354.76806	1354.76806	1354.76806	1354.76806
Power	0.98409053	0.99999793	1	1	1

#### 3. IBM® MarketScan®

Superiority Analysis - MarketScan					
Number of patients matched	61,846	61,846	61,846	61,846	61,846
Reference	30,923	30,923	30,923	30,923	30,923
Exposure	30,923	30,923	30,923	30,923	30,923
Risk per 1,000 patients	28.0384028	28.0384028	28.0384028	28.0384028	28.0384028
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	1734.06306	1734.06306	1734.06306	1734.06306	1734.06306
Power	0.99638561	0.99999998	1	1	1

#### 4. <u>CMS – NOAC</u>

Superiority Analysis – CMS NOAC					
Number of patients matched	238,234	238,234	238,234	238,234	238,234
Reference	119,117	119,117	119,117	119,117	119,117
Exposure	119,117	119,117	119,117	119,117	119,117
Risk per 1,000 patients	52.5732835	52.5732835	52.5732835	52.5732835	52.5732835
Alpha (2-sided)	0.05	0.05	0.05	0.05	0.05
Desired HR from RCT	0.8	0.7	0.6	0.5	0.4
Number of events expected	12524.7436	12524.7436	12524.7436	12524.7436	12524.7436
Power	1	1	1	1	1

• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:	Date reviewed:	
Reviewed by FDA:	Date reviewed:	
Reasons for stopping		
analysis (if required):		

#### 11. Study Confidence and Concerns

Deadline for voting on study confidence and listing concerns: Date votes and concerns are summarized:

- If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps.
- All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the success of the RWD study in the <u>Google Form</u>. This form also provides space for reviewers to list any concerns that they feel may contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the individual respondent.
- After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here.

#### 12. Register study protocol on clinicalTrials.gov

Date conducted:

Register the study on <u>clinicalTrials.gov</u> and upload this document.

#### **13. Comparative Analyses**

Aetion report name: Date conducted:

- 13.1 For primary analysis:
- 13.2 For sensitivity analyses:

#### 14. Requested Results

#### 14.1 Table 1: Baseline characteristics before and after adjustment

Variable	Before adjustment		After adjustment			
	Referent	Exposure	Std. diff.	Referent	Exposure	Std. diff.
Number of patients			-			-
Age categories						

#### 14.2 <u>Table 2: Follow-up time</u>

Patient Group	Median Follow-Up Time (Days) [IQR]
Overall Patient Population	
Referent	
Exposure	

### 14.3 <u>Table 3: Censoring events</u>

	Overall	Referent	Exposure
--	---------	----------	----------

#### Effectiveness research with Real World Data to support FDA's regulatory decision making

Outcome		
Death		
Start of an additional exposure		
End of index exposure		
Specified date reached		
End of patient data		
End of patient enrollment		

#### 14.4 <u>Table 4: Results from primary analyses;</u>

Analysis	No. exposed events	No. referent events	Exposed rate	Referent rate	HR (95% CI)
Crude					
Analysis 1					
Analysis 2					

HR, Hazard Ratio; CI, Confidence Interval.

#### 14.5 <u>Table 5: Results from secondary analyses;</u>

#### 15. References

- 1. Chow S, Shao J, Wang H. 2008. Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 177
- Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22. PMID: 29167388.

-۱

Image: Control of the second	sin Elderly can't be measured in clain but not important for the analysis .5954 
Image: Control in the stand of the	Can be replicated in claim Using dummy definitions for measuring in claims Can't be measured in claim
Textu, DETAILS     TEXAL DETAILS     Inclusion       Contraction     EXPOSURE vs. CONPARISON     EXPOSURE vs. CONPARISON       Advatants 5 mg PO, wice daily for 12 months of beatment. A dose reduction to 2.5 mg twice daily will apply 14 paleters three 2.7 dite following FO, once daily for 12 months of treatment. A dose reduction to 2.5 mg twice daily will apply 14 paleters with AF sho are receiving DOAC should have their rend function assessed at baseline and at least annually     Advatant: Advatant: The relief of adjudicated clinically relevant bleeding (CRB) events for the duration of the study: 12 beeding (CRB) weets are defined as and or file study: 12 beeding (CRB) weets are defined as and or file study: 12 beeding (CRB) weets are defined as and or file study: 12 beeding (CRB) weets are defined as and or file study: 12 beeding (CRB) weets are defined as and or file study: 12 beeding (CRB) weets are defined as and clinically relevant beeding (MB) events and clinically relevant for file study: 12 beeding (CRB) weets are defined as and clinically relevant for file study: 12 beeding (CRB) weets are defined as and clinically relevant for file study: 12 beeding (CRB) weets and clinically relevant for file study: 12 beeding (CRB) weets and clinically relevant for file study: 12 beeding (CRB) weets and clinically relevant for file study: 12 beeding (CRB) weets and clinically relevant for file study: 12 beeding (CRB) weets and clinically relevant for matching file study: 12 beeding (CRB) weets and clinically relevant for matching file study: 12 beeding (CRB) weets and clinically relevant for matching file study: 12 beeding (CRB) weets and clinically relevant for matching file study: 12 beeding (CRB) weets and clinically relevant for matching file study: 12 beeding (CRB) weets and clinically relevant for matching file study: 12 beeding (CRB) weets and clinically relevant for matching file study: 12 beeding (CRB)	Can be replicated in claim Using dummy definitions for measuring in claims Can't be measured in claim
Aptabases Smg PO, Wice daily for 12 months of treatment. A dose reduction to 2.5 mg brice daily will apply if patterns met 2 of the following 3 criteria age > 80 years, weight, 60 ag; creatinine > 133 micromotil. vs.       Aptabases Smg PO, Wice daily for 12 months of treatment. A dose reduction to 15 mg daily will apply if patterns with creatinine dealing for 22 months of treatment. A dose reduction to 15 mg daily will apply if patterns with creatinine dealing for 22 months of treatment. A dose reduction to 15 mg daily will apply if patterns with creating dealing for 22 months of treatment. A dose reduction to 15 mg daily will apply if patterns with creating dealing for 22 months of treatment. A dose reduction to 15 mg daily will apply if patterns with creating dealing for 20 months apply data and the attern	Using dummy definitions for measuring in claims Can't be measured in clair sin Elderly h but not important for the analysis .5954
plants meel 2 of the following 3 circuits: age > 80 years, weight, 60 kg; creatine > 133 micromath vs.       Accoban: vs.         vs.       vs.       vs.         vs.       vs.       vs.       vs.         vs.       vs.       vs.       vs.         vs.       vs.       vs.       vs.       vs.         vs.       vs.       vs.       vs.       vs.       vs.         vs.       vs.       vs.       vs.       vs.       vs.       vs.         vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs.       vs. <td>for measuring in claims Can't be measured in claim is in Elderly Can't be measured in claim th th</td>	for measuring in claims Can't be measured in claim is in Elderly Can't be measured in claim th
with creating clearance < 50 mil/min	Can't be measured in clair s in Elderly th valvular 5954
Image: A start of adjudicated clinically relevant bleeding (CRB) events [Time frame: For the duration of the study: 12; months] (CRB events are defined as the composite of major bleeding (MB) events and clinically relevant non-major bleeding (MB) events and clinically relevant non-major bleeding (SB) in any diagnosis position in an inpatient setting (transfusion codes required for non-critical sites)       Graham D.J. Richman ME. Wern Stroka Bleeding, Str	ke M, et al. s in Elderly th th can't be measured in clair can't be measured in clair but not important for the analysis .5954 
Mesaured [0, 365] in any diagnosis position in an inpatient setting (transfusion codes required for non-critical sites)         Graham DJ, Reichman ME, Wern Stroke, Biedding:           The rate of adjudicated clinically relevant bleeding (CRB) events Time frame: For the duration of the study: 12 months] CRB events are defined as the compsoite of major bleeding (MB) events and clinically relevant non-major bleeding (CRNMB) events         Maior Bleeding: See "Major Bleeding: See "CRNM Bleeding: See "CRNM Bleeding: See "CRNM Bleeding Events: See "CRNM Bleeds Sheet"         Masured [0, 365] in any diagnosis position in an inpatient setting (transfusion codes not required for non-critical sites)         Arrun Fibridiation. JAMA Intern doi:10.1001/jamainternmed.20           Confirmed new diagnosis of AF on ECG with an indication to start anticoaguilation according to Canadian Cardiovascular Society guidelines         Mesaured [10, 00 in any diagnosis position in either an inpatient or outpatient care setting         Prescribing guidelines for AF in CC https://ccc.aclappluploads/2020/ (CD-9 Diagnosis: 148.0, 10 in any diagnosis: 148.0, 148.1, 148.2, 148.91           Age >= 18 years         EXCLUSION CRITERIA Age >= 18         Mesaured [-180, 0] in prescription claims Use of Anticoaguilation         Mesaured [-180, 0] in prescription claims Use of Anticoaguilation.         Mesaured [-180, 0] in prescription claims	ke M, et al. s in Elderly th th can't be measured in clair can't be measured in clair but not important for the analysis .5954 
Parte of adjudicated clinically relevant bleeding (CRB) events [Time frame: For the duration of the study: 12]       Maior Bleeding: Store Medicate Beenficiales is position in an inpatient setting (transfusion codes not required for non-critical sites)       Graam DJ, Reichman EW, Wents Store Medicate Beenficiales Transdot Debleeding (CRNMB) events       See "Major Bleeding: Sheet       See "Major Bleeding: Sheet       Maior Bleeding: Sheet	sin Elderly can't be measured in clain but not important for the analysis .5954 
Image: Inclusion according to Canadian       Inclusion criteria       Image: Inclusion criteria       Prescribing guidelines for AF in Ca         Image: Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian       Measured [-180, 0] in any diagnosis position in either an inpatient or outpatient care setting       Prescribing guidelines for AF in Ca         Image: Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian       Atrial fibrillation (Non-Valvular)       Integrite case adaption (Non-Valvular) </td <td></td>	
Image: Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian       Measured [-180, 0] in any diagnosis position in either an inpatient or outpatient care setting       Prescribing guidelines for AF in CA         Cardiovascular Society guidelines       Atrial fibrillation (Non-Valvular)       https://ccs.ca/appluploads/2020/         ICD-9 Diagnosis: 427.31       ICD-10 Diagnosis: 427.31       icd-10 Diagnosis: 148.0, 148.1, 148.2, 148.91         Age >= 18 years       Age >= 18       Age >= 18       EXCLUSION CRITERIA       Image: Additional Construction of thereapeutic anticoagulation       Image: Additional Construction of thereapeutic anticoagulation of the construction of thereapeutic anticoagulation       Image: Additional Construction of thereapeutic a	
Confirmed new diagnosis of AF on ECG with an indication to start anticoagulation according to Canadian       Atrial fibrillation (Non-Valvular) (CD-9 Diagnosis: 427.31 (CD-9 Diagnosis: 427.31)       https://cos.acaapulupioads/2020// 018_PG_EN_web.pdf         2       Age >= 18 years       Age >= 18 years       Age >= 10, 00, 00, 00, 00, 00, 00, 00, 00, 00,	
EXCLUSION CRITERIA       Image: A roly beals       EXCLUSION CRITERIA       Image: A roly beals       Image: A roly b	AF_GUI_2
Have received >72 hours of thereapeutic anticoagulation       Measured [- 180, 0] in prescription claims         Use of Anticoagulants:       Adeparin Sodium, Porcine, Argatroban in 0.9% Sodium Chloride, Argatroban in Sodium, Chloride, Iso-osmotic, Bivalirudin, Dabigatran Etexilate Mesylate, Dalteparin Sodium Porcine,	
Have received >72 hours of thereapeutic anticoagulation Use of Anticoagulants: Adeparin Sodium, Porcine, Argatroban in 0.9% Sodium Chloride, Argatroban in Sodium Chloride, Iso-osmotic, Bivalirudin, Dabigatran Etexilate Mesylate, Dalteparin Sodium Porcine,	
Heparin Sodium Porcine/Dextrose (5% in water or 5% in water/PF), Heparin Sodium, Program Sodium Porcine, and Warfarin Sodium	
2       Creatine clearance < 15 ml/min calculated with the Cockcroft-Gault formula	
Any contradiction for anticoagulation with apixaban or rivaroxaban as determined by the treating physician such as, but not limited to one of the following:	
Mesaured [-180, 0] in any diagnosis position and in an inpatient setting (transfusion codes required for non-critical sites)	
Maior Bleeding See "Major Bleeding" Sheet	
Active Bleeding     Measured [-180,0] in any diagnosis position in an inpatient setting (transfusion codes not required for non-critical sites)     Clinically Relevant Non-Major Bleeding Events	
See "CRNM Bleeds Sheet"	
Measuered [-180, 0] in any diagnosis position in an inpatient or oupatient setting:           DVT           ICD-9 Diagnosis: 451.1x, 451.2x, 451.81, 451.9x, 453.1x, 453.2x, 453.8x, 453.9x, 453.40, 453.41, 453.42, 453.0           ICD-10 Diagnosis: 180.1x, 180.2, 180.3, 180.9, 182.0, 182.1, 182.2x (except 182.21), 182.4x, 182.6x, 182.80, 182.90, 181.A1x, 182.E1x, 182.C1x	
2) Other Indication for anticoagulation (e.g. mechanical valves, venous thromosis)       PE         ICD-9 Diagnosis:       415.1, 415.10, 415.11, 415.12, 415.13, 415.5, 415.16, 417.17, 415.19, 41	
Prosthetic Heart Valve ICD-9 Diagnosis: V43.3 ICD-10 Diagnosis: Z95.2	

1

	Measured [-180, 0] in prescription claims	
3) Dual Antiplatelet Use	Use of Antiplaelets Any of the following: cilostazol, dipyridamole, ticlopidine HCl, aspirin, clopidogrel bisulfate, prasugrel HCl, ticagerlor, aspirin/dipyridamole, ezetimibe	
4) Known liver disease with coagulopathy	Measured [-180,0] in any diagnosis position in an inpatient or outpatient setting Significant Liver Disease ICD-9 Diagnosis: 070 xx, 570 xx, 573 xx, 456 0x, 456 2x, 576 8x, 782 4x, 789 5x ICD-10 Diagnosis: 071 xx, 570 xx, 573 xx, 456 0x, 456 2x, 576 8x, 782 4x, 789 5x ICD-10 Diagnosis: 071 x, 576 6, K76 89, B19.0, B19.9, I85.11, K71.10, K71.0, K71.2, K71.3, K71.51, K72.01, K72.10, K73.9, K74.3, K74.69, K75.2, K75.81, K75.89, K76.0 K76.1, K76.3, K76.6, K76.89, B19.0, B19.9, I85.11, K71.11, K71.7, K71.9, K72.11, K74.1, K74.4, K74.5, K75.3, K76.7, K87, R18.8, B15.9, B16.0, B16.2, B16.9, B18.0, B18.9, B19.10, B19.11, K70.10, K70.41, K71.4, K71.50, K72.91, K74.0, K74.2, K74.60, K75.1, K75.2, K76.81, K83.8, R17, B15.0, B19.21, B25.1, I85.00, K70.0, K70.0, K70.01, K70.2, K70.9, K72.00, K72.00, K73.2, K75.8, K75.0, K76.9, R18.0, B17.0, B17.0, B17.8, B18.1, B19.20, I85.01, I85.10, K70.30, K70.31, K70.40, K71.6, K71.8, K73.0, K73.2, K75.4, K75.9, K76.4, K76.5, K77, K83.5 ICD-9 Procedure: 39, X, 42.91 ICD-10 Procedure: See "Liver Bypass" Sheet Coaguionativ	
	10D-9 Diagnosis: 286, 286.1, 286.4, 286.5, 286.52, 286.53, 286.59, 287.5, 286.0, 286.2, 286.3, 286.6, 286.7, 286.9, 287.1, 287.3, 287.4 10D-10 Dignosis: D67, D68, D68.1, D68.2, D68.3, D68.31, D68.311, D68.318, D68.4, D68.52, D68.61, D68.69, D68.8, D69.41, D69.49, D69.51, D69.59, D65, D66, D68.0, D68.312, D68.32, D68.35, D68.51, D68.59, D68.51, D68.50, D68.40, D69.41, D69.42, D69.51, D69.50, D68.51, D69.59, D65, D66, D68.00, D68.312, D68.32, D68.35, D68.51, D68.55, D68.51, D68.62, D68.61, D69.42, D69.42, D69.42, D69.5, D69.6	
5)Use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein)	Measured [-180, 0] in prescription claims <u>Strong CYP3A4 Inhibitors/Inducers</u> Inhibitors: Keloconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir Inducers: Rifampin, rifampicin/rifampin, phenytoin, carbamazepine <u>P-go Inhibitors/Inducers</u> cobicistat, conivaptan, tipranavir	https://depts.washington.edu/anticoag/home/ content/apixaban
6) Promannu	Measured [-180, 0] in any diagnosis position and inpatient and outpatient care setting  Pregnancy Construction	
7) Active malignancy, defined as a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally	Measured [-180, 0] in any diagnosis position in an inpatient or outpatient setting <u>Cancer</u> I <u>CD-9 Diagnosis</u> : 140.x-209.x (except 209.4x, 209.5x, 209.6x) I <u>CD-10 Diagnosis</u> : C00.x-C96, D45	
8) Weight > 120 kg	Measured [-180,0] in any diagnosis position in an inpatient or outpatient setting:           Brypass Surgery           ILCD-9 Encodure:         343842, 52082, 433644, 43645, 43770, 43843, 43845, 43846, 43847           ICD-9 Procedure:         00160JB, 00160KL, 0016029, 00164JL, 001687L, 00168JB, 00168Z9, 00168Z1, 00190ZA, 00194J9, 00194K9, 00194ZA, 00198K9, 00198ZA, 00140ZB, 00140ZB, 00140ZB, 00140ZB, 00140ZB, 00146XA, 00148KB, 00164KD, 00160ZL, 00166ZL, 00190ZA, 00147B, 00134JA, 00144KD, 00148KB, 00164KD, 00160ZL, 00166ZZ, 00196ZZ, 00064ZZ, 00196ZZ, 00196ZZ, 00196ZZ, 00166ZZ, 00166ZZ, 00166ZZ, 00166ZZ, 00166ZZ, 00146Z, 00146ZB, 00160ZL, 00164ZD, 00164ZD, 00146ZB, 00146XD, 00146ZB, 00146ZD, 00164ZD, 00146ZD, 001	
	5)Use of contraindicated medications (strong inducers/inhibitors of CYP 3A4/5, P-glycoprotein) 6) Pregnancy 7) Active malignancy, defined as a) diagnosed with cancer within the past 6 months; or b) recurrent, regionally advanced or metastatic disease; or c) currently receiving treatment or have received any treatment for cancer during	1) Deal Adaptability Deal       Marked Head Streams       Marked Head St

Appendix A
------------

Г	Measured [-180, 0] in any diagnosis position and inpatient and outpatient care setting	1
	ICD-9 Diagnosis:         394.0           ICD-10 Diagnosis:         105.0	
	Mitral Rheumatic Insufficiency ICD-9 Diagnosis: 394.1 ICD-10 Diagnosis: 105.1	
12	Mitral Stenosis with Insufficiency ICD-9 Diagnosis: 394.2 ICD-10 Diagnosis: 105.2	
	Other and Unspecified Mitral Valve Disorders ICD-9 Diagnosis: 394.9 ICD-10 Diagnosis: 105.9, 105.8	
9	Prosthetic Heart Valve ICD-9 Diagnosis: V43.3 ICD-10 Diagnosis: 295.2 ICD-10 Diagnosis: 295.2	

# Information from Trial Trial Name: COBRRA - AF https://clinicaltrials.gov/ct2/show/NCT04642430 NCT: NCT04642430 Therapeutic Area: Cardiology RCT Category: Equivalence/Superiority Brand Name: Eliquis and Xarelto Generic Name: Apixaban and Rivaroxaban Sponsor: Ottwa Hospital Research Institute Year: 2020 - Present Measurable Endpoint: Major Bleeding and Clinically Relevant Non-Major Bleeding Exposure: Apixaban Comparator: Rivaroxaban Populuation: Men and women ages 18 and older presenting with AF No. of Patients: 3,018 Power: TBD

#### ICI

I Т

ICD-9 Dx	
336.1	VASCULAR MYELOPATHIES
363.61	CHOROIDAL HEMORRHAGE UNSPECIFIED
363.62	EXPULSIVE CHOROIDAL HEMORRHAGE
376.32	ORBITAL HEMORRHAGE
377.42	HEMORRHAGE IN OPTIC NERVE SHEATHS
379.23	VITREOUS HEMORRHAGE
431	INTRACEREBRAL HEMORRHAGE
432	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE
432	NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1	SUBDURAL HEMORRHAGE
432.9	UNSPECIFIED INTRACRANIAL HEMORRHAGE
	HEMARTHROSIS
	HERARTHROSIS INVOLVING SHOULDER REGION
	HEMARTHORSIS INVOLVING UPPER ARM
	HEMARTHROSIS INVOLVING HAND
	HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
-	HEMARTHROSIS INVOLVING ANKLE AND FOOT
	HEMARTHROSIS INVOLVING MULTIPLE SITES
	NONTRAUMATIC HEMATOMA OF SOFT TISSUE
	SUBARACHNOID SUBDURAL AND EXTRADURAL HEMORRHAGE FOLLOWING INJURY
	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1 - 24 HOURS) LOSS OF CONSCIOUSNESS)
	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION
	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
	SUBARACHINOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
	SUBARACINOID HEMORITIABLE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOOND WITH BRIEF (LESS THAT ORE HOOR) LOSS OF CONSCIOUSNESS
	SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND
852.3	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
852.31	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
852.32	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS
852.33	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
	SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL
	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN 1 HOUR) LOSS OF CONSCIOUSNESS
	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE
	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-24 HOURS) LOSS OF CONSCIOUSNESS-EXISTING CONSCIOUS LEVEL
	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED
	EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY
	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED
	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS
	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL
	OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETORN TO PRE-EXISTING CONSCIOUS LEVEL
	OTHER AND UNSPECIFIED INTRACRANIAL HEMORNIAGE OLEOWING INJURY WITH OPEN INTRACRANIAL WOORD WITH NO LOSS OF CONSCIOUSNESS
	OTHER AND UNSPECIFIED INTRACRAMAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRAMIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS
	THER AND UNSPECTED INTRACRAMIAL HEMORPHASE FOLLOWING IN JURY WITH OPEN INTRACRAMIAL WOUND WITH OPEN UNDER THAN 24 HOURS LOSS OF CONSCIOUSNESS AND RETURN TO DREEVISTING CONSCIOUS LEVEL

853.14 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED( MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL

853.15 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL

866.02 LACERATION OF KIDNEY WITHOUT OPEN WOUND INTO CAVITY

363.72 HEMORRHAGIC CHOROIDAL DETACH 423 HEMOPERICARDIUM 430 SUBARACHNOID HEMORRHAGE 568.81 HEMOPERITONEUM (NONTRAUMATIC) 719.1 HEMARTHROSIS SITE UNSPECIFIED 719.13 HEMARTHROSIS INVOLVING FOREARM 719.16 HEMARTHROSIS INVOLVING LOWER LEG 719.18 HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES 852 SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND 852.02 SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 852.04 SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 852.1 SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND 852.13 SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 852.14 SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 852.16 SUBARACHNOID HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 852.2 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND 852.21 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 852.23 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 852.24 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL 852.26 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 852.29 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 852.36 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 852.39 SUBDURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 852.4 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND 852 4 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 852.41 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 852.44 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS AND RETURN TO PRE-EXISTING CONSCIOUS LEVEL EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 852.46 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND 852.5 852.5 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 852.51 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH NO LOSS OF CONSCIOUSNESS 852.52 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH MODERATE (1-24 HOURS) LOSS OF CONSCIOUSNESS 852 53 852.55 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH PROLONGED (MORE THAN 24 HOURS) LOSS OF CONSCIOUSNESS WITHOUT RETURN TO PRE-EXISTING CONSCIOUS LEVEL EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 852.56 852.59 EXTRADURAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 853 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT MENTION OF OPEN INTRACRANIAL WOUND OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH BRIEF (LESS THAN ONE HOUR) LOSS OF CONSCIOUSNESS 853 02 853.06 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED 853.09 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITHOUT OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 853 1 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH STATE OF CONSCIOUSNESS UNSPECIFIED 853.16 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH LOSS OF CONSCIOUSNESS OF UNSPECIFIED DURATION 853.19 OTHER AND UNSPECIFIED INTRACRANIAL HEMORRHAGE FOLLOWING INJURY WITH OPEN INTRACRANIAL WOUND WITH CONCUSSION UNSPECIFIED 866.01 HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITHOUT OPEN WOUND INTO CAVITY HEMATOMA OF KIDNEY WITHOUT RUPTURE OF CAPSULE WITH OPEN WOUND INTO CAVITY 866 11 LACERATION OF KIDNEY WITH OPEN WOUND INTO CAVIT 866 12 The occurrence of Inpatient Confinement with the following attributes: Procedure Code (Any Confinement Position) is any of: { "99.05", "99.03", "99.04", "99.06" 99 05 TRANSFUSION OF PLATELETS 99.03 OTHER TRANSFUSION OF WHOLE BLOOD 99.04 TRANSFUSION OF PACKED CELLS

99.06 TRANSFUSION OF COAGULATION FACTORS

AND

ICD-9 Dx

- 455.1 INTERNAL THROMBOSED HEMORRHOIDS
- 455.7 UNSPECIFIED THROMBOSED HEMORRHOIDS
- 455.8 UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION
- 455.9 RESIDUAL HEMORRHOIDAL SKIN TAGS
- 459 HEMORRHAGE UNSPECIFIED
- 530.1 ESOPHAGITIS
- 530.1 ESOPHAGITIS UNSPECIFIED
- 530.13 EOSINOPHILIC ESOPHAGITIS
- 530.19 OTHER ESOPHAGITIS
- 530.7 GASTROESOPHAGEAL LACERATION-HEMORRHAGE SYNDROME
- 530.82 ESOPHAGEAL HEMORRHAGE
- 531 ACUTE GASTRIC ULCER WITH HEMORRHAGE
- 531.01 ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
- 531.2 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
- 531.21 ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
- 531.3 ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 531.4 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
- 531.5 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION
- 531.6 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
- 531.61 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
- 531.7 CHRONIC GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 531.9 GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 532 ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
- 532.01 ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
- 532.1 ACUTE DUODENAL ULCER WITH PERFORATION
- 532.3 ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 532.4 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
- 532.41 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
- 532.5 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION
- 532.9 DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 533.1 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION
- 533.2 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
- 533.21 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
- 533.4 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
- 533.41 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
- 533.5 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION
- 533.6 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
- 533.9 PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 534 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
- 534.2 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
- 534.21 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
- 534.4 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
- 534.4 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
- 534.6 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
- 534.6 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
- 534.9 GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION
- 535.11 ATROPHIC GASTRITIS WITH HEMORRHAGE
- 535.31 ALCOHOLIC GASTRITIS WITH HEMORRHAGE
- 535.4 OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE)
- 535.51 UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH HEMORRHAGE
- 535.61 DUODENITIS WITH HEMORRHAGE
- 562.01 DIVERTICULITIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)
- 562.03 DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
- 562.11 DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE)
- 562.12 DIVERTICULOSIS OF COLON WITH HEMORRHAGE
- 569.85 ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
- 578.1 BLOOD IN STOOL
- 599.71 GROSS HEMATURIA
- 623.8 OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF VAGINA
- 626.8 OTHER DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT

- 784.7 EPISTAXIS 784.8 HEMORRHAGE FROM THROAT 786.3 HEMOPTYSIS 786.39 OTHER HEMOPTYSIS 280 IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC) 285.1 ACUTE POSTHEMORRHAGIC ANEMIA 455.2 INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 455.4 EXTERNAL THROMBOSED HEMORRHOIDS 455.5 EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 455.6 UNSPECIFIED HEMORRHOIDS WITHOUT COMPLICATION 456 ESOPHAGEAL VARICES WITH BLEEDING 456.2 ESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE WITH BLEEDING 530.11 REFLUX ESOPHAGITIS 530.12 ACUTE ESOPHAGITIS 531 ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 531.1 ACUTE GASTRIC ULCER WITH PERFORATION ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 531.2 5314 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE 531.41 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION 531.6 CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 532 ACUTE DUODENAL ULCER WITH HEMORRHAGE 532.2 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 532.2 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 532.21 ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 532.4 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 532.6 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 532.6 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 532.61 CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 532.7 CHRONIC DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 533 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 533 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION 533.01 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION 533.2 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 533.3 ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE AND PERFORATION 533.4 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 533.6 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 533.61 CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 533.7 CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 534 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 534.01 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 534.1 ACUTE GASTROJEJUNAL ULCER WITH PERFORATION 534.2 ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 534.3 ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 534.41 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 534.5 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH PERFORATION 534.61 CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 534.7 CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 535 ACUTE GASTRITIS (WITHOUT HEMORRHAGE) 535.01 ACUTE GASTRITIS WITH HEMORRHAGE 535.1 ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE) 535.2 GASTRIC MUCOSAL HYPERTROPHY (WITHOUT HEMORRHAGE) 535.21 GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE 535.3 ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE) 535.41 OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE 535.5 UNSPECIFIED GASTRITIS AND GASTRODUODENITIS (WITHOUT HEMORRHAGE) 535.6 DUODENITIS (WITHOUT HEMORRHAGE)
- 537.83 ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH HEMORRHAGE
- 562 DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE)
- 562.02 DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
- 562.1 DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE)

562.13 DIVERTICULITIS OF COLON WITH HEMORRHAGE

- 569.3 HEMORRHAGE OF RECTUM AND ANUS
- 578 HEMATEMESIS
- 578.9 HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
- 593.81 VASCULAR DISORDERS OF KIDNEY
- 599.7 HEMATURIA UNSPECIFIED
- 623.6 VAGINAL HEMATOMA
- 626.6 METRORRHAGIA
- 786.3 HEMOPTYSIS UNSPECIFIED
- 786.31 ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS

#### ICD-10 Dx

- G95.19 Other vascular myelopathies
- H05.232 Hemorrhage of left orbit
- H05.239 Hemorrhage of unspecified orbit
- H31.30 Unspecified choroidal hemorrhage
- H31.301 Unspecified choroidal hemorrhage, right eye
- H31.303 Unspecified choroidal hemorrhage, bilateral
- H31.312 Expulsive choroidal hemorrhage, left eye
- H31.313 Expulsive choroidal hemorrhage, bilateral
- H31.411 Hemorrhagic choroidal detachment, right eye
- H31.419 Hemorrhagic choroidal detachment, unspecified eye
- H43.1 Vitreous hemorrhage
- H43.10 Vitreous hemorrhage, unspecified eye
- H43.11 Vitreous hemorrhage, right eye
- H43.13 Vitreous hemorrhage, bilateral
- H47.022 Hemorrhage in optic nerve sheath, left eye
- H47.023 Hemorrhage in optic nerve sheath, bilateral
- H47.029 Hemorrhage in optic nerve sheath, unspecified eye
- 160.0 Nontraumatic subarachnoid hemorrhage from carotid siphon and bifurcation
- 160.00 Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
- 160.01 Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
- I60.1 Nontraumatic subarachnoid hemorrhage from middle cerebral artery
- I60.11 Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
- 160.31 Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
- I60.4 Nontraumatic subarachnoid hemorrhage from basilar artery
- 160.51 Nontraumatic subarachnoid hemorrhage from right vertebral artery
- 160.7 Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
- I60.8 Other nontraumatic subarachnoid hemorrhage
- 161.0 Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
- I61.2 Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
- I61.3 Nontraumatic intracerebral hemorrhage in brain stem
- I61.5 Nontraumatic intracerebral hemorrhage, intraventricular
- I61.6 Nontraumatic intracerebral hemorrhage, multiple localized
- I61.8 Other nontraumatic intracerebral hemorrhage
- I62 Other and unspecified nontraumatic intracranial hemorrhage
- I62.0 Nontraumatic subdural hemorrhage
- 162.00 Nontraumatic subdural hemorrhage, unspecified
- I62.01 Nontraumatic acute subdural hemorrhage
- 162.02 Nontraumatic subacute subdural hemorrhage
- 162.9 Nontraumatic intracranial hemorrhage, unspecified
- K66.1 Hemoperitoneum
- M25.0 Hemarthrosis
- M25.01 Hemarthrosis, shoulder
- M25.012 Hemarthrosis, left shoulder
- M25.019 Hemarthrosis, unspecified shoulder
- M25.021 Hemarthrosis, right elbow
- M25.029 Hemarthrosis, unspecified elbow
- M25.03 Hemarthrosis, wrist
- M25.039 Hemarthrosis, unspecified wrist
- M25.05 Hemarthrosis, hip

•

ł

	Hemarthrosis, right hip
	Hemarthrosis, left hip
	Hemathrosis, knee
	Hemarthrosis, right knee
	Tematinosa, nake and foot
	Hemathrosis, right ankle
	Hemarthrosis, unspecified ankle
	Hemarthrosis, right foot
	Hemarthrosis, left foot
	Hemarthrosis, other specified site Nontraumatic hematoma of soft tissue
	Epidural hemorrhage
	Epidural hemorhage
	Epidural hemorrhage without loss of consciousness
	Epidural hemorrhage without loss of consciousness, subsequent encounter
	Epidural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, sequela Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes
	Epidural hemorrhage with loss of consciousness of 1 hours to 5 hours 59 minutes, initial encounter Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours
	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours
	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
	Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter
	Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
	Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
	Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness
	Epidural hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter
	Epidural hemorrhage with loss of consciousness of unspecified duration
	Epidural hemorrhage with loss of consciousness of unspecified duration, initial encounter
	Traumatic subdural hemorrhage
	Traumatic subdural hemorrhage
	Traumatic subdral hemorrhage without loss of consciousness
	Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes
	Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter
	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
	Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
	Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela
	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level
	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter
	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter
	Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
	Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness
	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, initial encounter
	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter
	Traumatic subdural hemorrhage with loss of consciousness of unspecified duration, sequela
	Traumatic subarachnoid hemorrhage
	Traumatic subarachnoid hemorrhage without loss of consciousness
	Traumatic subarachnoid hemorrhage without loss of consciousness, initial encounter
	Traumatic subarachnoid hemorrhage without loss of consciousness, subsequent encounter
	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less
	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, initial encounter
	Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, sequela
	Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.6X3D	Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
000 01/ 3	Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours
	•
S06.6X4A	Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter
S06.6X4A S06.6X4S	•

- \$06.6X5S Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, sequela
- S06.6X6 Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving
- S06.6X6A Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter
- S06.6X6S Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, sequela
- \$06.6X7 Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness
- S06.6X8A Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness, initial encounter
- S06.6X9S Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, sequela
- S26.0 Injury of heart with hemopericardium
- S26.01 Contusion of heart with hemopericardium
- S26.01XA Contusion of heart with hemopericardium, initial encounter
- S26.020 Mild laceration of heart with hemopericardium
- S26.020A Mild laceration of heart with hemopericardium, initial encounter
- S26.021D Moderate laceration of heart with hemopericardium, subsequent encounter
- S26.021S Moderate laceration of heart with hemopericardium, sequela
- S26.022 Major laceration of heart with hemopericardium
- S26.022D Major laceration of heart with hemopericardium, subsequent encounter
- S26.09 Other injury of heart with hemopericardium
- S26.09XD Other injury of heart with hemopericardium, subsequent encounter
- S26.09XS Other injury of heart with hemopericardium, sequela
- S37.01 Minor contusion of kidney
- S37.011D Minor contusion of right kidney, subsequent encounter
- S37.011S Minor contusion of right kidney, sequela
- S37.012A Minor contusion of left kidney, initial encounter
- S37.012D Minor contusion of left kidney, subsequent encounter
- S37.012S Minor contusion of left kidney, sequela
- S37.02 Major contusion of kidney
- S37.021 Major contusion of right kidney
- S37.021D Major contusion of right kidney, subsequent encounter
- S37.021S Major contusion of right kidney, sequela
- S37.022D Major contusion of left kidney, subsequent encounter
- S37.022S Major contusion of left kidney, sequela
- S37.029 Major contusion of unspecified kidney
- S37.031A Laceration of right kidney, unspecified degree, initial encounter
- S37.031D Laceration of right kidney, unspecified degree, subsequent encounter
- S37.032 Laceration of left kidney, unspecified degree
- S37.032D Laceration of left kidney, unspecified degree, subsequent encounter
- S37.032S Laceration of left kidney, unspecified degree, sequela
- S37.039 Laceration of unspecified kidney, unspecified degree
- S37.039D Laceration of unspecified kidney, unspecified degree, subsequent encounter
- S37.04 Minor laceration of kidney
- S37.041 Minor laceration of right kidney
- S37.041A Minor laceration of right kidney, initial encounter
- S37.041D Minor laceration of right kidney, subsequent encounter
- S37.041S Minor laceration of right kidney, sequela
- S37.042A Minor laceration of left kidney, initial encounter
- S37.042D Minor laceration of left kidney, subsequent encounter
- S37.042S Minor laceration of left kidney, sequela
- S37.051 Moderate laceration of right kidney
- S37.051A Moderate laceration of right kidney, initial encounter
- S37.051S Moderate laceration of right kidney, sequela
- S37.052S Moderate laceration of left kidney, sequela
- S37.059D Moderate laceration of unspecified kidney, subsequent encounter
- S37.059S Moderate laceration of unspecified kidney, sequela
- S37.061S Major laceration of right kidney, seguela
- S37.062 Major laceration of left kidney
- S37.062S Major laceration of left kidney, sequela
- S37.069A Major laceration of unspecified kidney, initial encounter
- S37.069S Major laceration of unspecified kidney, seguela
- H05.23 Hemorrhage of orbit
- H05.231 Hemorrhage of right orbit

•

L

т

H05.233	Hemorrhage of bilateral orbit
H31.302	Unspecified choroidal hemorrhage, left eye
H31.309	Unspecified choroidal hemorrhage, unspecified eye
H31.31	Expulsive choroidal hemorrhage
H31.311	Expulsive choroidal hemorrhage, right eye
H31.319	Expulsive choroidal hemorrhage, unspecified eye
H31.41	Hemorrhagic choroidal detachment
H31.412	Hemorrhagic choroidal detachment, left eye
H31.413	Hemorrhagic choroidal detachment, bilateral
H43.12	Vitreous hemorrhage, left eye
H47.02	Hemorrhage in optic nerve sheath
H47.021	Hemorrhage in optic nerve sheath, right eye
123.0	Hemopericardium as current complication following acute myocardial infarction
131.2	Hemopericardium, not elsewhere classified
160	Nontraumatic subarachnoid hemorrhage
160.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
160.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
160.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
160.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery
160.3	Nontraumatic subarachnoid hemorrhage from posterior communicating artery
160.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
160.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
160.5	Nontraumatic subarachnoid hemorrhage from vertebral artery
160.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
160.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery
160.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries
160.9	Nontraumatic subarachnoid hemorrhage, unspecified
161	Nontraumatic intracerebral hemorrhage
161.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical
161.4	Nontraumatic intracerebral hemorrhage in cerebellum
161.9	Nontraumatic intracerebral hemorrhage, unspecified
162.03	Nontraumatic chronic subdural hemorrhage
162.1	Nontraumatic extradural hemorrhage
M25.00	Hemarthrosis, unspecified joint
M25.011	Hemarthrosis, right shoulder
M25.02	Hemarthrosis, elbow
M25.022	Hemarthrosis, left elbow
M25.031	Hemarthrosis, right wrist
M25.032	Hemarthrosis, left wrist
M25.04	Hemarthrosis, hand
M25.041	Hemarthrosis, right hand
M25.042	Hemarthrosis, left hand
M25.049	Hemarthrosis, unspecified hand
M25.059	Hemarthrosis, unspecified hip
M25.062	Hemarthrosis, left knee
M25.069	Hemarthrosis, unspecified knee
M25.072	Hemarthrosis, left ankle
M25.076	Hemarthrosis, unspecified foot
S06.4X0A	Epidural hemorrhage without loss of consciousness, initial encounter
S06.4X0S	Epidural hemorrhage without loss of consciousness, sequela
S06.4X1	Epidural hemorrhage with loss of consciousness of 30 minutes or less
S06.4X1D	Epidural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter
S06.4X1S	Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela
S06.4X2	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes
S06.4X2A	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter
S06.4X2D	Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter
S06.4X3D	Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, subsequent encounter
S06.4X3S	Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, sequela
S06.4X4D	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter
S06 4X4S	Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela

S06.4X4S Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela

S06.4X5 Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level S06.4X5A Epidural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter S06.4X6 Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving S06 4X6A Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, initial encounter S06 4X6S Epidural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, seguela S06.4X8 Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness S06.4X8A Epidural hemorrhage with loss of consciousness of any duration with death due to other causes prior to regaining consciousness, initial encounter S06.4X9D Epidural hemorrhage with loss of consciousness of unspecified duration, subsequent encounter S06.4X9S Epidural hemorrhage with loss of consciousness of unspecified duration, seguela S06.5X0A Traumatic subdural hemorrhage without loss of consciousness initial encounter S06.5X0D Traumatic subdural hemorrhage without loss of consciousness, subsequent encounter S06.5X0S Traumatic subdural hemorrhage without loss of consciousness, sequela S06.5X1 Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less S06.5X1A Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, initial encounter S06.5X1D Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter S06.5X1S Traumatic subdural hemorrhage with loss of consciousness of 30 minutes or less, seguela S06.5X2D Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, subsequent encounter S06 5X2S Traumatic subdural hemorrhage with loss of consciousness of 31 minutes to 59 minutes, seguela S06.5X3 Traumatic subdural hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes S06 5X4 Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours S06.5X4A Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial encounter S06.5X4D Traumatic subdural hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter S06.5X5D Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter S06 5X6 Traumatic subdural hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving S06 5X7 Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness S06.5X7A Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to brain injury before regaining consciousness, initial encounter S06 5X8A Traumatic subdural hemorrhage with loss of consciousness of any duration with death due to other cause before regaining consciousness, initial encounter S06 5X9 Traumatic subdural hemorrhage with loss of consciousness of unspecified duration S06.6 Traumatic subarachnoid hemorrhage S06.6X0S Traumatic subarachnoid hemorrhage without loss of consciousness, seguela S06.6X1D Traumatic subarachnoid hemorrhage with loss of consciousness of 30 minutes or less, subsequent encounter S06.6X2 Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes S06.6X2A Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, initial encounter S06.6X2S Traumatic subarachnoid hemorrhage with loss of consciousness of 31 minutes to 59 minutes, seguela S06.6X3 Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes S06.6X3A Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, initial encounter S06.6X3S Traumatic subarachnoid hemorrhage with loss of consciousness of 1 hour to 5 hours 59 minutes, seguela S06.6X4D Traumatic subarachnoid hemorrhage with loss of consciousness of 6 hours to 24 hours, subsequent encounter S06 6X5A Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, initial encounter S06.6X5D Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours with return to pre-existing conscious level, subsequent encounter S06 6X6D Traumatic subarachnoid hemorrhage with loss of consciousness greater than 24 hours without return to pre-existing conscious level with patient surviving, subsequent encounter S06.6X7A Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to brain injury prior to regaining consciousness, initial encounter S06.6X8 Traumatic subarachnoid hemorrhage with loss of consciousness of any duration with death due to other cause prior to regaining consciousness S06 6X9 Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration S06 6X9A Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, initial encounter S06 6X9D Traumatic subarachnoid hemorrhage with loss of consciousness of unspecified duration, subsequent encounter S26.00 Unspecified injury of heart with hemopericardium S26.00XA Unspecified injury of heart with hemopericardium, initial encounter S26.00XD Unspecified injury of heart with hemopericardium, subsequent encounter S26.00XS Unspecified injury of heart with hemopericardium, sequela S26.01XD Contusion of heart with hemopericardium, subsequent encounter S26.01XS Contusion of heart with hemopericardium, sequela S26.02 Laceration of heart with hemopericardium S26.020D Mild laceration of heart with hemopericardium, subsequent encounter S26.020S Mild laceration of heart with hemopericardium, sequela S26.021 Moderate laceration of heart with hemopericardium S26.021A Moderate laceration of heart with hemopericardium, initial encounter S26.022A Major laceration of heart with hemopericardium, initial encounter S26.022S Major laceration of heart with hemopericardium, sequela S26.09XA Other injury of heart with hemopericardium, initial encounter

- S37.011 Minor contusion of right kidney S37.011A Minor contusion of right kidney, initial encounter S37.012 Minor contusion of left kidney S37.019 Minor contusion of unspecified kidney S37.019A Minor contusion of unspecified kidney, initial encounter S37.019D Minor contusion of unspecified kidney, subsequent encounter S37.019S Minor contusion of unspecified kidney, sequela S37.021A Major contusion of right kidney, initial encounter S37.022 Major contusion of left kidney S37.022A Major contusion of left kidney, initial encounter S37.029A Major contusion of unspecified kidney, initial encounter S37.029D Major contusion of unspecified kidney, subsequent encounter S37.029S Major contusion of unspecified kidney, sequela S37.03 Laceration of kidney, unspecified degree S37.031 Laceration of right kidney, unspecified degree S37.031S Laceration of right kidney, unspecified degree, sequela S37.032A Laceration of left kidney, unspecified degree, initial encounter S37.039A Laceration of unspecified kidney, unspecified degree, initial encounter S37.039S Laceration of unspecified kidney, unspecified degree, sequela S37.042 Minor laceration of left kidney S37.049 Minor laceration of unspecified kidney Minor laceration of unspecified kidney, initial encounter S37.049A S37.049D Minor laceration of unspecified kidney, subsequent encounter S37.049S Minor laceration of unspecified kidney, seguela S37.05 Moderate laceration of kidney S37.051D Moderate laceration of right kidney, subsequent encounter S37.052 Moderate laceration of left kidney S37.052A Moderate laceration of left kidney, initial encounter S37.052D Moderate laceration of left kidney, subsequent encounter S37.059 Moderate laceration of unspecified kidney S37.059A Moderate laceration of unspecified kidney, initial encounter S37.06 Major laceration of kidney S37.061 Major laceration of right kidney S37.061A Major laceration of right kidney, initial encounter S37.061D Major laceration of right kidney, subsequent encounter S37.062A Major laceration of left kidney, initial encounter S37.062D Major laceration of left kidney, subsequent encounter S37.069 Major laceration of unspecified kidney S37.069D Major laceration of unspecified kidney, subsequent encounter The occurrence of Inpatient Confinement with the following attributes: Procedure Code (Any Confinement is any of: { "30 30 ", "30 30 ", "30 30 ", "30 30 ", "30 30 ", "30 30 ", "30 30 ", "30 33 ", "30 33 ", "30 33 ", "30 33 ", "30 40 ", "30 40 ", "30 40 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 40 ", "30 40 ", "30 40 ", "30 40 ", "30 40 ", "30 43 ", "30 43 ", "30 43 ", "30 43 ", "30 30 ", Position) "30 30L ", "30 30 ", "30 33 ", "30 33L ", "30 33 ", "30 33 ", "30 33 ", "30 33 ", "30 43 ", "30 40 ", "30 40 ", "30 40 ", "30 40 V ", "30 40 ", "30 43 ", AND D50.0 Iron deficiency anemia secondary to blood loss (chronic) D62 Acute posthemorrhagic anemia 185.11 Secondary esophageal varices with bleeding K20 Esophagitis K20.0 Eosinophilic esophagitis K20.8 Other esophagitis K20.9 Esophagitis, unspecified K21.0 Gastro-esophageal reflux disease with esophagitis K22.11 Ulcer of esophagus with bleeding K25.1 Acute gastric ulcer with perforation K25.2 Acute gastric ulcer with both hemorrhage and perforation K25.4 Chronic or unspecified gastric ulcer with hemorrhage
  - K25.5 Chronic or unspecified gastric ulcer with perforation

- K26.2 Acute duodenal ulcer with both hemorrhage and perforation
- K26.4 Chronic or unspecified duodenal ulcer with hemorrhage
- K26.6 Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
- K27.4 Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
- K27.5 Chronic or unspecified peptic ulcer, site unspecified, with perforation
- K27.6 Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
- K28.1 Acute gastroieiunal ulcer with perforation
- K28.2 Acute gastrojejunal ulcer with both hemorrhage and perforation
- K29.31 Chronic superficial gastritis with bleeding
- K29.91 Gastroduodenitis, unspecified, with bleeding
- K57.11 Diverticulosis of small intestine without perforation or abscess with bleeding
- K57.21 Diverticulitis of large intestine with perforation and abscess with bleeding
- K57.51 Diverticulosis of both small and large intestine without perforation or abscess with bleeding
- K57.53 Diverticulitis of both small and large intestine without perforation or abscess with bleeding
- K57.93 Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
- K62.5 Hemorrhage of anus and rectum
- K64.1 Second degree hemorrhoids
- K64.3 Fourth degree hemorrhoids
- K64.9 Unspecified hemorrhoids
- K92.0 Hematemesis
- K92.1 Melena
- N89.7 Hematocolpos
- N92.1 Excessive and frequent menstruation with irregular cycle
- N93.8 Other specified abnormal uterine and vaginal bleeding
- R04.0 Epistaxis
- R31.0 Gross hematuria
- R31.9 Hematuria, unspecified
- R58 Hemorrhage, not elsewhere classified
- 185.01 Esophageal varices with bleeding
- K22.6 Gastro-esophageal laceration-hemorrhage syndrome
- K25.0 Acute gastric ulcer with hemorrhage
- K25.6 Chronic or unspecified gastric ulcer with both hemorrhage and perforation
- K26.0 Acute duodenal ulcer with hemorrhage
- K26.1 Acute duodenal ulcer with perforation
- K26.5 Chronic or unspecified duodenal ulcer with perforation
- K27.0 Acute peptic ulcer, site unspecified, with hemorrhage
- K27.1 Acute peptic ulcer, site unspecified, with perforation
- K27.2 Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
- K28.0 Acute gastroieiunal ulcer with hemorrhage
- K28.4 Chronic or unspecified gastrolejunal ulcer with hemorrhage
- K28.5 Chronic or unspecified gastroleiunal ulcer with perforation
- K28.6 Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
- K29.01 Acute gastritis with bleeding
- K29.21 Alcoholic gastritis with bleeding
- K29.41 Chronic atrophic gastritis with bleeding
- K29.51 Unspecified chronic gastritis with bleeding
- K29.61 Other gastritis with bleeding
- K29.71 Gastritis, unspecified, with bleeding
- K29.81 Duodenitis with bleeding
- K31.811
- Angiodysplasia of stomach and duodenum with bleeding
- K55.21 Angiodysplasia of colon with hemorrhage
- K57.01 Diverticulitis of small intestine with perforation and abscess with bleeding
- K57.31 Diverticulosis of large intestine without perforation or abscess with bleeding
- K57.41 Diverticulitis of both small and large intestine with perforation and abscess with bleeding
- K57.81 Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
- K57.91 Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
- K64.0 First degree hemorrhoids
- K64.2 Third degree hemorrhoids
- K64.4 Residual hemorrhoidal skin tags
- K64.5 Perianal venous thrombosis
| K64.8 | 3 | Other hemorrhoids                                   |
|-------|---|---|
| K92.2 | 2 | Gastrointestinal hemorrhage, unspecified            |
| N89.8 |   | Other specified noninflammatory disorders of vagina |
| N93.9 | ) | Abnormal uterine and vaginal bleeding, unspecified  |
| R04.1 |   | Hemorrhage from throat                              |
| R04.2 | 2 | Hemoptysis  |

Ξ.

Inpatient, Any Diagnosis: ICD-9 Codes 280.0 - IRON DEFICIENCY ANEMIA SECONDARY TO BLOOD LOSS (CHRONIC) 455.7 - UNSPECIFIED THROMBOSED HEMORRHOIDS 459.0 - HEMORRHAGE UNSPECIFIED 530.10 - ESOPHAGITIS UNSPECIFIED 530.13 - EOSINOPHILIC ESOPHAGITIS 531.0 - ACUTE GASTRIC ULCER WITH HEMORRHAGE 531.1 - ACUTE GASTRIC UI CER WITH PERFORATION 531.2 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 531.20 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 531.3 - ACUTE GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 531.4 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE 531.6 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION 531.61 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 531.9 - GASTRIC ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 532.0 - ACUTE DUODENAL ULCER WITH HEMORRHAGE 532.00 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 532.01 - ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 532.2 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 532.20 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 532.3 - ACUTE DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 532.4 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE 532.41 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 532.5 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH PERFORATION 532.61 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 533.0 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 533.00 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION 533.01 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION 533.1 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION 533.2 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 533.20 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 533.3 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE AND PERFORATION 533.6 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 533.60 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 533.7 - CHRONIC PEPTIC ULCER OF UNSPECIFIED SITE WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 534.00 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 534.01 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 534.20 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 534.3 - ACUTE GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 534.40 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 534.41 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION 534.61 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 534.7 - CHRONIC GASTROJEJUNAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 534.9 - GASTROJEJUNAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 535.00 - ACUTE GASTRITIS (WITHOUT HEMORRHAGE) 535.01 - ACUTE GASTRITIS WITH HEMORRHAGE 535.10 - ATROPHIC GASTRITIS (WITHOUT HEMORRHAGE) 535.20 - GASTRIC MUCOSAL HYPERTROPHY (WITHOUT HEMORRHAGE)

535.21 - GASTRIC MUCOSAL HYPERTROPHY WITH HEMORRHAGE 535.31 - ALCOHOLIC GASTRITIS WITH HEMORRHAGE 535.40 - OTHER SPECIFIED GASTRITIS (WITHOUT HEMORRHAGE) 535.41 - OTHER SPECIFIED GASTRITIS WITH HEMORRHAGE 562.00 - DIVERTICULOSIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE) 562.01 - DIVERTICULITIS OF SMALL INTESTINE (WITHOUT HEMORRHAGE) 562.03 - DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE 562.11 - DIVERTICULITIS OF COLON (WITHOUT HEMORRHAGE) 562.13 - DIVERTICULITIS OF COLON WITH HEMORRHAGE 569.85 - ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE 578.0 - HEMATEMESIS 578.1 - BLOOD IN STOOL 578.9 - HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED 593.81 - VASCULAR DISORDERS OF KIDNEY 599.70 - HEMATURIA UNSPECIFIED 599.71 - GROSS HEMATURIA 623.6 - VAGINAL HEMATOMA 626.6 - METRORRHAGIA 784.7 - FPISTAXIS 784.8 - HEMORRHAGE FROM THROAT 786.31 - ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS 285.1 - ACUTE POSTHEMORRHAGIC ANEMIA 455.1 - INTERNAL THROMBOSED HEMORRHOIDS 455.2 - INTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 455.4 - EXTERNAL THROMBOSED HEMORRHOIDS 455.5 - EXTERNAL HEMORRHOIDS WITH OTHER COMPLICATION 455.6 - UNSPECIFIED HEMORRHOIDS WITHOUT COMPLICATION 455.8 - UNSPECIFIED HEMORRHOIDS WITH OTHER COMPLICATION 455.9 - RESIDUAL HEMORRHOIDAL SKIN TAGS 456.0 - ESOPHAGEAL VARICES WITH BLEEDING 456.20 - ESOPHAGEAL VARICES IN DISEASES CLASSIFIED ELSEWHERE WITH BLEEDING 530.1 - ESOPHAGITIS 530.11 - REFLUX ESOPHAGITIS 530.12 - ACUTE ESOPHAGITIS 530.19 - OTHER ESOPHAGITIS 530.7 - GASTROESOPHAGEAL LACERATION-HEMORRHAGE SYNDROME 530.82 - ESOPHAGEAL HEMORRHAGE 531.00 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 531.01 - ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION 531.21 - ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 531.40 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION 531.41 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION 531.5 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH PERFORATION 531.60 - CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 531.7 - CHRONIC GASTRIC ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 532.1 - ACUTE DUODENAL ULCER WITH PERFORATION 532.21 - ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 532.40 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION

532.6 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION 532.60 - CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 532.7 - CHRONIC DUODENAL ULCER WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 532.9 - DUODENAL ULCER UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 533.21 - ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 533.4 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE 533.40 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION 533.41 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION 533.5 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH PERFORATION 533.61 - CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 533.9 - PEPTIC ULCER OF UNSPECIFIED SITE UNSPECIFIED AS ACUTE OR CHRONIC WITHOUT MENTION OF HEMORRHAGE OR PERFORATION 534.0 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE 534.1 - ACUTE GASTROJEJUNAL ULCER WITH PERFORATION 534.2 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION 534,21 - ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION 534.4 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE 534.5 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH PERFORATION 534.6 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION 534.60 - CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION 535.11 - ATROPHIC GASTRITIS WITH HEMORRHAGE 535.30 - ALCOHOLIC GASTRITIS (WITHOUT HEMORRHAGE) 535.50 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS (WITHOUT HEMORRHAGE) 535.51 - UNSPECIFIED GASTRITIS AND GASTRODUODENITIS WITH HEMORRHAGE 535.60 - DUODENITIS (WITHOUT HEMORRHAGE) 535.61 - DUODENITIS WITH HEMORRHAGE 537.83 - ANGIODYSPLASIA OF STOMACH AND DUODENUM WITH HEMORRHAGE 562.02 - DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE 562.10 - DIVERTICULOSIS OF COLON (WITHOUT HEMORRHAGE) 562.12 - DIVERTICULOSIS OF COLON WITH HEMORRHAGE 569.3 - HEMORRHAGE OF RECTUM AND ANUS 623.8 - OTHER SPECIFIED NONINFLAMMATORY DISORDERS OF VAGINA 626.8 - OTHER DISORDERS OF MENSTRUATION AND OTHER ABNORMAL BLEEDING FROM FEMALE GENITAL TRACT 786.3 - HEMOPTYSIS 786.30 - HEMOPTYSIS UNSPECIFIED 786.39 - OTHER HEMOPTYSIS 285.9 - ANEMIA UNSPECIFIED 790.92 - ABNORMAL COAGULATION PROFILE 363.63 - CHOROIDAL RUPTURE 626.2 - EXCESSIVE OR FREQUENT MENSTRUATION 372.72 - CONJUNCTIVAL HEMORRHAGE

#### Inpatient, Any Diagnosis: ICD-10 Codes

D50.0 - Iron deficiency anemia secondary to blood loss (chronic)

- D62 Acute posthemorrhagic anemia
- 185.01 Esophageal varices with bleeding
- 185.11 Secondary esophageal varices with bleeding
- K20.0 Eosinophilic esophagitis
- K20.8 Other esophagitis

K22.11 - Ulcer of esophagus with bleeding

- K22.6 Gastro-esophageal laceration-hemorrhage syndrome
- K25.0 Acute gastric ulcer with hemorrhage
- K25.1 Acute gastric ulcer with perforation
- K25.2 Acute gastric ulcer with both hemorrhage and perforation
- K25.4 Chronic or unspecified gastric ulcer with hemorrhage
- K25.5 Chronic or unspecified gastric ulcer with perforation
- K26.1 Acute duodenal ulcer with perforation
- K26.2 Acute duodenal ulcer with both hemorrhage and perforation
- K26.4 Chronic or unspecified duodenal ulcer with hemorrhage
- K27.1 Acute peptic ulcer, site unspecified, with perforation
- K27.2 Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
- K27.5 Chronic or unspecified peptic ulcer, site unspecified, with perforation
- K27.6 Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
- K28.0 Acute gastrojejunal ulcer with hemorrhage
- K28.4 Chronic or unspecified gastrojejunal ulcer with hemorrhage
- K28.6 Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
- K29.01 Acute gastritis with bleeding
- K29.31 Chronic superficial gastritis with bleeding
- K29.41 Chronic atrophic gastritis with bleeding
- K29.51 Unspecified chronic gastritis with bleeding
- K29.71 Gastritis, unspecified, with bleeding
- K57.11 Diverticulosis of small intestine without perforation or abscess with bleeding
- K57.21 Diverticulitis of large intestine with perforation and abscess with bleeding
- K57.41 Diverticulitis of both small and large intestine with perforation and abscess with bleeding
- K57.51 Diverticulosis of both small and large intestine without perforation or abscess with bleeding
- K57.81 Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
- K57.91 Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
- K57.93 Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
- K62.5 Hemorrhage of anus and rectum
- K64.0 First degree hemorrhoids
- K64.5 Perianal venous thrombosis
- K64.8 Other hemorrhoids
- K64.9 Unspecified hemorrhoids
- K92.0 Hematemesis
- K92.2 Gastrointestinal hemorrhage, unspecified
- N89.7 Hematocolpos
- N93.8 Other specified abnormal uterine and vaginal bleeding
- R04.2 Hemoptysis
- R31.0 Gross hematuria
- K20 Esophagitis
- K20.9 Esophagitis, unspecified
- K21.0 Gastro-esophageal reflux disease with esophagitis
- K25.6 Chronic or unspecified gastric ulcer with both hemorrhage and perforation
- K26.0 Acute duodenal ulcer with hemorrhage
- K26.5 Chronic or unspecified duodenal ulcer with perforation
- K26.6 Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
- K27.0 Acute peptic ulcer, site unspecified, with hemorrhage

- K27.4 Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
- K28.1 Acute gastrojejunal ulcer with perforation
- K28.2 Acute gastrojejunal ulcer with both hemorrhage and perforation
- K28.5 Chronic or unspecified gastrojejunal ulcer with perforation
- K29.21 Alcoholic gastritis with bleeding
- K29.61 Other gastritis with bleeding
- K29.81 Duodenitis with bleeding
- K29.91 Gastroduodenitis, unspecified, with bleeding
- K31.811 Angiodysplasia of stomach and duodenum with bleeding
- K55.21 Angiodysplasia of colon with hemorrhage
- K57.01 Diverticulitis of small intestine with perforation and abscess with bleeding
- K57.31 Diverticulosis of large intestine without perforation or abscess with bleeding
- K57.53 Diverticulitis of both small and large intestine without perforation or abscess with bleeding
- K64.1 Second degree hemorrhoids
- K64.2 Third degree hemorrhoids
- K64.3 Fourth degree hemorrhoids
- K64.4 Residual hemorrhoidal skin tags
- K92.1 Melena
- N89.8 Other specified noninflammatory disorders of vagina
- N93.9 Abnormal uterine and vaginal bleeding, unspecified
- R04.0 Epistaxis
- R04.1 Hemorrhage from throat
- R58 Hemorrhage, not elsewhere classified
- D64.9 Anemia, unspecified
- R79.1 Abnormal coagulation profile
- H11.30 Conjunctival hemorrhage, unspecified eye
- H11.31 Conjunctival hemorrhage, right eye
- H11.32 Conjunctival hemorrhage, left eye
- H11.33 Conjunctival hemorrhage, bilateral
- H31.321 Choroidal rupture, right eye
- H31.322 Choroidal rupture, left eye
- H31.323 Choroidal rupture, bilateral
- H31.329 Choroidal rupture, unspecified eye
- N92.1 Excessive and frequent menstruation with irregular cycle
- R31.1 Benign essential microscopic hematuria
- R31.2 Other microscopic hematuria
- R31.29 Other microscopic hematuria
- N92.0 Excessive and frequent menstruation with regular cycle
- R31.21 Asymptomatic microscopic hematuria
- R31.9 Hematuria, unspecified

Procedure	<b>Codes Description</b>	

- CPT-4 codes
- 1960 Anesthesia for vaginal delivery only
- 1961 Anesthesia for cesarean delivery only
- 1962 Anesthesia for urgent hysterectomy following delivery
- 1963 Anesthesia for cesarean hysterectomy w/o any labor analgesia/anesthesia care
- 1967 Neuraxial labor analgesia/anesthesia, planned vaginal delivery
- 1968 Anesthesia for cesarean delivery following neuraxial labor analgesia/anesthesia
- 1969 Anes for cesarean hysterectomy following neuraxial labor analgesia/anesthesia
- 59050 Fetal monitoring in labor, physician w/written report; s & i
- 59051 Fetal monitoring in labor, physician w/written report; intrepretation only
- 59400 ROUTINE TOTAL OBSTETRIC CARE including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care.
- 59409 Vaginal delivery only (w/wo episiotomy &/or forceps)
- 59410 Vaginal delivery only (w/wo episiotomy &/or forceps); w/postpartum care
- 59412 Ext cephalic version, w/wo tocolysis
- 59414 Delivery of placenta (separate proc)
- 59430 Postpartum care only
- 59510 Routine obstetric care w/antepartum care, cesarean delivery, & postpartum care
- 59514 Cesarean delivery only
- 59515 Cesarean delivery only; w/postpartum care
- 59525 Subtotal/total hysterectomy after cesarean delivery
- 59610 Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery
- 59612 Vaginal delivery only, after previous cesarean delivery (with or without episiotomy and/or forceps)
- 59614 Vaginal delivery only, previous cesarean delivery w/postpartum care
- 59618 Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery
- 59620 Cesarean delivery after failed vaginal delivery, previous cesarean delivery
- 59622 Cesarean delivery after failed vaginal delivery, previous cesarean delivery; w/postpartum care
- 99436 Attendance at delivery, at request of delivering physician, & stabilization of newborn
- 99440 Newborn resuscitation

#### ICD-9 procedure

codes

- 72.xx Forceps, vacuum, & breech 73.xx Other including manual delivery 74xx Cesarean section 75.4x Manual removal of placenta ICD-10 procedure codes Normal Delivery 10E0X22 Delivery of Products of Conception, External Approach C-Section 10D0020 Extraction of Products of Conception, High, Open Approach 10D0021 Extraction of Products of Conception, Low, Open Approach Extraction of Products of Conception, Extraperitoneal, Open Approach 10D0022 Other assisted delivery (forceps, vacuum, internal version, other) 10D0723 Extraction of Products of Conception, Low Forceps, Via Natural or Artificial Opening 10D0724 Extraction of Products of Conception, Mid Forceps, Via Natural or Artificial Opening 10D0725 Extraction of Products of Conception, High Forceps, Via Natural or Artificial Opening 10D0726 Extraction of Products of Conception, Vacuum, Via Natural or Artificial Opening 10D0727 Extraction of Products of Conception, Internal Version, Via Natural or Artificial Opening 10D0728
  - Extraction of Products of Conception, Other, Via Natural or Artificial Opening

ICD-9 code	Definition	Gestational A	ge
		Weeks	Days
765.21	Less than 24 c	:24	168
765.22	24 completed	weeks of gest	ation
765.23	25-26 comple	26	182
765.24	27-28 comple	28	196
765.25	29-30 comple	30	210
765.26	31-32 comple	32	224
765.27	33-34 comple	34	238
765.28	35-36 comple	36	252

ICD-10 code Definition Gestational Age

•

I

		Weeks	Days
P07.21	Extreme imm	23	161
P07.22	Extreme imm	23	161
P07.23	Extreme imm	24	168
P07.24	Extreme imm	25	175
P07.25	Extreme imm	26	182
P07.26	Extreme imm	27	189
P07.31	Preterm new	28	196
P07.32	Preterm new	29	203
P07.33	Preterm new	30	210
P07.34	Preterm new	31	217
P07.35	Preterm new	32	224
P07.36	Preterm new	33	231
P07.37	Preterm new	34	238
		25	245
P07.38	Preterm new	35	245
P07.38 P07.39	Preterm new Preterm new		245 252
	Preterm new	36	
P07.39	Preterm new	36	252
P07.39 Codes indicating	Preterm new extreme prem	36 naturity	252
P07.39 Codes indicating	Preterm new extreme prem	36 naturity Gestational A Weeks	252 ge
P07.39 Codes indicating ICD-9 code	Preterm new extreme prem Definition Disorders rela	36 naturity Gestational A Weeks	252 ge Days 196
P07.39 Codes indicating ICD-9 code 765.0	Preterm new extreme prem Definition Disorders rela Extreme imm	36 naturity Gestational A Weeks 128	252 ge Days 196 cified [weight
P07.39 Codes indicating ICD-9 code 765.0 765.00	Preterm new extreme prem Definition Disorders rela Extreme imm Extreme imm	36 Gestational A Weeks 128 aturity, unspe	252 Days 196 cified [weight an 500 grams
P07.39 Codes indicating ICD-9 code 765.0 765.00 765.01	Preterm new extreme prem Definition Disorders rela Extreme imm Extreme imm Extreme imm	36 Gestational A Weeks 128 aturity, unspe- aturity, less tha	252 Days 196 cified [weight an 500 grams 9 grams
P07.39 Codes indicating ICD-9 code 765.0 765.00 765.01 765.02	Preterm new extreme prem Definition Disorders rela Extreme imm Extreme imm Extreme imm Extreme imm	36 aturity Gestational A Weeks 28 aturity, unspe- aturity, less tha aturity, 500-74	ge Days 196 cified [weight an 500 grams 9 grams 9 grams
P07.39 Codes indicating ICD-9 code 765.0 765.00 765.01 765.02 765.03	Preterm new extreme prem Definition Disorders rela Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm	36 aturity Gestational A Weeks 128 aturity, unspe- aturity, less tha aturity, 500-74 aturity, 750-99	ge Days 196 cified [weight an 500 grams 9 grams 9 grams 1,249 grams
P07.39 Codes indicating ICD-9 code 765.0 765.00 765.01 765.02 765.03 765.03 765.04	Preterm new extreme prem Definition Disorders rela Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm	36 aaturity Gestational A Weeks 128 aturity, unspe aturity, less tha aturity, 500-74 aturity, 750-99 aturity, 1,000-1	252 Days 196 cified [weight an 500 grams 9 grams 9 grams 1,249 grams 1,499 grams
P07.39 Codes indicating ICD-9 code 765.00 765.01 765.02 765.03 765.04 765.04 765.05	Preterm new extreme prem Definition Disorders rela Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm	36 aaturity Gestational A Weeks 128 aturity, unspe aturity, less tha aturity, 500-74 aturity, 750-99 aturity, 1,000-1 aturity, 1,250-1	ge Days 196 cified [weight an 500 grams 9 grams 1,249 grams 1,499 grams 1,749 grams
P07.39 Codes indicating <b>ICD-9 code</b> 765.00 765.01 765.02 765.02 765.03 765.04 765.05 765.06	Preterm new extreme prem Definition Disorders rela Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm Extreme imm	36 Gestational A Weeks 128 aturity, unspe aturity, less tha aturity, 500-74 aturity, 750-99 aturity, 1,000-1 aturity, 1,250-1 aturity, 1,500-1	ge Days 196 cified [weight an 500 grams 9 grams 9 grams 1,249 grams 1,499 grams 1,749 grams 1,749 grams

	2011111011	e o o ta ti o ti a ti o	
		Weeks	Days
P07.2	Extreme imm	28	196
P07.20	Extreme imm	aturity of newb	porn, unspecified weeks of gestation
O42.012	Preterm prem	ature rupture	of membranes, onset of labor within 24 hours of rupture, second trimester

Other preterm

codes				
ICD-9 code	Definition	Gestationa	l Age	
		Weeks	Days	
765.1	Disorders re	la 35	245	
765.10	Other prete	rm infants, u	nspecified [weigh	nt]
765.11	Other preter	m infants, les	s than 500 gram	S
765.12	Other prete	rm infants, 5	00-749 grams	
765.13	Other prete	rm infants, 7	50-999 grams	
765.14	Other preter	m infants, 1,0	00-1,249 grams	
765.15	Other preter	m infants, 1,	250-1,499 grams	
765.16	Other preter	m infants, 1,	00-1,749 grams	
765.17	Other preter	m infants, 1,	50-1,999 grams	
765.18	Other preter	m infants, 2,0	00-2,499 grams	
644.21	Onset of de	livery before	37 completed we	eks of gestation
ICD-10 code	Definition	Gestationa	l Age	
		Weeks	Days	

	WEEKS	Days
P05.01	Disorders of n 35	245
P05.02	Disorders of newborn relate	d to slow fetal growth and fetal malnutrition, 500-749 grams
P05.03	Disorders of newborn relate	d to slow fetal growth and fetal malnutrition, 750-999 grams
P05.04	Disorders of newborn relate	d to slow fetal growth and fetal malnutrition, 1000-1249 grams
P05.05	Disorders of newborn relate	d to slow fetal growth and fetal malnutrition, 1250-1499 grams
P05.06	Disorders of newborn relate	d to slow fetal growth and fetal malnutrition, 1500-1749 grams
P05.07	Disorders of newborn relate	d to slow fetal growth and fetal malnutrition, 1750-1999 grams
P05.11	Newborn small for gestationa	al age, less than 500 grams

P05.12 P05.13 Newborn small for gestational age, 500-749 grams

Newborn small for gestational age, 750-999 grams

P05.14 Newborn small for gestational age, 1000-1249 grams

- P05.15 Newborn small for gestational age, 1250-1499 grams P05.16
- Newborn small for gestational age, 1500-1749 grams Newborn small for gestational age, 1750-1999 grams
- P05.17
- P07.0 Extremely low birth weight newborn P07.00
- Extremely low birth weight newborn, unspecified weight P07.01 Extremely low birth weight newborn, less than 500 grams
- P07.02 Extremely low birth weight newborn, 500-749 grams
- P07.03 Extremely low birth weight newborn, 750-999 grams
- P07.1 Other low birth weight newborn
- P07.10 Other low birth weight newborn, unspecified weight
- P07.14 Other low birth weight newborn,1000-1249 grams
- P07.15 Other low birth weight newborn, 1250-1499 grams
- P07.16 Other low birth weight newborn, 1500-1749 grams
- P07.17 Other low birth weight newborn, 1750-1999 grams
- P07.3 Preterm [premature] newborn [other]
- P07.30 Preterm newborn, unspecified weeks of gestation
- 060.1 Preterm labor with preterm delivery
- O42.01 Preterm premature rupture of membranes, onset of labor within 24 hours of rupture
- 042.019 Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, unspecified trimester
- 042.013 Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, third trimester
- 644.2 early onset of delivery
- 644.20 Early onset of delivery, unspecified as to episode of care or not applicable
- 644.21 Early onset of delivery, delivered, with or without mention of antepartum condition
- 776.6 anemia of prematurity
- 362.20 retinopathy of prematurity, unspecified
- 362.22 retinopathy of prematurity, stage 0
- 362.23 retinopathy of prematurity, stage 1
- 362.24 retinopathy of prematurity, stage 2
- 362.25 retinopathy of prematurity, stage 3
- 362.26 retinopathy of prematurity, stage 4 362 27 retinopathy of prematurity, stage 5
- CPT
- 49491 repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception
- 49492 repair, initial inguinal hernia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception
- 67229 treatment of extensive or progressive retinopathy, 1 or more sessions; preterm infant (less than 37 weeks gestation at birth), performed from
- 836 anesthesia for hernia repairs in the lower abdomen not otherwise specified, infants younger than 37 weeks gestational age at birth

#### ICD-10 code Definition

- H35.1 Retinopathy of prematurity
- P61.2 Anemia of prematurity
- V27.2 Twins both liveborn
- V27.3 Mother with twins one liveborn and one stillborn
- V27.4 Mother with twins both stillborn
- V27.5 Other multiple birth, all liveborn
- V27.6 Other multiple birth, some liveborn
- V31 Twin, mate liveborn
- V32 Twin birth mate stillborn
- V33 Twin, unspecified
- V34 Other multiple, mates all liveborn
- V35 Other multiple birth (three or more) mates all stillborn
- V36 Other multiple, mates live- and stillborn
- V37 Other multiple, unspecified
- 651 Multiple gestation
- 651.0 X Twin Pregnancy
- 651.1 X Triplet pregnancy
- 651.2 X Quadruplet pregnancy
- 651.3 X Twin pregnancy with fetal loss and retention of one fetus
- 651.4 X Triplet pregnancy with fetal loss and retention of one or more fetus(es)
- 651.5 X Quadruplet pregnancy with fetal loss and retention of one or more fetus(es)
- 651.6 X Other multiple pregnancy with fetal loss and retention of one or more fetus(es)
- 651.7 X Multiple gestation following (elective) fetal reduction
- 651.8 X Other specified multiple gestation
- 651.9 X Unspecified multiple gestation

- 652.6x Multiple gestation with malpresentation of one fetus or more
- 660.5x Locked Twins
- 662.3x Delayed delivery of second twin, triplet, etc.
- 761.5x Multiple pregnancy

ICD10 Code Description 030xxxx Multiple gestation

Complications specific to multiple gestation 031xxxx 043.02 Fetus-to-fetus placental transfusion syndrome 063.2 Delayed delivery of second twin, triplet, etc. 237.2 Twins, both liveborn 237.3 Twins, one liveborn and one stillborn 237.5 Other multiple births, all liveborn 237.50 Multiple births, unspecified, all liveborn 237.51 Triplets, all liveborn 237.52 Quadruplets, all liveborn 237.53 Quintuplets, all liveborn 237.54 Sextuplets, all liveborn 237.59 Other multiple births, all liveborn 237.6 Other multiple births, some liveborn 237.60 Multiple births, unspecified, some liveborn 237.61 Triplets, some liveborn 237.62 Quadruplets, some liveborn 237.63 Quintuplets, some liveborn 237.64 Sextuplets, some liveborn 237.69 Other multiple births, some liveborn 238.3 Twin liveborn infant, born in hospital 238.30 Twin liveborn infant, delivered vaginally 238.31 Twin liveborn infant, delivered by cesarean 238.4 Twin liveborn infant, born outside hospital 238.5 Twin liveborn infant, unspecified as to place of birth 238.6 Other multiple liveborn infant, born in hospital 238.61 Triplet liveborn infant, delivered vaginally 238.62 Triplet liveborn infant, delivered by cesarean 238.63 Quadruplet liveborn infant, delivered vaginally 238.64

- Quadruplet liveborn infant, delivered by cesarean
- 238.65 Quintuplet liveborn infant, delivered vaginally
- 238.66 Quintuplet liveborn infant, delivered by cesarean 238.68
- Other multiple liveborn infant, delivered vaginally 238.69
- Other multiple liveborn infant, delivered by cesarean
- 238.7 Other multiple liveborn infant, born outside hospital 238.8
- Other multiple liveborn infant, unspecified as to place of birth P01.5 Newborn affected by multiple pregnancy

645 Late Pregnancy

- 645.1 Post term pregnancy
- 645.10 Post term pregnancy, unspecified as to episode of care or not applicable
- 645.11 Post term pregnancy, delivered, with or without mention of antepartum condition
- 645.13 Post term pregnancy, antepartum condition or complication
- 645.2 Prolonged pregnancy
- 645.20 Prolonged pregnancy, unspecified as to episode of care or not applicable
- 645.21 Prolonged pregnancy, delivered, with or without mention of antepartum condition
- 645.23 Prolonged pregnancy, antepartum condition or complication
- 766.2 Late infant, not 'heavy-for-dates'
- 766.21 Post-term infant
- 766.22 Prolonged gestation of infant
- 048 Late pregnancy
- 048.0 Post-term pregnancy
- 048.1 Prolonged pregnancy
- P08.2 Late newborn, not heavy for gestational age
- P08.21 Post-term newborn
- P08.22 Prolonged gestation of newborn
- 23A.41 41 weeks gestation of pregnancy
- 23A.42 42 weeks gestation of pregnancy

23A.49 Greater than 42 weeks gestation of pregnancy

ICD-10 CODES INDICATING PREGNANCY Dx codes: 009.XY2 Supervision of high risk pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) 011 Pre-existing hypertension with pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O13 Gestational [pregnancy-induced] hypertension without significant proteinuria (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O14 Pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O15 Eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O16 Unspecified maternal hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O20 Hemorrhage in early pregnancy O21 Excessive vomiting in pregnancy (last digit refers to first/second/third/unspecified trimester) O22 Venous complications and hemorrhoids in pregnancy O23 Infections of genitourinary tract in pregnancy (last digit refers to first/second/third/unspecified trimester) O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O25 Malnutrition in pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O26 Maternal care for other conditions predominantly related to pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O28 Abnormal findings on antenatal screening of mother O29 Complications of anesthesia during pregnancy (last digit refers to first/second/third/unspecified trimester) O30 Multiple gestation (last digit refers to first/second/third/unspecified trimester) O31 Complications specific to multiple gestation (certain digit refers to first/second/third/unspecified trimester) O32 Maternal care for malpresentation of fetus O33 Maternal care for disproportion O34 Maternal care for abnormality of pelvic organs (most codes indicate first/second/third/unspecified trimester) 035 Maternal care for known or suspected fetal abnormality and damage O36 Maternal care for other fetal problems (codes indicate first/second/third/unspecified trimester) O40 Polyhydramnios (codes indicate first/second/third/unspecified trimester) O41 Other disorders of amniotic fluid and membranes (codes indicate first/second/third/unspecified trimester) 042.1 Premature rupture of membranes, onset of labor more than 24 hours following rupture 042.9 Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor 043 Placental disorders (last digit refers to first/second/third/unspecified trimester) O44 Placenta previa (last digit refers to first/second/third/unspecified trimester) O45 Premature separation of placenta (last digit refers to first/second/third/unspecified trimester) O46 Antepartum hemorrhage, not elsewhere classified (last digit refers to first/second/third/unspecified trimester) 047 False labor O60.0 Preterm labor without delivery O61 Failed induction of labor 071.0 Rupture of uterus (spontaneous) before onset of labor 072 Postpartum hemorrhage 72.2 Delayed and secondary postpartum hemorrhage 72.3 Postpartum coagulation defects 073 Retained placenta and membranes, without hemorrhage O75 Other complications of labor and delivery, not elsewhere classified 094 Sequelae of complication of pregnancy, childbirth, and the puerperium 098 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 099 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) 09A Maternal malignant neoplasms, traumatic in uries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium {if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing} 232.01 Encounter for pregnancy test - result positive 233 Pregnant state 234 Encounter for supervision of normal pregnancy 236 Encounter for antenatal screening of mother 239 Encounter for maternal postpartum care and examination 239.1 Encounter for care and examination of lactating mother 239.2 Encounter for routine postpartum follow-up 23A Weeks of gestation Proc codes: 102 Change 109 Drainage 10H Insertion 10J Inspection 10P Removal 10Q Repair

10S Reposition
10Y Transplantation
ICD-10 CODES INDICATING DELIVERY (diagnostic codes that were not considered in the algorithm to identify delive ries)
Dx codes:
Use the following codes only if the last digit indicates childbirth or puerperium or labor
O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium
011 Pre-existing hypertension with pre-eclampsia
012 Gestational [pregnancy-induced] edema and proteinuria without hypertension
013 Gestational [pregnancy-induced] hypertension without significant proteinuria
O14 Pre-eclampsia
015 Eclampsia
016 Unspecified maternal hypertension
024 Diabetes mellitus in pregnancy, childbirth, and the puerperium
025 Malnutrition in pregnancy, childbirth and the puerperium O26 Maternal care for other conditions predominantly related to pregnancy
042.0 Premature rupture of membranes, onset of labor within 24 hours of rupture, except 042.011 (first trimester)
048 Late pregnancy 048 Late pregnancy
Of 0.1 Preterm labor with preterm delivery
Coc. 1 Freedmin above with preterm labor Co6.0 2 Term delivery with preterm labor
O64 Obstructed labor due to malposition and malpresentation of fetus
O65 Obstructed labor due to maternal pelvic abnormality
O66 Other obstructed labor
O67 Labor and delivery complicated by intrapartum hemorrhage, not elsewhere classified
O68 Labor and delivery complicated by abnormality of fetal acid-base balance
O69 Labor and delivery complicated by umbilical cord complications
O70 Perineal laceration during delivery
71.1 Rupture of uterus during labor
71.2 Postpartum inversion of uterus
71.3 Obstetric laceration of cervix
71.4 Obstetric high vaginal laceration alone
72.0 Third-stage hemorrhage
72.1 Other immediate postpartum hemorrhage
O74 Complications of anesthesia during labor and delivery
O76 Abnormality in fetal heart rate and rhythm complicating labor and delivery
O77 Other fetal stress complicating labor and delivery
O80 Encounter for full-term uncomplicated delivery
O82 Encounter for cesarean delivery without indication
098 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium)
099 0ther maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium)
09A Maternal malignant neoplasms, traumatic in uries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium)
237 Outcome of delivery {For livebirth cohort, exclude 237.1, 237.4, 237.7 - all stillbirth codes}
238 Liveborn infants according to place of birth and type of delivery
239.0 Encounter for care and examination of mother immediately after delivery
ICD-10 CODES INDICATING PREGNANCY WITH ABORTIVE/NON-LIVE BIRTH OUTCOMES
Dx codes: O00-O08 Pregnancy with abortive outcome
Proc codes:
IOA Abortion
100 1729 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening
100 1725 wantad Extraction of Products of Conception, Rectained, Via Natural of Antificial Opening 100 1725 Extraction of Products of Conception, Rectained, Via Natural of Antificial Opening
100 1/22 Extraction of Products of Conception, Retained, via Natural of Antincia Opening 100 1829 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic
100 1625 Walkad Extraction of Products of Conception, Retained, Via Natural or Afficial Opening Endoscopic 100 1822 Extraction of Products of Conception, Retained, Via Natural or Afficial Opening Endoscopic
TOP
1002722 Extraction of Products of Conception, Ectopic, Via Natural or Artificial Opening
1002822 Extraction of Products of Conception, Ectopic, Via Natural of Antinicia Opening Endoscopic
1052 Reposition Products of Conception, Ecopy i al factal of manager opport
Tor Rescion (Ectopic)

#### **Dialysis Codes** Codes include: ICD9 prox codes: 39.95, Hemodialysis 54.98, Peritoneal dialysis - ICD9 dx codes: 585.5x, Chronic kidney disease, Stage V (for ESRD with no mention of dialysis) 585.6x, End stage renal disease (for ESRD with dialysis) V56.0x, encounter for dialysis NOS V56.8x, encounter for peritoneal dialysis V45.1x, renal dialysis status CPT4 codes: 90957, 90960, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 4 or more face-to-face physician visits per month 90958, 90961, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 2-3 face-to-face physician visits 90959, 90962, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 1 face-to-face physician visit per 90920, 90921, ESRD related services per full month; for patients 12-19 and twenty years of age and over 90924, 90925, ESRD related services (less than full month), per day; for patients 12-19 and twenty years of age and over 90935, Hemodialysis procedure with single physician evaluation 90937, Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription 90945, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single physician evaluation 90947, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated physician evaluations, with or without substantial revision of dialysis prescription 90965, 90966, ESRD related services for home dialysis per full month, for patients 12-19 and 20 years of age and older 90969, 90970, ESRD related services for dialysis less than a full month of service, per day; for patients 12-19 and 20 years of age and 90989, Dialysis training, patient, including helper where applicable, any mode, completed course 90993, Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session 90999, Unlisted dialysis procedure, inpatient or outpatient 99512, Home visit for hemodialysis - HCPCS codes:

G0257, Unscheduled or emergency dialysis treatment for ESRD patient in a hospital outpatient dept. that is not certified as an ESRD

G0314, G0317, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age an over to include monitoring for the adequacy of nutrition, etc. w/4 or more physician visit per month

G0315, G0318, ESRD related services during the course of treatment, for patients 12-19 and 20yrs of age and over to include monitoring for the adequacy of nutrition, etc. w/2 or 3 physician visit per month

G0316, G0319, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age and over to include monitoring for the adequacy of nutrition, etc. w/1 physician visit per month

G0322, G0323, ESRD related services for home dialysis patients per full month: for patients 12-19 and 20 yrs of age and over to include monitoring for adequacy of nutrition and etc.

G0326, G0327, ESRD related services for home dialysis (less than full month), per day; for patients 12-19 and 20 yrs of age and over S9335, Home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately), per diem

S9339, Home therapy, peritoneal dialysis, administrative services, care coordination and all necessary supplies and equipment, per

#### OR

Kidney transplant, defined as either 1 inpatient or 1 outpatient code Codes include:

-ICD9 dx codes:

V42.0x, Kidney transplant status

996.81 Complications of transplanted kidney

#### -ICD9 prox codes:

55.6x, Transplant of kidney (Exclude 55.61)

#### - CPT4 codes:

50360, Renal allotransplantation, implantation, graft, w/o donor & recipient nephrectomy 50365, Renal allotransplantation, implantation, graft, w/ donor & recipient nephrectomy

Liver Bypass ICD-10 Procedure Codes 06100Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Open Approach 0610496 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06104K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute. Percutaneous Endoscopic Approach 06104Z5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein, Percutaneous Endoscopic Approach 06104ZY - Bypass Inferior Vena Cava to Lower Vein, Percutaneous Endoscopic Approach 061107B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach 0611099 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach 06110AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 06110J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Open Approach 0611479 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 061147Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 06114J9 - Bypass Splenic Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06120ZY - Bypass Gastric Vein to Lower Vein, Open Approach 06140AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 061507Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 061509Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 061549Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06154AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 061647Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 061709Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Open Approach 061807Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 061809B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach 061809Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Open Approach 06180J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Open Approach 06180Z9 - Bypass Portal Vein to Right Renal Vein, Open Approach 0618479 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 061849B - Bypass Portal Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06184AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06184JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06184ZB - Bypass Portal Vein to Left Renal Vein, Percutaneous Endoscopic Approach 06190ZY - Bypass Right Renal Vein to Lower Vein, Open Approach 061947Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 061949Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach

061B0ZY - Bypass Left Renal Vein to Lower Vein, Open Approach 061B4AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 061B4KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 061J09Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 061J0KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 06L30ZZ - Occlusion of Esophageal Vein, Open Approach 061007Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Open Approach 06100A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Open Approach 06100J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Open Approach 06100K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach 06110JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Open Approach 06110KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach 06114JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 061207Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 061407Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 061409Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Open Approach 061449Y - Bypass Hepatic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06144AY - Bypass Hepatic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06150KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 06154ZY - Bypass Superior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach 061607Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 06160ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Open Approach 06164AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 061749Y - Bypass Colic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06174AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06174KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 0618099 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Open Approach 06180K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach 06184J9 - Bypass Portal Vein to Right Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06184JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute. Percutaneous Endoscopic Approach 06184Z9 - Bypass Portal Vein to Right Renal Vein, Percutaneous Endoscopic Approach 061909Y - Bypass Right Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach 061J4JY - Bypass Left Hypogastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06L34CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Endoscopic Approach

0610075 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Open Approach 06100A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Open Approach 06100K5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Nonautologous Tissue Substitute, Open Approach 06100KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Open Approach 06100ZY - Bypass Inferior Vena Cava to Lower Vein, Open Approach 061049Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06104A5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06104A6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06104JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06104Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Percutaneous Endoscopic Approach 061107Y - Bypass Splenic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 06110KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 06110ZB - Bypass Splenic Vein to Left Renal Vein, Open Approach 061149Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06114A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06114AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06114AY - Bypass Splenic Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06114ZB - Bypass Splenic Vein to Left Renal Vein, Percutaneous Endoscopic Approach 06140KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 06140ZY - Bypass Hepatic Vein to Lower Vein, Open Approach 06144ZY - Bypass Hepatic Vein to Lower Vein, Percutaneous Endoscopic Approach 06150AY - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 06150ZY - Bypass Superior Mesenteric Vein to Lower Vein, Open Approach 061609Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 061649Y - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06164JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06164KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06164ZY - Bypass Inferior Mesenteric Vein to Lower Vein, Percutaneous Endoscopic Approach 06170KY - Bypass Colic Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 061807B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Open Approach 06180JB - Bypass Portal Vein to Left Renal Vein with Synthetic Substitute, Open Approach 06180KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 06180ZY - Bypass Portal Vein to Lower Vein, Open Approach 061847Y - Bypass Portal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach

06184DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Endoscopic Approach 06184KY - Bypass Portal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06190AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 06194JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 061B07Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 061B0AY - Bypass Left Renal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 061B4ZY - Bypass Left Renal Vein to Lower Vein, Percutaneous Endoscopic Approach 061J07Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 061J4ZY - Bypass Left Hypogastric Vein to Lower Vein, Percutaneous Endoscopic Approach 06L33DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Approach 06L34DZ - Occlusion of Esophageal Vein with Intraluminal Device, Percutaneous Endoscopic Approach 0610096 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Venous Tissue, Open Approach 061009Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Venous Tissue, Open Approach 06100Z6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein, Open Approach 0610476 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 06104AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06104J5 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06104J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06104KY - Bypass Inferior Vena Cava to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06110JY - Bypass Splenic Vein to Lower Vein with Synthetic Substitute, Open Approach 06110K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Open Approach 06110ZY - Bypass Splenic Vein to Lower Vein, Open Approach 0611499 - Bypass Splenic Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06114JB - Bypass Splenic Vein to Left Renal Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06114K9 - Bypass Splenic Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06114KB - Bypass Splenic Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06114KY - Bypass Splenic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06114Z9 - Bypass Splenic Vein to Right Renal Vein, Percutaneous Endoscopic Approach 06114ZY - Bypass Splenic Vein to Lower Vein, Percutaneous Endoscopic Approach 06120KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 061247Y - Bypass Gastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 061249Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06124AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06150JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach

06154JY - Bypass Superior Mesenteric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06160KY - Bypass Inferior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 061747Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 06174ZY - Bypass Colic Vein to Lower Vein, Percutaneous Endoscopic Approach 0618079 - Bypass Portal Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach 06180AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 06180JY - Bypass Portal Vein to Lower Vein with Synthetic Substitute, Open Approach 06180KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Open Approach 06180ZB - Bypass Portal Vein to Left Renal Vein, Open Approach 06183DY - Bypass Portal Vein to Lower Vein with Intraluminal Device, Percutaneous Approach 061847B - Bypass Portal Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 0618499 - Bypass Portal Vein to Right Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06184AY - Bypass Portal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06184K9 - Bypass Portal Vein to Right Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06184ZY - Bypass Portal Vein to Lower Vein, Percutaneous Endoscopic Approach 061907Y - Bypass Right Renal Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 06194ZY - Bypass Right Renal Vein to Lower Vein, Percutaneous Endoscopic Approach 061B0JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Open Approach 061B0KY - Bypass Left Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 061B47Y - Bypass Left Renal Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 061B4JY - Bypass Left Renal Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 061J0AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 061J0ZY - Bypass Left Hypogastric Vein to Lower Vein, Open Approach 061J47Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 06L30CZ - Occlusion of Esophageal Vein with Extraluminal Device, Open Approach 06L30DZ - Occlusion of Esophageal Vein with Intraluminal Device, Open Approach 06L33CZ - Occlusion of Esophageal Vein with Extraluminal Device, Percutaneous Approach 06L33ZZ - Occlusion of Esophageal Vein, Percutaneous Approach 0610076 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Autologous Tissue Substitute, Open Approach 0610095 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Open Approach 06100AY - Bypass Inferior Vena Cava to Lower Vein with Autologous Arterial Tissue, Open Approach 06100J6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Synthetic Substitute, Open Approach 06100JY - Bypass Inferior Vena Cava to Lower Vein with Synthetic Substitute, Open Approach 0610475 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach

061047Y - Bypass Inferior Vena Cava to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 0610495 - Bypass Inferior Vena Cava to Superior Mesenteric Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06104K6 - Bypass Inferior Vena Cava to Inferior Mesenteric Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 0611079 - Bypass Splenic Vein to Right Renal Vein with Autologous Tissue Substitute, Open Approach 061109B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Open Approach 061109Y - Bypass Splenic Vein to Lower Vein with Autologous Venous Tissue, Open Approach 06110A9 - Bypass Splenic Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach 06110AB - Bypass Splenic Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach 06110Z9 - Bypass Splenic Vein to Right Renal Vein, Open Approach 061147B - Bypass Splenic Vein to Left Renal Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 061149B - Bypass Splenic Vein to Left Renal Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 061209Y - Bypass Gastric Vein to Lower Vein with Autologous Venous Tissue, Open Approach 06120AY - Bypass Gastric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 06120JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Open Approach 06124JY - Bypass Gastric Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06124KY - Bypass Gastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06124ZY - Bypass Gastric Vein to Lower Vein, Percutaneous Endoscopic Approach 06140JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Open Approach 061447Y - Bypass Hepatic Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 06144JY - Bypass Hepatic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06144KY - Bypass Hepatic Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 061547Y - Bypass Superior Mesenteric Vein to Lower Vein with Autologous Tissue Substitute, Percutaneous Endoscopic Approach 06154KY - Bypass Superior Mesenteric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06160AY - Bypass Inferior Mesenteric Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 06160JY - Bypass Inferior Mesenteric Vein to Lower Vein with Synthetic Substitute, Open Approach 061707Y - Bypass Colic Vein to Lower Vein with Autologous Tissue Substitute, Open Approach 06170AY - Bypass Colic Vein to Lower Vein with Autologous Arterial Tissue, Open Approach 06170JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Open Approach 06170ZY - Bypass Colic Vein to Lower Vein, Open Approach 06174JY - Bypass Colic Vein to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach 06180A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Open Approach 06180AB - Bypass Portal Vein to Left Renal Vein with Autologous Arterial Tissue, Open Approach 061849Y - Bypass Portal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 06184A9 - Bypass Portal Vein to Right Renal Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach

06184KB - Bypass Portal Vein to Left Renal Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 06190JY - Bypass Right Renal Vein to Lower Vein with Synthetic Substitute, Open Approach 06190KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Open Approach 06194AY - Bypass Right Renal Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 06194KY - Bypass Right Renal Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 061809Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Open Approach 061B49Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 061B49Y - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 061J0JY - Bypass Left Renal Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 061J44Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 061J49Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 061J44Y - Bypass Left Hypogastric Vein to Lower Vein with Autologous Venous Tissue, Percutaneous Endoscopic Approach 061J4AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 061J4AY - Bypass Left Hypogastric Vein to Lower Vein with Autologous Arterial Tissue, Percutaneous Endoscopic Approach 061J4KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 061J4KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach 061J4KY - Bypass Left Hypogastric Vein to Lower Vein with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach

Procedure Codes	Description		
CPT-4 codes	A		
1960	Anesthesia for		
1961	Anesthesia for		
1962			rectomy following delivery
1963	Anesthesia for	cesarean hyste	rectomy w/o any labor analgesia/anesthesia care 1967
Neuraxial labor a	nalgesia/anes	sthesia, plann	ed vaginal delivery
1968	Anesthesia for	cesarean deliv	ery following neuraxial labor analgesia/anesthesia 1969
Anes for cesarear	n hysterectomy	following neu	raxial labor analgesia/anesthesia 59050
Fetal monitoring			
59051			nysician w/written report; intrepretation only
59400			C CARE including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care. 59409
Vaginal delivery	onlv (w/wo epi	isiotomv &/or	(orceps)
59410		-	isiotomy &/or forceps); w/postpartum care 59412
Ext cephalic vers	ion w/wo.toco	lveis	
59414	Delivery of pla		
59430	Postpartum ca		
59430 59510		-	vartum care, cesarean delivery, & postpartum care 59514
Cesarean delivery 59515		very only: w/m	ostpartum care
59525			after cesarean delivery
59610			ng antepartum care, vaginal delivery (with or without episiotomy, and/or forceps) and postpartum care, after previous cesarean delivery 59612
			n delivery (with or without episiotomy and/or forceps)
59614	Vaginal delive	ry only, previo	us cesarean delivery w/postpartum care
ICD-9 procedure			
codes			
72. X	Forceps, vacu	um, & breech	
73. <b>X</b>	Other includin	g manual deli	very
74xx	Cesarean sect	ion	
75.4x	Manual remov	al of placenta	
ICD-10			
procedure			
codes			
Normal			
Delivery			
10E0XZZ	Delivery of Pro	oducts of Con	eption, External Approach
C-Section			
10D00Z0	Extraction of F	Products of Co	nception, High, Open Approach
10D00Z1			Low, Open Approach
10D00Z2			nception, Extraperitoneal, Open Approach
			ernal version, other)
10D07Z3			seption, Low Forceps, Via Natural or Artificial Opening 10D07Z4
Extraction of Proc	ducts of Conce	ption, Mid For	seps, Via Natural or Artificial Opening 10D07Z5
Extraction of Proc	lucts of Concer	ntion High Fo	ceps, Via Natural or Artificial Opening 10D07Z6
		-	
			, Via Natural or Artificial Opening 10D07Z7
ICD-9 code		Gestational A	-
		Weeks	Days
	Less than 24 c		168
	24 completed		
	25-26 comple		182
765.24	27-28 comple	28	196
765.25	29-30 comple	30	210
765.26	31-32 comple	32	224
	33-34 comple		238
765.28	35-36 comple		252
ICD 10 anda	Definition	Contation-1 A	
ICD-10 code	Definition	Gestational A	ge

P07.2	Weeks	Days
1 P07.2	Extreme imm 23Extreme	161
2 P07.2	imm 23 Extreme	161
3 P07.2	imm 24 Extreme	168
4 P07.2	imm 25 Extreme	175
5 P07.2	imm 26 Extreme	182
6 P07.3	imm 27 Preterm	189
1 P07.3	new 28 Preterm	196
2 P07.3	new 29 Preterm	203
3 P07.3	new 30 Preterm	210
4 P07.3	new 31 Preterm	217
5 P07.3	new 32 Preterm	224
6 P07.3	new 33 Preterm	231
7 P07.3	new 34 Preterm	238
8 P07.3	new 35 Preterm	245
9	new 36	252
	extreme prematurity	
ICD-9 code	Definition Gestational	-
765.	Weeks	Days
0	Disorders rela 28	196
765.00	Extreme immaturity, unspecifie	
765.01	immaturity, less than 500	
765.02	immaturity, 500-749 gram	
765.03	immaturity, 750-999 gram	
765.04	immaturity, 1,000-1,249 g	
765.05	immaturity, 1,250-1,499 g	
765.06	immaturity, 1,500-1,749 g	
765.07	immaturity, 1,750-1,999 g	
765.08	immaturity, 2,000-2,499 gr	rams
ICD-10 code	Definition Gestational	4.50
P07.2	Weeks	-
P07.20	Extreme imm 28	Days 196
	Extreme min 20	
	Extromo immoturity of nor	where upprovided weaks of acctation
O42.012		wborn, unspecified weeks of gestation
042.012		wborn, unspecified weeks of gestation re of membranes, onset of labor within 24 hours of rupture, second trimester
Other preterm		
	Preterm premature ruptur	re of membranes, onset of labor within 24 hours of rupture, second trimester
Other preterm codes ICD-9 code	Preterm premature ruptur Definition Gestational	re of membranes, onset of labor within 24 hours of rupture, second trimester
Other preterm codes	Preterm premature ruptur Definition Gestational Weeks	re of membranes, onset of labor within 24 hours of rupture, second trimester
Other preterm codes ICD-9 code	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35	re of membranes, onset of labor within 24 hours of rupture, second trimester           Age           Days           245
Other preterm codes ICD-9 code 765. 1	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe	re of membranes, onset of labor within 24 hours of rupture, second trimester           Age           Days           245           sciled [weight] Other
Other preterm codes ICD-9 code 765. 1 765.10	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than	re of membranes, onset of labor within 24 hours of rupture, second trimester           Age           Days           245           Solided [weight] Other           500 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe	re of membranes, onset of labor within 24 hours of rupture, second trimester           Age         Days           245         scilled [weight] Other           500 grams Other         grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, 500-749 g	re of membranes, onset of labor within 24 hours of rupture, second trimester <b>Age Days</b> 245 sociated (weight) Other 500 grams Other grams Other grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, fs00-749 g preterm infants, 500-749 g	Age Days 245 Sodied [weight] Other 500 grams Other grams Other 49 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, sound so that preterm infants, 750-999 g preterm infants, 750-999 g	Age Days 245 colled [weight] Other 500 grams Other grams Other 49 grams Other 99 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.14	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, 1000-749 preterm infants, 1000-72 preterm infants, 1000-12 preterm infants, 1,250-1,4	e of membranes, onset of labor within 24 hours of rupture, second trimester           Age         Days           245         Solided [weight] Other           500 grams Other         grams Other           99 grams Other         99 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.15 765.16	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, 1500-149 preterm infants, 1,200-14, preterm infants, 1,200-14, preterm infants, 1,500-17	Age Days 245 socilied [weight] Other 500 grams Other grams Other 49 grams Other 49 grams Other 49 grams Other 49 grams Other 49 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.15 765.16 765.16	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, f50-749 g preterm infants, 750-999 g preterm infants, 750-999 g preterm infants, 750-17 preterm infants, 1,250-1,4 preterm infants, 1,250-1,9 preterm infants, 1,250-1,9	Age Days 245 sociled [weight] Other 500 grams Other grams Other 49 grams Other 49 grams Other 49 grams Other 49 grams Other 49 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, less than preterm infants, 1,500-1,2 preterm infants, 1,500-1,2 preterm infants, 1,500-1,7 preterm infants, 2,500-1,4 Onset of delivery before 3	Age Days 245 sodied (weight) Other 500 grams Other grams Other 49 grams Other 99 grams Other 49 grams Other 99 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.12 765.12 765.13 765.14 765.15 765.16 765.17 765.17	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, 500-749 c preterm infants, 750-799 c preterm infants, 750-799 c preterm infants, 1,000-1,2 preterm infants, 1,000-1,2 preterm infants, 1,000-1,2 preterm infants, 1,000-1,3 preterm	Age Days 245 bodied [weight] Other 500 grams Other grams Other 49 grams Other 49 grams Other 99 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.12 765.12 765.13 765.14 765.15 765.16 765.16 765.18 644.21 ICD-10 code	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, less than preterm infants, 1,000-1,2 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 Preterm infants, 1,250-1,4 Preterm infants, 1,250-1,3 preterm infants, 1,250-1,3 preterm infants, 2,000-2,4 Onset of delivery before 3 Definition Gestational Weeks	Age Days 245 ediled [weight] Other 500 grams Other grams Other 49 grams Other 49 grams Other 99 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, less than preterm infants, 1,250-149 preterm infants, 1,000-12, preterm infants, 1,000-12, preterm infants, 1,000-12, preterm infants, 1,000-14, preterm infants, 1,000-14, preterm infants, 2,000-24, Onset of delivery before 3 Definition Gestational Weeks Disorders of n 35	Age Days 245 colled [weight] Other 500 grams Other 99 grams Other 49 grams Other 99 grams Other
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, less than preterm infants, less than preterm infants, 1000-1,2 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 preterm infants, 1,500-1,7 preterm infants, 1,500-1,7 preterm infants, 1,250-1,4 preterm infants, 1,500-1,7 preterm infants, 2,2000-2,4 Onset of delivery before 3 Definition Gestational Weeks Disorders of n 35 Disorders of n ewbom relate	Age Days 245 Color of membranes, onset of labor within 24 hours of rupture, second trimester Days 245 Color Java Color grams Other grams Other 49 grams Other 99 grams Other 90 grams Ot
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02 P05.03	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, sous-rd9 cg preterm infants, 750-990 preterm infants, 750-990 preterm infants, 1,250-1,4 preterm infants, 1,250-1,9 preterm infants, 1,500-1,7 preterm infants, 1,500-1,7 preterm infants, 1,500-1,9 preterm infants, 1,500-1,9 preterm infants, 1,500-1,9 Disorders of one Gestational Weeks Disorders of newborn related of newborn related to slo	Age Days 245 badied [weight] Other 500 grams Other grams Other 99 grams Other 90
Other preterm codes ICD-9 code 765. 1 765.10 765.12 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02 P05.03 P05.04	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Ofher preterm infants, unspe preterm infants, less than preterm infants, less than preterm infants, 1,000-1,2 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 Preterm infants, 1,250-1,4 Preterm infants, 2,000-2,4 Onset of delivery before 3 Definition Gestational Weeks Disorders of n 35 Disorders of n 35 Disorders of newborn related to slov	Age Days 245 245 245 245 245 245 245 245 245 245
Other preterm codes ICD-9 code 765. 1 765.10 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02 P05.03 P05.04 P05.04 P05.05	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, less than preterm infants, 1,250-149 preterm infants, 1,250-14, preterm infants, 1,250-17, preterm infants, 1,250-14, preterm infants, 1,250-14, preterm infants, 1,250-14, preterm infants, 1,750-19, preterm infants, 2,000-24, Onset of delivery before 3 Definition Gestational Weeks Disorders of n 35 Disorders of newborn related to sloo of newborn related to sloo of newborn related to sloo	Age Days 245 collected (weight) Other 500 grams Other 99 grams Other 90 grams 0 does 90 grams 9
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.15 765.16 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02 P05.03 P05.04 P05.05 P05.06	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, 500-749 c preterm infants, 750-999 preterm infants, 750-999 preterm infants, 1,250-1,4 preterm infants, 1,250-1,9 preterm infants, 1,250-1,9 preterm infants, 1,250-1,9 preterm infants, 1,250-1,9 preterm infants, 2,000-2,4 Onset of delivery before 3 Definition Gestational Weeks Disorders of na35 Disorders of na450 of newborn related to sloo of newborn related to sloo of newborn related to sloo	Age Days 245 contemportanes, onset of labor within 24 hours of rupture, second trimester 245 bodied [weight] Other 500 grams Other grams Other grams Other grams Other 99 grams Disorders 90 grams Disorders 90 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Disorders 90 fetal growth and fetal malnutrition, 1250-1499 grams Di
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02 P05.03 P05.04 P05.05 P05.06 P05.07	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, sous r49 g preterm infants, f500-749 g preterm infants, 750-999 g preterm infants, 750-999 g preterm infants, 750-149 preterm infants, 750-19 preterm infants, 1,500-17 preterm infants, 1,500-17 preterm infants, 1,500-17 preterm infants, 1,500-17 preterm infants, 1,500-17 Determ infants, 1,500-17 Determ infants, 1,500-17 Determ infants, 1,500-17 Disorders of n35 Disorders of n35 Disorders of n35 Disorders of n35 Disorders of n35 Disorders of newborn related to sloo of newborn related to sloo	Age Days 245 codied [weight] Other 500 grams Other grams Other grams Other 99 grams Other 99 gra
Other preterm codes ICD-9 code 765. 1 765.10 765.12 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02 P05.03 P05.04 P05.05 P05.06 P05.06 P05.07 P05.11	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, less than preterm infants, 1,000-1,2 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 Preterm infants, 1,250-1,4 Preterm infants, 1,250-1,3 preterm infants, 2,200-2,4 Onset of delivery before 3 Definition Gestational Weeks Disorders of n 35 Disorders of n 35 Disorders of n avborn related of newborn related to slov of newborn related to slov	Age Days 245 collection of the provided of the
Other preterm codes ICD-9 code 765. 1 765.10 765.11 765.12 765.13 765.14 765.15 765.16 765.16 765.17 765.18 644.21 ICD-10 code P05.01 P05.02 P05.03 P05.04 P05.05 P05.06 P05.07	Preterm premature ruptur Definition Gestational Weeks Disorders rela 35 Other preterm infants, unspe preterm infants, less than preterm infants, less than preterm infants, 1,000-1,2 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 preterm infants, 1,250-1,4 Preterm infants, 1,250-1,4 Preterm infants, 1,250-1,3 preterm infants, 2,200-2,4 Onset of delivery before 3 Definition Gestational Weeks Disorders of n 35 Disorders of n 35 Disorders of n avborn related of newborn related to slov of newborn related to slov	Age Days 245 500 grams Other 500 grams Disorders witelal growth and fetal malnutrition, 1500-1749 grams Disorders witelal growth and fetal malnutrition, 1750-1999 grams Disorders witelal growth and fetal malnutrition, 1750-1999 grams Disorders witelal growth and fetal malnutrition, 1250-1499 grams Disorders witelal growth and fetal malnutrition, 1750-1999 grams Disorders witelal growth and fetal malnutrition, 1250-1499 grams Disorders witelal growth and fetal malnutrition, 1250-149

P05.13 small for gestational age, 750-999 grams No P05.14 small for gestational age, 1000-1249 grams

P07.00 P0 O60.1 O42	Newbom small for gestational age, 1250-1499 grams Newbom small for gestational age, 1500-1749 grams Newborn small for gestational age, 1500-1999 grams Extremely low birth weight newborn Extremely low birth weight newborn, unspecified weight Extremely
060.1 04	low birth weight newborn
	5
	Extremely law hith weight newhere unenegified weight Extremely
	Externely low birth weight newborn, unspecified weight Extremely
	low birth weight newborn, less than 500 grams Extremely
	low birth weight newborn, 500-749 grams Extremely
	low birth weight newborn, 750-999 grams Other
	low birth weight newborn
	Other low birth weight newborn, unspecified weight Other
	low birth weight newborn,1000-1249 grams Other
	low birth weight newborn,1250-1499 grams Other low birth weight newborn,1500-1749 grams Other
	low birth weight newborn,1750-1999 grams Preterm
	[premature] newborn [other]
	Preterm newborn, unspecified weeks of gestation Preterm
	labor with preterm delivery
	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture
	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, unspecified trimester
	Preterm premature rupture of membranes, onset of labor within 24 hours of rupture, third trimester
644.2	early onset of delivery
644.20	Early onset of delivery, unspecified as to episode of care or not applicable
644.21	Early onset of delivery, delivered, with or without mention of antepartum condition anemia
776.6	of prematurity
362.20	retinopathy of premalurity, unspecified retinopathy
362.22	of prematurity, stage 0 retinopathy
362.23	of prematurity, stage 1 retinopathy
362.24	of prematurity, stage 2 retinopathy
362.25	of prematurity, stage 3 retinopathy
362.26 362.27	of prematurity, stage 4 retinopathy
CPT	of prematurity, stage 5
49491	repair, initial inguinal hemia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception repair,
49492	initial inguinal hemia, preterm infant (younger than 37 weeks gestation at birth), performed from birth up to 50 weeks postconception treatment
67229	of extensive or progressive retinopathy, 1 or more sessions; preterm infant (less than 37 weeks gestation at birth), performed from anesthesia
836	for hernia repairs in the lower abdomen not otherwise specified, infants younger than 37 weeks gestational age at birth
ICD-10 code	Definition
H35.	
1 P61.	Retiropathy of prematurity Anemia
2	of prematurity
V27.2	Twins both liveborn
V27.2 V27.3	Nother with twins one liveborn and one stillborn Mother
V27.4	with twins both stillborn
V27.5	Other multiple birth, all liveborn Other
V27.6	multiple birth, some liveborn Twin,
V31 V	mate liveborn
32 V33	Twin birth mate stillborn Twin,
V34 V	unspecified
35 V36	Other multiple, mates all liveborn
V37 6	Other multiple birth (three or more) mates all stillborn Other
51 651.0 x	multiple, mates live- and stillborn
651.1 X	Othermuliple, unspecified Multiple gestation
651.2 X	Twin Pregnancy Triplet
651.3 X	pregnancy Quadruplet
651.4 X	pregnancy
651.5 X	Twin pregnancy with fetal loss and retention of one fetus
651.6 X	Triplet pregnancy with fetal loss and retention of one or more fetus(es) Quadruplet
651.7 X	pregnancy with fetal loss and retention of one or more fetus(es) Other
651.8 X	multiple pregnancy with fetal loss and retention of one or more fetus(es) Multiple
	gestation following (elective) fetal reduction
651.9 X	
651.9 X	Otherspecified multiple gestation Unspecified multiple gestation

- 652.6x Multiple gestation with malpresentation of one fetus or more Locked
- 660.5x Twins
- 662.3x Delayed delivery of second twin, triplet,
- 761.5x etc. Multiple pregnancy

ICD10 Code Description O30xxxx Multiple gestation

O31xxxx Complications specific to multiple gestation Fetus-to-fetus O43.02 placental transfusion syndrome Delayed O63.2 delivery of second twin, triplet, etc. Twins, Z37.2 both liveborn Z37.3 Twins, one liveborn and one stillborn Other Z37.5 multiple births, all liveborn Multiple Z37.50 births, unspecified, all liveborn Triplets, Z37.51 all liveborn Z37.52 Quadruplets, all liveborn Quintuplets. Z37.53 all liveborn Sextuplets, Z37.54 all liveborn Other multiple births, all liveborn Other Z37.59

- Z37.6 multiple births, some liveborn
- Z37.60 Multiple births, unspecified, some liveborn Triplets,
- Z37.61 some liveborn
- Z37.62 Quadruplets, some liveborn Quintuplets,
- Z37.63 some liveborn Sextuplets,
- Z37.64 some liveborn
- Z37.69 Other multiple births, some liveborn Twin
- Z38.3 liveborn infant, born in hospital Twin
- Z38.30 liveborn infant, delivered vaginally
- Z38.31 Twin liveborn infant, delivered by cesarean Twin
- Z38.4 liveborn infant, born outside hospital
- Z38.5 Twin liveborn infant, unspecified as to place of birth Other
- Z38.6 multiple liveborn infant, born in hospital Triplet Z38.61
- liveborn infant, delivered vaginally
- Z38.62 Triplet liveborn infant, delivered by cesarean Quadruplet
- Z38.63 liveborn infant, delivered vaginally Quadruplet Z38.64
- liveborn infant, delivered by cesarean Quintuplet
- Z38.65 liveborn infant, delivered vaginally Quintuplet
- Z38.66 liveborn infant, delivered by cesarean Other
- Z38.68 multiple liveborn infant, delivered vaginally Other
- Z38.69 multiple liveborn infant, delivered by cesarean Other
- Z38.7 multiple liveborn infant, born outside hospital
- Z38.8 Other multiple liveborn infant, unspecified as to place of birth Newborn
- P01.5 affected by multiple pregnancy

64 5

Late Pregnancy

645.1 Post term pregnancy

- 645.10 Post term pregnancy, unspecified as to episode of care or not applicable
- 645.11 Post term pregnancy, delivered, with or without mention of antepartum condition Post
- 645.13 term pregnancy, antepartum condition or complication
- 645.2 Prolonged pregnancy
- 645.20 Prolonged pregnancy, unspecified as to episode of care or not applicable Prolonged
- 645.21 pregnancy, delivered, with or without mention of antepartum condition Prolonged
- 645.23 pregnancy, antepartum condition or complication
- 766.2 Late infant, not 'heavy-for-dates' Post-term
- 766.21 infant
- 766.22 Prolonged gestation of infant
- O48 Late pregnancy O48.0
- Posterm pregnancy Prolonged pregnancy
- O48.1
- P08.2 Late newborn, not heavy for gestational age Post-term P08.21 newborn
- P08.22
- Prolonged gestation of newborn 41
- Z3A.41 weeks gestation of pregnancy 42
- Z3A.42 weeks gestation of pregnancy

Z3A.49 Greater than 42 weeks gestation of pregnancy

ICD-10 CODES INDICATING PREGNANCY Dx codes: O09.XYZ Supervision of high risk pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O11 Pre-existing hypertension with pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O13 Gestational [pregnancy-induced] hypertension without significant proteinuria (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O14 Pre-eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O15 Eclampsia (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O16 Unspecified maternal hypertension (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O20 Hemorrhage in early pregnancy O21 Excessive vomiting in pregnancy (last digit refers to first/second/third/unspecified trimester) O22 Venous complications and hemorrhoids in pregnancy O23 Infections of genitourinary tract in pregnancy (last digit refers to first/second/third/unspecified trimester) O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O25 Malnutrition in pregnancy, childbirth and the puerperium (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O26 Maternal care for other conditions predominantly related to pregnancy (if last digit indicating first/second/third/unspecified trimester/unspecified as to time period) O28 Abnormal findings on antenatal screening of mother O29 Complications of anesthesia during pregnancy (last digit refers to first/second/third/unspecified trimester) O30 Multiple gestation (last digit refers to first/second/third/unspecified trimester) O31 Complications specific to multiple gestation (certain digit refers to first/second/third/unspecified trimester) O32 Maternal care for malpresentation of fetus O33 Maternal care for disproportion O34 Maternal care for abnormality of pelvic organs (most codes indicate first/second/third/unspecified trimester) O35 Maternal care for known or suspected fetal abnormality and damage O36 Maternal care for other fetal problems (codes indicate first/second/third/unspecified trimester) O40 Polyhydramnios (codes indicate first/second/third/unspecified trimester) O41 Other disorders of amniotic fluid and membranes (codes indicate first/second/third/unspecified trimester) O42.1 Premature rupture of membranes, onset of labor more than 24 hours following rupture O42.9 Premature rupture of membranes, unspecified as to length of time between rupture and onset of labor O43 Placental disorders (last digit refers to first/second/third/unspecified trimester) O44 Placenta previa (last digit refers to first/second/third/unspecified trimester) O45 Premature separation of placenta (last digit refers to first/second/third/unspecified trimester) O46 Antepartum hemorrhage, not elsewhere classified (last digit refers to first/second/third/unspecified trimester) O47 False labor O60.0 Preterm labor without delivery O61 Failed induction of labor O71.0 Rupture of uterus (spontaneous) before onset of labor O72 Postpartum hemorrhage O72.2 Delayed and secondary postpartum hemorrhage O72.3 Postpartum coagulation defects 073 Retained placenta and membranes, without hemorrhage O75 Other complications of labor and delivery, not elsewhere classified O94 Sequelae of complication of pregnancy, childbirth, and the puerperium O98 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) O9A Maternal malignant neoplasms, traumatic injuries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates first trimester, second trimester, third trimester, unspecified, or nothing) Z32.01 Encounter for pregnancy test - result positive Z33 Pregnant state Z34 Encounter for supervision of normal pregnancy Z36 Encounter for antenatal screening of mother Z39 Encounter for maternal postpartum care and examination Z39.1 Encounter for care and examination of lactating mother Z39.2 Encounter for routine postpartum follow-up Z3A Weeks of gestation Proc codes: 102 Change 109 Drainage 10H Insertion 10J Inspection 10P Removal 10Q Repair

10S Reposition . 10Y Transplantation ICD-10 CODES INDICATING DELIVERY (diagnostic codes that were not considered in the algorithm to identify delive ries) Dx codes: Use the following codes only if the last digit indicates childbirth or puerperium or labor O10 Pre-existing hypertension complicating pregnancy, childbirth and the puerperium O11 Pre-existing hypertension with pre-eclampsia O12 Gestational [pregnancy-induced] edema and proteinuria without hypertension O13 Gestational [pregnancy-induced] hypertension without significant proteinuria O14 Pre-eclampsia O15 Eclampsia O16 Unspecified maternal hypertension O24 Diabetes mellitus in pregnancy, childbirth, and the puerperium O25 Malnutrition in pregnancy, childbirth and the puerperium O26 Maternal care for other conditions predominantly related to pregnancy O42.0 Premature rupture of membranes, onset of labor within 24 hours of rupture, except 042.011 (first trimester) O48 Late pregnancy O60.1 Preterm labor with preterm delivery O60.2 Term delivery with preterm labor O62 Abnormalities of forces of labor O63 Long labor O64 Obstructed labor due to malposition and malpresentation of fetus 065 Obstructed labor due to maternal pelvic abnormality O66 Other obstructed labor O67 Labor and delivery complicated by intrapartum hemorrhage, not elsewhere classified O68 Labor and delivery complicated by abnormality of fetal acid-base balance O69 Labor and delivery complicated by umbilical cord complications 070 Perineal laceration during delivery 071.1 Rupture of uterus during labor O71.2 Postpartum inversion of uterus O71.3 Obstetric laceration of cervix O71.4 Obstetric high vaginal laceration alone O72.0 Third-stage hemorrhage O72.1 Other immediate postpartum hemorrhage O74 Complications of anesthesia during labor and delivery O76 Abnormality in fetal heart rate and rhythm complicating labor and delivery 077 Other fetal stress complicating labor and delivery O80 Encounter for full-term uncomplicated delivery O82 Encounter for cesarean delivery without indication O98 Maternal infectious and parasitic diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium) O99 Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium) O9A Maternal malignant neoplasms, traumatic injuries and abuse classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (if last digit indicates childbirth or puerperium) Z37 Outcome of delivery (For livebirth cohort, exclude Z37.1, Z37.4, Z37.7 - all stillbirth codes) Z38 Liveborn infants according to place of birth and type of delivery ICD-10 CODES INDICATING PREGNANCY WITH ABORTIVE/NON-LIVE BIRTH OUTCOMES Dx codes: O00-O08 Pregnancy with abortive outcome Proc codes: 10A Abortion 10D17Z9 Manual Extraction of Products of Conception, Retained, Via Natural or Artificial Opening 10D17ZZ Extraction of Products of Conception, Retained, Via Natural or Artificial Opening 10D18Z9 Manual Extraction of Products of Conception. Retained, Via Natural or Artificial Opening Endoscopic 10D18ZZ Extraction of Products of Conception, Retained, Via Natural or Artificial Opening Endoscopic ICD-10 CODES INDICATING ECTOPIC PREGNAN CY 10D27ZZ Extraction of Products of Conception, Ectopic, Via Natural or Artificial Opening 10D28ZZ Extraction of Products of Conception, Ectopic, Via Natural or Artificial Opening Endoscopic 10S2 Reposition Products of Conception, Ectopic

10T Resection (Ectopic)

Unmatched Optum MarketScan Medicare Pooled												
		-										
riable mber of patients	Rivaroxaban 39.574	Apixaban 72.261	St. Diff	Rivaroxaban 41.932	Apixaban 49.503	St. Diff	Rivaroxaban 148.933	Apixaban 176.546	St. Diff	Rivaroxaban 230.439	Apixaban 298.310	St. Diff
	,	,			,							
ean (sd)	71.62 (10.97)	74.33 (10.14)	-0.26	66.38 (12.81) 65.00 (58.00.	68.13 (13.18)	-0.13	76.19 (8.31) 76.00 [70.00,	77.68 (8.32) 77.00 [72.00,	-0.18	73.62 (9.75)	75.28 (9.73)	-0.17
edian (IOR)	73.00 [66.00, 80.00]	75.00 [68.00, 82.00]	-0.19	76.00]	67.00 [59.00, 79.00]	-0.15	82.00]	77.00 [72.00, 84.00]	-0.12	73.48 (9.75)	74.86 (9.73)	-0.14
categories							,					
- 54; n (%)	2,971 (7.5%)	3,087 (4.3%)	0.14	6,634 (15.8%)	6,712 (13.6%)	0.06	1,576 (1.1%)	1,057 (0.6%)	0.05	11,181 (4.9%)	10,856 (3.6%)	0.06
i - 64; n (%) i - 74: n (%)	5,841 (14.8%) 13 453 (34 0%)	7,454 (10.3%) 22 947 (31.8%)	0.14	14,308 (34.1%) 8 881 (21.2%)	16,051 (32.4%) 9 746 (19.7%)	0.04	4,325 (2.9%) 59,453 (39,9%)	3,681 (2.1%) 61,457 (34,8%)	0.05	24,474 (10.6%) 81,787 (35.5%)	27,186 (9.1%) 94,150 (31.6%)	0.05
- /4; n (%) : 75; n (%)	13,453 (34.0%) 17,309 (43.7%)	22,947 (31.8%) 38,773 (53.7%)	-0.20	8,881 (21.2%) 12,109 (28.9%)	9,746 (19.7%) 16,994 (34.3%)	-0.12	59,453 (39.9%) 83,579 (56.1%)	61,457 (34.8%) 110,351 (62.5%)		81,787 (35.5%) 112,997 (49.0%)	94,150 (31.6%) 166,118 (55.7%)	
ndar Year	11,000 (40.176)	30,113 (33.176)	-0.20	12,103 (20.376)	10,334 (34.376)	-0.12	00,010 (00.176)	110,551 (02.576)	-0.10	112,007 (40.070)	100,110 (00.170	1) -0.15
12-2013; n (%)	4,197 (10.6%)	867 (1.2%)	0.41	9,233 (22.0%)	2,364 (4.8%)		25,035 (16.8%)	6,172 (3.5%)				_
14; n (%)	4,602 (11.6%)	2,864 (4.0%)	0.29	9,189 (21.9%)	5,504 (11.1%)	0.29	31,251 (21.0%)	22,092 (12.5%)	0.23	45,042 (19.5%)	30,460 (10.2%)	
15; n (%) 16: n (%)	4,140 (10.5%) 4,683 (11.8%)	4,852 (6.7%) 7,836 (10.8%)	0.14	5,973 (14.2%) 5,979 (14.3%)	6,793 (13.7%) 9.613 (19.4%)	0.01 -0.14	28,517 (19.1%) 29.375 (19.7%)	38,857 (22.0%) 54,270 (30.7%)	-0.07 -0.26	38,630 (16.8%) 40,037 (17.4%)	50,502 (16.9%) 71,719 (24.0%)	
17; n (%)	6.255 (15.8%)	11.432 (15.8%)	0.00	4.651 (11.1%)	8.328 (16.8%)	-0.17	34.755 (23.3%)	55,155 (31.2%)	-0.18	45.661 (19.8%)	74.915 (25.1%)	-0.13
18; n (%)	6,939 (17.5%)	16,269 (22.5%)	-0.13	3,747 (8.9%)	8,107 (16.4%)	-0.23	0 (0.0%)	0 (0.0%)	0.00	10,686 (4.6%)	24,376 (8.2%)	-0.15
19; n (%)	6,025 (15.2%)	18,766 (26.0%)	-0.27	3,160 (7.5%)	8,794 (17.8%)	-0.31	0 (0.0%)	0 (0.0%)	0.00	9,185 (4.0%)	27,560 (9.2%)	-0.21
20; n (%)	2,733 (6.9%)	9,375 (13.0%)	-0.20	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	2,733 (1.2%)	9,375 (3.1%)	-0.13
e hite; n (%)	30,226 (76.4%)	54,845 (75.9%)	0.01	0 (0.0%)	0 (0.0%)	0.00	135,426 (90.9%)	162,189 (91.9%)	-0.04	165,652 (71.9%)	217.034 (72.8%)	) -0.02
ian; n (%)	1,106 (2.8%)	1,674 (2.3%)	0.03	0 (0.0%)	0 (0.0%)	0.00	2,255 (1.5%)	2,276 (1.3%)	0.02	3,361 (1.5%)	3,950 (1.3%)	0.02
ick; n (%)	3,074 (7.8%)	6,306 (8.7%)	-0.03	0 (0.0%)	0 (0.0%)	0.00	5,771 (3.9%)	6,463 (3.7%)	0.01	8,845 (3.8%)	12,769 (4.3%)	-0.03
spanic; n (%)	3,338 (8.4%)	5,831 (8.1%)	0.01	0 (0.0%)	0 (0.0%)	0.00	1,831 (1.2%)	1,723 (1.0%)	0.02	5,169 (2.2%)	7,554 (2.5%)	-0.02
rth American Native; n (%)	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	488 (0.3%)	394 (0.2%)	0.02	488 (0.2%)	394 (0.1%)	0.03
ther; n (%)	0 (0.0%)	0 (0.0%)	0.00	0 (0.0%)	0 (0.0%)	0.00	1,695 (1.1%)	1,871 (1.1%)	0.00	1,695 (0.7%)	1,871 (0.6%)	0.01
ıknown/Missing; n (%) der	1,830 (4.6%)	3,605 (5.0%)	-0.02	0 (0.0%)	0 (0.0%)	0.00	1,467 (1.0%)	1,630 (0.9%)	0.01	3,297 (1.4%)	5,235 (1.8%)	-0.03
ales; n (%)	22,017 (55.6%)	35,331 (48.9%)	0.13	25,981 (62.0%)	28,450 (57.5%)	0.09	69,102 (46.4%)	74,655 (42.3%)	0.08	117,100 (50.8%)	138,436 (46.4%)	) 0.09
males; n (%)	17,557 (44.4%)	36,930 (51.1%)	-0.13	15,951 (38.0%)	21,053 (42.5%)	-0.09	79,831 (53.6%)	101,891 (57.7%)	-0.08	113,339 (49.2%)	159,874 (53.6%	) -0.09
ion												
ortheast; n (%)	5,135 (13.0%) 15.708 (39.7%)	8,428 (11.7%) 31,239 (43.2%)	0.04 -0.07	9,129 (21.8%)	10,796 (21.8%) 19.405 (39.2%)	0.00 -0.05	28,936 (19.4%) 58,960 (39.6%)	33,847 (19.2%) 75,552 (42.8%)	0.01 -0.07	43,200 (18.7%) 90,064 (39.1%)	53,071 (17.8%) 126,196 (42,3%)	
uth; n (%) dwest; n (%)	15,708 (39.7%) 8,152 (20.6%)	31,239 (43.2%) 14,311 (19.8%)	-0.07	15,396 (36.7%) 11,112 (26.5%)	19,405 (39.2%) 12.993 (26.2%)	-0.05	58,960 (39.6%) 33.349 (22.4%)	75,552 (42.8%) 37,469 (21.2%)	-0.07	52,613 (22.8%)	126,196 (42.3%) 64,773 (21.7%)	
uwest, n (%) ast; n (%)	10,532 (26.6%)	18,224 (25.2%)	0.02	5,984 (14.3%)	6,136 (12.4%)	0.06	27,511 (18.5%)	29,543 (16.7%)	0.05	44,027 (19.1%)	53,903 (18.1%)	
known+missing; n (%)	47 (0.1%)	59 (0.1%)	0.00	311 (0.7%)	173 (0.3%)	0.06	177 (0.1%)	135 (0.1%)	0.00	535 (0.2%)	367 (0.1%)	0.03
bined comorbidity score, 180 days												
ean (sd)	2.18 (2.11)	2.63 (2.37)	-0.20	1.53 (1.58)	1.80 (1.80)	-0.16	1.83 (1.81)	2.04 (1.95)	-0.11	1.84 (1.83)	2.14 (2.04)	-0.15
adian [IQR] style Factors	2.00 [1.00, 3.00]	2.00 [1.00, 4.00]	0.00	1.00 [0.00, 2.00	] 1.00 [0.00, 3.00]	0.00	1.00 [0.00, 3.00]	2.00 [1.00, 3.00]	-0.53	1.17 (1.83)	1.83 (2.04)	-0.34
style - Smoking : n (%)	7,264 (18.4%)	16,958 (23.5%)	-0.13	3,833 (9.1%)	5,125 (10.4%)	-0.04	31,110 (20.9%)	40,944 (23.2%)	-0.06	42,207 (18.3%)	63,027 (21.1%)	-0.07
style - Drug abuse or dependence; n (%)	635 (1.6%)	1,364 (1.9%)	-0.02	301 (0.7%)	479 (1.0%)	-0.03	930 (0.6%)	1,139 (0.6%)	0.00	1,866 (0.8%)	2,982 (1.0%)	-0.02
style - Alcohol abuse or dependence ; n (%)	942 (2.4%)	1,620 (2.2%)	0.01	789 (1.9%)	879 (1.8%)	0.01	1,437 (1.0%)	1,907 (1.1%)	-0.01	3,168 (1.4%)	4,406 (1.5%)	-0.01
norbidities	005 (4 59)	4.077 (4.09()		000/0.00/1	100 (1 00)		4 400 (4 00)	4 750 (4 00)		0.400 (4.49()	0.500 (4.0%)	
- Diabetic Retinopathy; n (%)	605 (1.5%) 2,112 (5.3%)	1,277 (1.8%) 4,428 (6.1%)	-0.02 -0.03	338 (0.8%) 1,314 (3.1%)	493 (1.0%) 1,911 (3.9%)	-0.02 -0.04	1,490 (1.0%) 5,262 (3.5%)	1,758 (1.0%) 6,754 (3.8%)	0.00	2,433 (1.1%) 8,688 (3.8%)	3,528 (1.2%) 13,093 (4.4%)	-0.01 -0.03
- Diabetic Neuropathy; n (%) - Diabetic Nephropathy; n (%)	2,112 (5.3%) 1,839 (4.6%)	4,384 (6.1%)	-0.03	658 (1.6%)	1,260 (2.5%)	-0.04	2,798 (1.9%)	4,613 (2.6%)	-0.02	5,295 (2.3%)	13,093 (4.4%) 10,257 (3.4%)	-0.03
- Diabetic Nephopadiy, if (%)	237 (0.6%)	219 (0.3%)	0.04	246 (0.6%)	217 (0.4%)	0.03	1.080 (0.7%)	971 (0.5%)	0.03	1.563 (0.7%)	1,407 (0.5%)	0.03
- Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%)	400 (1.0%)	559 (0.8%)	0.02	317 (0.8%)	311 (0.6%)	0.02	1,507 (1.0%)	1,501 (0.9%)	0.01	2,224 (1.0%)	2,371 (0.8%)	0.02
- Diabetes with unspecified complications; n (%)	613 (1.5%)	1,427 (2.0%)	-0.04	489 (1.2%)	804 (1.6%)	-0.03	1,383 (0.9%)	2,009 (1.1%)	-0.02	2,485 (1.1%)	4,240 (1.4%)	-0.03
- Diabetes mellitus without mention of complications; n (%)	9,234 (23.3%)	17,107 (23.7%)	-0.01	8,582 (20.5%)	10,171 (20.5%)	0.00	36,047 (24.2%)	41,609 (23.6%)	0.01	53,863 (23.4%)	68,887 (23.1%)	0.01
Hypertension; n (%) Hyperlipidemia: n (%)	30,179 (76.3%) 22,249 (56.2%)	58,264 (80.6%) 42,515 (58,8%)	-0.10 -0.05	27,872 (66.5%) 19.838 (47.3%)	35,203 (71.1%) 24,998 (50.5%)	-0.10 -0.06	125,532 (84.3%) 77.340 (51.9%)	151,441 (85.8%) 94,591 (53.6%)	-0.04	183,583 (79.7%) 119,427 (51.8%)	244,908 (82.1% 162,104 (54.3%)	
Acute MI; n (%)	867 (2.2%)	2,489 (3.4%)	-0.07	789 (1.9%)	1.344 (2.7%)	-0.05	3,195 (2.1%)	5,006 (2.8%)	-0.05	4,851 (2.1%)	8.839 (3.0%)	-0.06
ACS/unstable angina; n (%)	879 (2.2%)	2,265 (3.1%)	-0.06	767 (1.8%)	1,230 (2.5%)	-0.05	3,023 (2.0%)	4,598 (2.6%)	-0.04	4,669 (2.0%)	8,093 (2.7%)	-0.05
Old MI; n (%)	1,608 (4.1%)	3,799 (5.3%)	-0.06	756 (1.8%)	1,138 (2.3%)	-0.04	5,844 (3.9%)	7,866 (4.5%)	-0.03	8,208 (3.6%)	12,803 (4.3%)	-0.04
Stable angina; n (%)	1,611 (4.1%)	3,872 (5.4%)	-0.06	1,167 (2.8%)	1,781 (3.6%)	-0.05	4,421 (3.0%)	6,189 (3.5%)	-0.03	7,199 (3.1%)	11,842 (4.0%)	-0.05
Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)	9,721 (24.6%)	20,300 (28.1%)	-0.08	8,115 (19.4%)	10,947 (22.1%)	-0.07	36,938 (24.8%)	47,627 (27.0%)	-0.05	54,774 (23.8%)	78,874 (26.4%)	-0.06
Other atherosclerosis; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA: n (%)	401 (1.0%) 2,438 (6.2%)	694 (1.0%) 5,874 (8.1%)	0.00 -0.07	361 (0.9%) 1,003 (2.4%)	359 (0.7%) 1,429 (2.9%)	0.02	1,575 (1.1%) 10,355 (7.0%)	1,739 (1.0%) 14,101 (8.0%)	0.01 -0.04	2,337 (1.0%) 13,796 (6.0%)	2,792 (0.9%) 21,404 (7.2%)	0.01 -0.05
Ischemic stroke: n (%)	3.999 (10.1%)	10.074 (13.9%)	-0.12	3,344 (8.0%)	5.013 (10.1%)	-0.07	16,170 (10,9%)	23.347 (13.2%)	-0.07	23,513 (10.2%)	38,434 (12.9%)	-0.03
Hemorrhagic stroke; n (%)	82 (0.2%)	276 (0.4%)	-0.04	34 (0.1%)	92 (0.2%)	-0.03	222 (0.1%)	448 (0.3%)	-0.04	338 (0.1%)	816 (0.3%)	-0.04
TIA; n (%)	1,479 (3.7%)	3,583 (5.0%)	-0.06	1,408 (3.4%)	1,972 (4.0%)	-0.03	5,760 (3.9%)	8,392 (4.8%)	-0.04	8,647 (3.8%)	13,947 (4.7%)	-0.04
Other cerebrovascular disease; n (%)	1,318 (3.3%)	3,880 (5.4%)	-0.10	923 (2.2%)	1,671 (3.4%)	-0.07	4,627 (3.1%)	7,613 (4.3%)	-0.06	6,868 (3.0%)	13,164 (4.4%)	-0.07
Late effects of cerebrovascular disease; n (%)	1,121 (2.8%)	3,137 (4.3%)	-0.08	630 (1.5%)	1,071 (2.2%)	-0.05	3,807 (2.6%)	5,928 (3.4%)	-0.05	5,558 (2.4%)	10,136 (3.4%)	-0.06
Heart failure (CHF); n (%) Peripheral Vascular Disease (PVD) or PVD Surgery; n (%)	8,081 (20.4%) 2,975 (7.5%)	18,051 (25.0%) 6,179 (8,6%)	-0.11	6,103 (14.6%) 1,711 (4.1%)	8,903 (18.0%) 2,377 (4.8%)	-0.09 -0.03	27,605 (18.5%) 9.848 (6.6%)	37,843 (21.4%) 12,738 (7.2%)	-0.07	41,789 (18.1%) 14.534 (6.3%)	64,797 (21.7%) 21.294 (7.1%)	-0.09 -0.03
Peripheral Vascular Disease (PVD) or PVD Surgery; h (%) Other cardiac dysrhythmia; h (%)	2,975 (7.5%) 31.139 (78.7%)	67,495 (93.4%)	-0.04 -0.43	1,711 (4.1%) 25.395 (60.6%)	2,377 (4.8%) 40,703 (82.2%)	-0.03	9,848 (6.6%) 90,828 (61.0%)	12,738 (7.2%) 135,567 (76.8%)		14,534 (6.3%) 147,362 (63.9%)	21,294 (7.1%) 243,765 (81.7%)	
Cardiac conduction disorders; n (%)	3,467 (8.8%)	8,478 (11.7%)	-0.10	2,711 (6.5%)	4,261 (8.6%)	-0.08	10,666 (7.2%)	15,813 (9.0%)	-0.07	16,844 (7.3%)	28,552 (9.6%)	-0.08
Other CVD; n (%)	13,558 (34.3%)	28,521 (39.5%)	-0.11	12,470 (29.7%)	16,958 (34.3%)	-0.10	42,634 (28.6%)	57,463 (32.5%)	-0.08	68,662 (29.8%)	102,942 (34.5%)	
edications - ACE inhibitors; n (%)	12,072 (30.5%)	22,048 (30.5%)	0.00	12,189 (29.1%)	14,397 (29.1%)	0.00	47,585 (32.0%)	56,121 (31.8%)	0.00	71,846 (31.2%)	92,566 (31.0%)	
edications - ARBs; n (%)	8,626 (21.8%)	16,995 (23.5%)	-0.04	9,120 (21.7%)	11,351 (22.9%)	-0.03	35,775 (24.0%)	43,883 (24.9%)	-0.02	53,521 (23.2%)	72,229 (24.2%)	
ledications - Alpha blockers; n (%) ledications - Beta blockers; n (%)	4,439 (11.2%) 25,750 (65.1%)	8,629 (11.9%) 49,038 (67.9%)	-0.02 -0.06	3,771 (9.0%) 27,693 (66.0%)	4,739 (9.6%) 33,905 (68.5%)	-0.02 -0.05	18,034 (12.1%) 101,223 (68.0%)	20,939 (11.9%) 123,946 (70.2%)	0.01 -0.05	26,244 (11.4%) 154,666 (67,1%)	34,307 (11.5%) 206.889 (69.4%)	
ledications - Beta blockers; n (%) ledications - Loop Diuretics: n (%)	25,750 (65.1%) 7,758 (19.6%)	49,038 (67.9%) 16.454 (22.8%)	-0.06	27,693 (66.0%) 6.412 (15.3%)	33,905 (68.5%) 8,884 (17.9%)	-0.05	101,223 (68.0%) 34.111 (22.9%)	123,946 (70.2%) 44.427 (25.2%)	-0.05	154,666 (67.1%) 48,281 (21.0%)	206,889 (69.4%)	
	1,689 (4.3%)	3,660 (5.1%)	-0.08	1,526 (3.6%)	2,269 (4.6%)	-0.05	6,693 (4.5%)	8,786 (5.0%)	-0.02	9,908 (4.3%)	14,715 (4.9%)	-0.03
Medications - Other diuretics: n (%)	1.781 (4.5%)	3,976 (5.5%)	-0.05	1,561 (3.7%)	2,176 (4.4%)	-0.04	9,111 (6.1%)	12,068 (6.8%)	-0.03	12,453 (5.4%)	18,220 (6.1%)	-0.03
					23,729 (47,9%)	0.07	78.449 (52.7%)	96 679 (54 8%)	-0.04	116.527 (50.6%)	158,982 (53.3%)	0.05
Aedications - Use of nitrates; n (%) Aedications - Use of statins; n (%)	19,481 (49.2%)	38,574 (53.4%)	-0.08	18,597 (44.4%)		-0.07						
Aedications - Use of nitrates; n (%) Aedications - Use of statins; n (%) Aedications - Use of other lipid-lowering drugs; n (%)	19,481 (49.2%) 1,491 (3.8%)	2,508 (3.5%)	0.02	1,972 (4.7%)	2,064 (4.2%)	0.02	6,587 (4.4%)	7,477 (4.2%)	0.01	10,050 (4.4%)	12,049 (4.0%)	0.02
Medications - Other diuretics; n (%) Medications - Use of nitrates; n (%) Medications - Use of statins; n (%) Medications - Use of other lipid-lowering drugs; n (%) Medications - calcium channel blockers; n (%)	19,481 (49.2%) 1,491 (3.8%) 14,755 (37.3%)	2,508 (3.5%) 28,557 (39.5%)	0.02	1,972 (4.7%) 15,341 (36.6%)	2,064 (4.2%) 18,852 (38.1%)	0.02 -0.03	6,587 (4.4%) 58,925 (39.6%)	7,477 (4.2%) 70,935 (40.2%)	0.01 -0.01	10,050 (4.4%) 89,021 (38.6%)	12,049 (4.0%) 118,344 (39.7%	0.02
Medications - Use of nitrates; n (%) Medications - Use of statins; n (%) Medications - Use of other lipid-lowering drugs; n (%)	19,481 (49.2%) 1,491 (3.8%)	2,508 (3.5%)	0.02	1,972 (4.7%)	2,064 (4.2%)	0.02	6,587 (4.4%)	7,477 (4.2%)	0.01	10,050 (4.4%)	12,049 (4.0%)	0.02

Other Comorbidity - Edema; n (%)	4,035 (10.2%)	8,491 (11.8%)	-0.05	2,909 (6.9%)	3,989 (8.1%)	-0.05	11,693 (7.9%)	14,969 (8.5%)	-0.02	18,637 (8.1%)	27,449 (9.2%)	-0.04
Other Comorbidity - Depression; n (%)	3,332 (8.4%)	6,763 (9.4%)	-0.04	2,627 (6.3%)	3,222 (6.5%)	-0.01	12,001 (8.1%)	14,544 (8.2%)	0.00	17,960 (7.8%)	24,529 (8.2%)	-0.01
Other Comorbidity - Anxiety; n (%)	4,297 (10.9%)	9,395 (13.0%)	-0.06	3,242 (7.7%)	4,742 (9.6%)	-0.07	12,625 (8.5%)	16,289 (9.2%)	-0.02	20,164 (8.8%)	30,426 (10.2%)	-0.05
Other Comorbidity - Pneumonia: n (%)	2,458 (6,2%)	6.015 (8.3%)	-0.08	2.008 (4.8%)	2.892 (5.8%)	-0.04	9,669 (6,5%)	13.219 (7.5%)	-0.04	14,135 (6,1%)	22,126 (7.4%)	-0.05
Other Comorbidity - COPD: n (%)	5.572 (14.1%)	11.986 (16.6%)	-0.07	3.710 (8.8%)	4.984 (10.1%)	-0.04	20.527 (13.8%)	25,900 (14,7%)	-0.03	29,809 (12.9%)	42,870 (14.4%)	-0.04
Other Comorbidity - Cor D, n (%)	2.490 (6.3%)	4.912 (6.8%)	-0.02	2.347 (5.6%)	2.880 (5.8%)	-0.01	9,009 (6.0%)	11,077 (6.3%)	-0.01	13.846 (6.0%)	18,869 (6.3%)	-0.01
Other Comorbidity - Acute renal disease; n (%)	1.850 (4.7%)	5,496 (7.6%)	-0.12	1,224 (2.9%)	2,272 (4.6%)	-0.09	6.220 (4.2%)	10.592 (6.0%)	-0.08	9.294 (4.0%)	18,360 (6.2%)	-0.10
Other Comorbidity CKD Stage 1: n (%)	136 (0.3%)	265 (0.4%)	-0.02	61 (0.1%)	84 (0.2%)	-0.03	278 (0.2%)	319 (0.2%)	0.00	475 (0.2%)	668 (0.2%)	0.00
Other Comorbidity CKD Stage 1, n (%) Other Comorbidity - CKD Stage 2, n (%)	867 (2.2%)	1,858 (2.6%)	-0.02	281 (0.7%)	485 (1.0%)	-0.03	1,473 (1.0%)	2,126 (1.2%)	-0.02	2,621 (1.1%)	4,469 (1.5%)	-0.04
Other Comorbidity - CKD Stage 2; n (%) Other Comorbidity - CKD Stage 3; n (%)	3.551 (9.0%)	8.834 (12.2%)	-0.10	1,276 (3.0%)	2.358 (4.8%)	-0.09	7,918 (5.3%)	13,220 (7.5%)	-0.02	12,745 (5.5%)	24,412 (8.2%)	-0.11
	3,551 (9.0%)	4.451 (6.2%)		863 (2.1%)	2,356 (4.6%) 1.459 (2.9%)		7,918 (5.3%) 5.890 (4.0%)	8.882 (5.0%)		8.577 (3.7%)	24,412 (0.2%)	
Other Comorbidity - Occurrence of chronic renal insufficiency w/o CKD ; n (%)			-0.07 -0.06			-0.05			-0.05 -0.03			-0.06
Other Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%)	2,103 (5.3%) 2,884 (7.3%)	4,886 (6.8%)	-0.06	1,364 (3.3%)	2,249 (4.5%) 2,361 (4.8%)	-0.06	6,344 (4.3%)	8,864 (5.0%)	-0.03	9,811 (4.3%)	15,999 (5.4%)	-0.05
Other Comorbidity - Hypertensive nephropathy; n (%)	=,== (	7,839 (10.8%)		1,129 (2.7%)	=,==: (,)		8,281 (5.6%)	13,721 (7.8%)		12,294 (5.3%)	23,921 (8.0%)	
Other Comorbidity - Obstructive sleep apnea; n (%)	4,313 (10.9%)	7,717 (10.7%)	0.01	5,200 (12.4%)	6,858 (13.9%)	-0.04	9,174 (6.2%)	11,567 (6.6%)	-0.02	18,687 (8.1%)	26,142 (8.8%)	-0.03
Other Comorbidity - Osteoarthritis; n (%)	8,123 (20.5%)	16,520 (22.9%)	-0.06	6,591 (15.7%)	7,983 (16.1%)	-0.01	31,918 (21.4%)	38,031 (21.5%)	0.00	46,632 (20.2%)	62,534 (21.0%)	-0.02
Other Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%)	15,178 (38.4%)	29,550 (40.9%)	-0.05	14,428 (34.4%)	17,421 (35.2%)	-0.02	54,846 (36.8%)	65,149 (36.9%)	0.00	84,452 (36.6%)	112,120 (37.6%)	
Other Comorbidity - Dorsopathies; n (%)	8,826 (22.3%)	17,719 (24.5%)	-0.05	8,294 (19.8%)	10,115 (20.4%)	-0.01	30,828 (20.7%)	38,050 (21.6%)	-0.02	47,948 (20.8%)	65,884 (22.1%)	-0.03
Other Comorbidity - Fractures; n (%)	1,798 (4.5%)	3,589 (5.0%)	-0.02	1,485 (3.5%)	1,806 (3.6%)	-0.01	7,167 (4.8%)	8,538 (4.8%)	0.00	10,450 (4.5%)	13,933 (4.7%)	-0.01
Other Comorbidity - Falls; n (%)	2,265 (5.7%)	5,681 (7.9%)	-0.09	834 (2.0%)	1,462 (3.0%)	-0.06	2,974 (2.0%)	4,471 (2.5%)	-0.03	6,073 (2.6%)	11,614 (3.9%)	-0.07
Other Comorbidity - Sleep Disorder; n (%)	2,301 (5.8%)	2,499 (3.5%)	0.11	3,477 (8.3%)	2,600 (5.3%)	0.12	8,065 (5.4%)	7,074 (4.0%)	0.07	13,843 (6.0%)	12,173 (4.1%)	0.09
Other Comorbidity - Delirium; n (%)	953 (2.4%)	2,815 (3.9%)	-0.09	596 (1.4%)	1,051 (2.1%)	-0.05	3,460 (2.3%)	5,237 (3.0%)	-0.04	5,009 (2.2%)	9,103 (3.1%)	-0.06
Other Comorbidity - Psychosis; n (%)	468 (1.2%)	911 (1.3%)	-0.01	352 (0.8%)	356 (0.7%)	0.01	2,692 (1.8%)	2,582 (1.5%)	0.02	3,512 (1.5%)	3,849 (1.3%)	0.02
Procedures												
Procedure - Hip Surgery; n (%)	258 (0.7%)	327 (0.5%)	0.03	272 (0.6%)	127 (0.3%)	0.04	1,111 (0.7%)	668 (0.4%)	0.04	1,641 (0.7%)	1,122 (0.4%)	0.04
Medications												
DM Medications - Meglitinides; n (%)	82 (0.2%)	127 (0.2%)	0.00	105 (0.3%)	111 (0.2%)	0.02	437 (0.3%)	536 (0.3%)	0.00	624 (0.3%)	774 (0.3%)	0.00
DM Medications - AGIs; n (%)	24 (0.1%)	48 (0.1%)	0.00	19 (0.0%)	27 (0.1%)	-0.04	119 (0.1%)	131 (0.1%)	0.00	162 (0.1%)	206 (0.1%)	0.00
DM Medications - Insulin; n (%)	1,672 (4.2%)	3,346 (4.6%)	-0.02	1,725 (4.1%)	2,154 (4.4%)	-0.01	5,099 (3.4%)	6,366 (3.6%)	-0.01	8,496 (3.7%)	11,866 (4.0%)	-0.02
DM Medications - Glitazones; n (%)	427 (1.1%)	755 (1.0%)	0.01	491 (1.2%)	536 (1.1%)	0.01	1,616 (1.1%)	1,879 (1.1%)	0.00	2,534 (1.1%)	3,170 (1.1%)	0.00
DM Medications - 1st and 2nd Generation SUs ; n (%)	2,450 (6.2%)	4,496 (6.2%)	0.00	2,195 (5.2%)	2,581 (5.2%)	0.00	9,651 (6.5%)	11,098 (6.3%)	0.01	14,296 (6.2%)	18,175 (6.1%)	0.00
DM Medications - DPP-4 Inhibitors; n (%)	1,017 (2.6%)	1,789 (2.5%)	0.01	1,326 (3.2%)	1,571 (3.2%)	0.00	4,342 (2.9%)	5,080 (2.9%)	0.00	6,685 (2.9%)	8,440 (2.8%)	0.01
DM Medications - GLP-1 RA; n (%)	380 (1.0%)	667 (0.9%)	0.01	561 (1.3%)	713 (1.4%)	-0.01	937 (0.6%)	1,146 (0.6%)	0.00	1,878 (0.8%)	2,526 (0.8%)	0.00
DM Medications - SGLT-2 Inhibitors ; n (%)	337 (0.9%)	636 (0.9%)	0.00	417 (1.0%)	604 (1.2%)	-0.02	561 (0.4%)	719 (0.4%)	0.00	1,315 (0.6%)	1,959 (0.7%)	-0.01
DM Medications - Metformin; n (%)	5,305 (13.4%)	9,656 (13.4%)	0.00	5,176 (12.3%)	6,296 (12.7%)	-0.01	18,756 (12.6%)	21,308 (12.1%)	0.02	29,237 (12.7%)	37,260 (12.5%)	0.01
DM Medciations - All antidiabetic medications except Insulin; n (%)	6,751 (17.1%)	12,368 (17.1%)	0.00	6,546 (15.6%)	7,917 (16.0%)	-0.01	24,529 (16.5%)	28,633 (16.2%)	0.01	37,826 (16.4%)	48,918 (16.4%)	0.00
Other Medications - Use of NSAIDs; n (%)	4,868 (12.3%)	8,492 (11.8%)	0.02	5,670 (13.5%)	6,544 (13.2%)	0.01	20,367 (13.7%)	22,723 (12.9%)	0.02	30,905 (13.4%)	37,759 (12.7%)	0.02
Other Medications - Use of other hypertension drugs; n (%)	2,563 (6.5%)	5,347 (7.4%)	-0.04	2,190 (5.2%)	2,886 (5.8%)	-0.03	11,081 (7.4%)	13,753 (7.8%)	-0.02	15,834 (6.9%)	21,986 (7.4%)	-0.02
Other Medications - Digoxin; n (%)	2,782 (7.0%)	4,295 (5.9%)	0.04	3,135 (7.5%)	3,139 (6.3%)	0.05	13,993 (9.4%)	14,506 (8.2%)	0.04	19,910 (8.6%)	21,940 (7.4%)	0.04
Other Medications - Use of Anti-arrhythmics; n (%)	6,439 (16.3%)	12,185 (16.9%)	-0.02	8,417 (20.1%)	9,802 (19.8%)	0.01	26,511 (17.8%)	33,196 (18.8%)	-0.03	41,367 (18.0%)	55,183 (18.5%)	-0.01
Other Medications - Use of antipsychotics; n (%)	711 (1.8%)	1,467 (2.0%)	-0.01	540 (1.3%)	716 (1.4%)	-0.01	3,972 (2.7%)	4,311 (2.4%)	0.02	5,223 (2.3%)	6,494 (2.2%)	0.01
Other Medications - Use of dementia meds; n (%)	1,201 (3.0%)	2,716 (3.8%)	-0.04	805 (1.9%)	1,121 (2.3%)	-0.03	6,454 (4.3%)	8,240 (4.7%)	-0.02	8,460 (3.7%)	12,077 (4.0%)	-0.02
Other Medications - Use of antiparkinsonian meds; n (%)	938 (2.4%)	1,975 (2.7%)	-0.02	806 (1.9%)	1,036 (2.1%)	-0.01	4,637 (3.1%)	5,777 (3.3%)	-0.01	6,381 (2.8%)	8,788 (2.9%)	-0.01
Other Medications - Use of anxiolytics/hypnotics; n (%)	1,964 (5.0%)	3,281 (4.5%)	0.02	2,493 (5.9%)	2,780 (5.6%)	0.01	9,800 (6.6%)	10,633 (6.0%)	0.02	14,257 (6.2%)	16,694 (5.6%)	0.03
Other Medications - Use of anticonvulsants; n (%)	4,174 (10.5%)	8,578 (11.9%)	-0.04	3,272 (7.8%)	4,291 (8.7%)	-0.03	16,973 (11.4%)	21,290 (12.1%)	-0.02	24,419 (10.6%)	34,159 (11.5%)	-0.03
Other Medications - Use of antidepressants; n (%)	7,779 (19.7%)	15,737 (21.8%)	-0.05	7,164 (17.1%)	9,240 (18.7%)	-0.04	32,504 (21.8%)	39,863 (22.6%)	-0.02	47,447 (20.6%)	64,840 (21.7%)	-0.03
Other Medications - Use of lithium; n (%)	40 (0.1%)	62 (0.1%)	0.00	35 (0.1%)	42 (0.1%)	0.00	156 (0.1%)	176 (0.1%)	0.00	231 (0.1%)	280 (0.1%)	0.00
Other Medications - Use of Benzos; n (%)	4,562 (11.5%)	8,618 (11.9%)	-0.01	4,763 (11.4%)	5,528 (11.2%)	0.01	20,836 (14.0%)	25,436 (14.4%)	-0.01	30,161 (13.1%)	39,582 (13.3%)	-0.01
Other Medication - Use of CNS stimulants; n (%)	118 (0.3%)	209 (0.3%)	0.00	218 (0.5%)	251 (0.5%)	0.00	404 (0.3%)	585 (0.3%)	0.00	740 (0.3%)	1,045 (0.4%)	-0.02
Other Medications - Use of opioids; n (%)	8,286 (20.9%)	14,637 (20.3%)	0.01	9,023 (21.5%)	9,723 (19.6%)	0.05	37,183 (25.0%)	41,507 (23.5%)	0.04	54,492 (23.6%)	65,867 (22.1%)	0.04
Other Medications - Use of COPD/asthma meds; n (%)	6,602 (16.7%)	13,136 (18.2%)	-0.04	6,715 (16.0%)	8,410 (17.0%)	-0.03	28,575 (19.2%)	35,038 (19.8%)	-0.02	41,892 (18.2%)	56,584 (19.0%)	-0.02
Other Medications - Use of oral corticosteroids; n (%)	7,388 (18.7%)	14,755 (20.4%)	-0.04	7,541 (18.0%)	9,394 (19.0%)	-0.03	31,608 (21.2%)	38,479 (21.8%)	-0.01	46,537 (20.2%)	62,628 (21.0%)	-0.02
Other Medications - Use of Sympatomimetic agents; n (%)	207 (0.5%)	292 (0.4%)	0.01	375 (0.9%)	426 (0.9%)	0.00	483 (0.3%)	490 (0.3%)	0.00	1,065 (0.5%)	1,208 (0.4%) 9,918 (3.3%)	0.01
Other Medications - Use of bisphosphonates; n (%)	1,255 (3.2%)	2,648 (3.7%)	-0.03	768 (1.8%)	1,035 (2.1%)	-0.02	5,308 (3.6%)	6,235 (3.5%)	0.01	7,331 (3.2%)		-0.01
Other Medications - Use of thiazide; n (%)	4 300 (10 9%)	8.543 (11.8%)	-0.03	4,137 (9.9%)	5,433 (11.0%)	-0.04	18,800 (12.6%)	22,881 (13.0%)	-0.01			
Other Medications - Use of estrogens, progestins, androgens; n (%)	.,	-,,						/		27,237 (11.8%)	36,857 (12.4%)	-0.02
	1,333 (3.4%)	2,276 (3.1%)	0.02	2,202 (5.3%)	2,415 (4.9%)	0.02	5,873 (3.9%)	6,737 (3.8%)	0.01	27,237 (11.8%) 9,408 (4.1%)		-0.02 0.02
Healthcare Utilization	1,333 (3.4%)	1			,,					9,408 (4.1%)	36,857 (12.4%) 11,428 (3.8%)	0.02
HU - Bone mineral density; n (%)	1,333 (3.4%) 1,408 (3.6%)	2,795 (3.9%)	-0.02	635 (1.5%)	804 (1.6%)	-0.01	6,141 (4.1%)	7,455 (4.2%)	-0.01	9,408 (4.1%) 8,184 (3.6%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%)	-0.01
HU - Bone mineral density; n (%) HU - Occurrence of creatinine tests ordered ; n (%)	1,333 (3.4%)	1			,,					9,408 (4.1%)	36,857 (12.4%) 11,428 (3.8%)	0.02
HU - Bone mineral density; n (%)	1,333 (3.4%) 1,408 (3.6%)	2,795 (3.9%)	-0.02	635 (1.5%)	804 (1.6%)	-0.01	6,141 (4.1%)	7,455 (4.2%)	-0.01	9,408 (4.1%) 8,184 (3.6%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%)	-0.01
HU - Bone mineral density; n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22)	-0.02 0.00 0.00	635 (1.5%) 1,800 (4.3%) 0.04 (0.23)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23)	-0.01 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21)	-0.01 0.00 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22)	-0.01 0.00 0.00
HU - Bone mineral density; n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meaian (tol) median (tolR)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%)	2,795 (3.9%) 3,659 (5.1%)	-0.02 0.00	635 (1.5%) 1,800 (4.3%)	804 (1.6%) 2,056 (4.2%)	-0.01 0.00	6,141 (4.1%) 10,228 (6.9%)	7,455 (4.2%) 12,445 (7.0%)	-0.01 0.00 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%)	-0.02 -0.01 0.00
HU - Bone mineral density; n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests mean (sd)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22)	-0.02 0.00 0.00	635 (1.5%) 1,800 (4.3%) 0.04 (0.23)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23)	-0.01 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21)	-0.01 0.00 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22)	-0.01 0.00 0.00
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (sd) HU - Number of CRP, high-sensitivity CRP tests mean (sd)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39)	-0.02 0.00 0.00 0.00	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30)	-0.01 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42)	-0.01 0.00 0.00 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40)	-0.02 -0.01 0.00 0.00 0.00
HU - Bone mineral density; n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests mean (sd) median [IQR] HU - Number of CRP, high-sensitivity CRP tests	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00]	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00]	-0.02 0.00 0.00 0.00 0.00	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00]	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00]	-0.01 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00]	-0.01 0.00 0.00 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40)	0.02 -0.01 0.00 0.00 0.00 0.00
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meainn [I0R] HU - Number of CRP, high-sensitivity CRP tests meainn [I0R] meainn [I0R]	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00]	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00]	-0.02 0.00 0.00 0.00 0.00 0.00	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00]	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00]	-0.01 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00]	-0.01 0.00 0.00 0.00 0.00 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00
HU - Bone mineral density; n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (d0) median [IQR] HU - Number of CRP, high-sensitivity CRP tests meain (d0) median [IQR] HU - Colonoscopy; n (%)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1,806 (4.3%) 5,148 (12.3%)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 48,520 (32.6%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.02	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0
HU - 6 one mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests median [IQR] HU - Number of CRP, high-sensitivity CRP tests median [IQR] HU - Colonoscopy: n (%) HU - Colonoscopy: n (%)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%)	2.795 (3.9%) 3.659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2.615 (3.6%) 12.910 (17.9%)	-0.02 0.00 0.00 0.00 0.00 0.00 0.02 0.01	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1,806 (4.3%) 5,148 (12.3%) 2,525 (6.0%)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 3,114 (6.3%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.02 -0.01	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 60,955 (26.5%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 28,207 (9.5%)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.02
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests mealan [t0R] HU - Number of CRP, high-sensitivity CRP tests mealan [t0R] HU - Colonescopy: n (%) HU - Flu vaccher, n (%)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 (0.00, 0.00] 0.07 (0.38) 0.00 (0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,563 (9.1%) 8,448 (11.7%)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1,806 (4.3%) 5,148 (12.3%)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.09 (0.43) 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 48,520 (32.6%) 15,435 (10.4%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 60,955 (26.5%) 21,426 (9.3%) 29,977 (13.0%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 28,207 (9.5%) 33,672 (11.3%)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests median [IQR] HU - Number of CRP, high-sensitivity CRP tests median [IQR] HU - Colonoscopy: n (%) HU - Colonoscopy: n (%) HU - Pla vecine: n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,667 (14.3%) 647 (16.5%)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 (0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,563 (9.1%) 8,448 (11.7%) 1,135 (1.6%)	-0.02 0.00 0.00 0.00 0.00 0.02 0.02 0.01 -0.01 0.08	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1.806 (4.3%) 5.148 (12.3%) 5.233 (12.5%) 1.022 (2.4%)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.05 (0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,439 (11.0%) 1,180 (2.4%)	-0.01 -0.00 0.00 0.00 0.00 0.00 0.00 0.0	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.100 [0.00, 0.00] 6,130 (4.1%) 48,520 (32.6%) 15,435 (10.4%) 19,077 (12.8%) 3,638 (2.4%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 19,785 (11.2%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.05	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 60,955 (26.5%) 21,426 (9.3%) 29,977 (13.0%) 5,308 (2.3%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.08 (0.40) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 33,672 (11.3%)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.02
HU - Bone mineral density: n (%) HU - Normber of Dreatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (IdR) HU - Number of CRP, high-sensitivity CRP tests mean (a) median (IDR) HU - Colonescopy: n (%) HU - Hu accher; n (%) HU - Mammogram; n (%)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,666 (8.8%) 5,687 (14.3%)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,563 (9.1%) 8,448 (11.7%)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1,806 (4.3%) 5,148 (12.3%) 2,525 (6.0%) 5,233 (12.5%)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,439 (11.0%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 6,130 (4.1%) 48,520 (32.6%) 15,435 (10.4%) 19,077 (12.8%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 19,785 (11.2%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.05 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 60,955 (26.5%) 21,426 (9.3%) 29,977 (13.0%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 28,207 (9.5%) 33,672 (11.3%)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain [t0R] HU - Number of CRP, high-sensitivity CRP tests meain(sd) median [t0R] HU - Golonescoy: n (%) HU - Flu vaccine: n (%) HU - Plu vaccine: n (%) HU - Pag smaar: n (%) HU - Pag smaar: n (%)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,667 (14.3%) 647 (16.5%)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 (0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,563 (9.1%) 8,448 (11.7%) 1,135 (1.6%)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1.806 (4.3%) 5.148 (12.3%) 5.233 (12.5%) 1.022 (2.4%)	804 (1.6%) 2,056 (4.2%) 0.04 (0.23) 0.05 (0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,439 (11.0%) 1,180 (2.4%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.100 [0.00, 0.00] 6,130 (4.1%) 48,520 (32.6%) 15,435 (10.4%) 19,077 (12.8%) 3,638 (2.4%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 19,785 (11.2%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.05 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 60,955 (26.5%) 21,426 (9.3%) 29,977 (13.0%) 5,308 (2.3%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.08 (0.40) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 33,672 (11.3%)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests median [IQR] HU - Number of CRP, high-sensitivity CRP tests median [IQR] HU - Colonoscopy: n (%) HU - Colonoscopy: n (%) HU - Namogram. n (%) HU - Manmogram. n (%) HU - Pagesmaer. n (%) HU - Pagesmaer. n (%) HU - Pagesmaer. n (%) HU - Pagesmaer. n (%)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,666 (8.8%) 5,667 (14.3%) 847 (1.6%) 7,329 (18.5%)	2,795 (3.9%) 3,659 (5.1%) 0.04 (0.22) 0.00 (0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,656 (3.1%) 8,448 (11.7%) 1,135 (1.6%) 16,159 (22.4%)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 0.00 -0.10	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1.806 (4.3%) 5.148 (12.3%) 2.525 (6.0%) 1.022 (2.4%) 3.782 (9.0%)	804 (1.6%) 2.056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2.083 (4.2%) 6.004 (12.1%) 5.439 (11.0%) 1.180 (2.4%) 6.392 (12.9%) 0.17 (0.05)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 (0.00, 0.00) 0.09 (0.43) 0.00 (0.00, 0.00) 6,130 (4.1%) 48,520 (32.6%) 15,435 (10.4%) 3,636 (2.4%) 3,2,767 (22.0%)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.09 (0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 19,785 (11.2%) 4,177 (2.4%) 51,792 (29.3%)	-0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 20,955 (26.5%) 21,426 (9.3%) 29,977 (13.0%) 43,878 (19.0%)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.08 (0.40) 0.00 (0.40) 0.00 (0.22) 0.08 (0.40) 0.00 (0.42) 0.00 (0.40) 0.00 (0.42) 0.00 (0.40) 0.00 (0.42) 0.00 (0.40) 0.00 (0.42) 0.00 (0.40) 0.00 (0.42) 0.00 (0.40) 0.00 (0.42) 0.00 (0.40) 0.00 (0.4	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.02
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (s0) mealian [ICR] HU - Number of CRP, high-sensitivity CRP tests mean (s0) mealian [ICR] HU - Solonecopy: n (%) HU - Flu vaccine; n (%) HU - Flu vaccine; n (%) HU - Pap smar; n (%) HU - Pap smar; n (%) Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) V2 mean (s0)	1.333 (3.4%) 1.408 (3.6%) 1.968 (5.0%) 0.04 (0.21) 0.07 (0.38) 0.00 [0.00, 0.00] 1.530 (3.9%) 7.287 (18.4%) 5.667 (14.3%) 647 (1.6%) 7.329 (18.5%) 0.18 (0.06)	2,755 (3.9%) 3,559 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,653 (3.1%) 8,444 (17.7%) 1,135 (1.6%) 16,159 (22.4%) 0.19 (0.06) 0.18 [0.15, 0.22]	-0.02 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17	635 (1.5%) 1,800 (4.3%) 0.04 (0.23) 0.00 (0.00, 0.00] 0.00 (0.00, 0.00] 1,806 (4.3%) 5,144 (12.3%) 5,252 (6.0%) 5,233 (12.5%) 1,022 (2.4%) 0,762 (0.0%) 0,17 (0.05)	804 (1.6%) 2.056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2.083 (4.2%) 6.004 (12.1%) 5.439 (11.0%) 1.180 (2.4%) 6.392 (12.9%) 0.17 (0.05)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.05 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 48,520 (32.6%) 15,435 (10.42%) 19,077 (12.8%) 3,636 (2.4%) 0.19 (0.06)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 19,785 (11.2%) 51,792 (29.3%) 0.19 (0.06)	-0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0	9,408 (4,1%) 8,184 (3.6%) 13,996 (6,1%) 0.04 (0.21) 0.08 (0.40) 0.00 (0.21) 9,466 (4,1%) 60,955 (26.5%) 29,977 (13.0%) 5,3878 (10.0%) 0.18 (0.06) 0.17 (0.06)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 11,054 (3.7%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 28,207 (9.5%) 33,672 (12.3%) 74,343 (24.9%) 0.19 (0.06) 0.18 (0.06)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.00 0.01
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain [IQR] HU - Number of CRP, high-sensitivity CRP tests meain (IQR] HU - Colonoscopy: n (%) HU - Colonoscopy: n (%) HU - Valumogram. n (%) HU - Pag smaar. n (%) HU - Pag smaar. n (%) HU - Pag smaar. n (%) Frailly Score. Empirical Version 365 days (ICD-9 and ICD-10) V2 meain (IQR) CHADS2 score. 180 CHADS2 sco	1.333 (3.4%) 1.408 (3.6%) 1.968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1.530 (3.9%) 7.287 (18.4%) 3.466 (8.8%) 5.667 (14.3%) 647 (1.6%) 7.329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1.41 (1.24)	2,755 (39%) 3,659 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,553 (0.1%) 8,648 (11.7%) 1,135 (1.6%) 16,159 (22.4%) 0.19 (0.06) 0.19 (0.06) 0.19 (0.06)	-0.02 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 -0.01 -0.17 -0.17 -0.09	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 (0.00, 0.00) 0.05 (0.29) 0.00 (0.00, 0.00] 1.806 (4.3%) 2.525 (6.0%) 5.233 (1255 (6.0%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19)	804 (1.5%) 2.056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2.083 (4.2%) 6.004 (12.1%) 5.439 (11.0%) 1.180 (2.4%) 6.392 (12.9%) 0.17 (0.05) 0.16 [0.14, 0.19] 1.23 (1.24)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6.141 (4.1%) 10.228 (6.9%) 0.04 (0.21) 0.09 (0.00, 0.00) 6.130 (4.1%) 14,520 (32.6%) 15,435 (10.4%) 3,636 (2.4%) 3,636 (2.4%) 3,636 (2.4%) 0.19 (0.06) 0.17 (0.14, 0.21] 1.37 (1.22)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 19,785 (11.2%) 4,177 (2.4%) 51,792 (29.3%) 51,792 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12)	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 13,996 (6.1%) 0.00 (0.21) 0.08 (0.40) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 60,955 (22.65%) 21,426 (9.3%) 23,977 (13.0%) 5,306 (2.3%) 43,878 (19.0%) 0.18 (0.06) 1.35 (1.22)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 28,207 (9.5%) 33,672 (11.3%) 6,492 (2.2%) 74,343 (24.9%) 0.19 (0.06) 0.18 (0.06) 1.28 (1.18)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.05 0.01 -0.17 -0.17 0.06
HU - Bone mineral density: n (%) HU - Bone mineral density: n (%) HU - Number of D-dimer tests meainn (tol) HU - Number of CRP, high-sensitivity CRP tests mean (sd) median (IQR] HU - Colonescopy: n (%) HU - Flu vaccine: n (%) HU - Flu vaccine: n (%) HU - Plu vaccine: n (%) HU - Paramear.n (%) HU - Pneumonia vaccine: n	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 (0.00, 0.00] 0.07 (0.38) 0.00 (0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,667 (14.3%) 647 (16.5%) 7,329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20]	2,755 (3.9%) 3,559 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,653 (3.1%) 8,444 (17.7%) 1,135 (1.6%) 16,159 (22.4%) 0.19 (0.06) 0.18 [0.15, 0.22]	-0.02 -0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.17	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 (0.00, 0.00] 1.806 (4.3%) 5.148 (12.3%) 5.252 (6.0%) 5.233 (12.5%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19]	804 (1.8%) 2.056 (4.2%) 0.04 (0.23) 0.00 (0.00, 0.00] 2.083 (4.2%) 6.004 (12.1%) 5.438 (10.3%) 5.438 (10.3%) 6.392 (12.9%) 0.17 (0.05) 0.16 [0.14, 0.19]	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00 -0.13 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 [0.00, 0.00] 6,130 (4.1%) 48,520 (32.6%) 15,435 (10.4%) 19,077 (12.8%) 36,362 (2.4%) 32,767 (22.0%) 0.19 (0.06) 0.17 [0.14, 0.21]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 [0.00, 0.00] 6,707 (3.8%) 18,530 (10.5%) 19,785 (11.2%) 4,177 (2.4%) 51,792 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22]	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.0	9,408 (4,1%) 8,184 (3.6%) 13,996 (6,1%) 0.04 (0.21) 0.08 (0.40) 0.00 (0.21) 9,466 (4,1%) 60,955 (26.5%) 29,977 (13.0%) 5,3878 (10.0%) 0.18 (0.06) 0.17 (0.06)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 11,054 (3.7%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 28,207 (9.5%) 33,672 (12.3%) 74,343 (24.9%) 0.19 (0.06) 0.18 (0.06)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.01 -0.14 -0.17 -0.17
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain [UR] HU - Number of CRP, high-sensitivity CRP tests meain (IDR] HU - Solonescoy; n (%) HU - Flu vaccine; n (%) HU - Flu vaccine; n (%) HU - Pap smaar, n (%) Frailty Score: Emplificative Version 365 days (ICD-9 and ICD-10) V2 mean (cd) mealian [IDR] CHADS2 score, 180 days mean (cl) mean (cl)	1.333 (3.4%) 1.408 (3.6%) 1.968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1.530 (3.9%) 7.287 (18.4%) 3.466 (8.8%) 5.687 (14.3%) 647 (1.6%) 7.329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1.41 (1.24) 1.00 [0.00, 2.00]	2,755 (39%) 3,656 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 8,748 (11.7%) 1,135 (1.6%) 16,159 (22.4%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.53 (1.29) 1.00 [1.00, 2.00]	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.17 -0.09 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 (0.00, 0.00) 0.05 (0.29) 0.00 (0.00, 0.00] 1.806 (4.3%) 2.525 (6.0%) 5.233 (12.52 (6.0%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00]	804 (1.8%) 2.056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.30) 0.00 [0.00, 0.00] 2.083 (4.2%) 6.004 (12.1%) 3.114 (6.3%) 5.439 (11.0%) 1.180 (2.4%) 6.392 (12.9%) 0.17 (0.05) 0.16 [0.14, 0.19] 1.23 (1.24) 1.00 [0.00, 2.00]	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6.141 (4.1%) 10.228 (6.9%) 0.04 (0.21) 0.09 (0.00, 0.00) 6.130 (4.1%) 15.435 (10.4%) 15.435 (10.4%) 13.635 (12.4%) 3.636 (2.4%) 3.636 (2.4%) 3.636 (2.4%) 0.19 (0.06) 0.17 (0.14, 0.21] 1.37 (1.22) 1.00 [1.00, 2.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.09 (0.00, 0.00] 6,707 (3.8%) 18,530 (10.5%) 19,785 (11.2%) 4,177 (2.4%) 51,792 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12) 1.00 [0.00, 2.00]	-0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.00 -0.05 0.00 -0.02 -0.17 0.00 -0.02	9,408 (4,1%) 8,184 (3.6%) 13,996 (6,1%) 13,996 (6,1%) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 0,08 (0,40) 0,00 (0,40) 9,466 (4,1%) 60,935 (22,5%) 21,426 (9,3%) 23,426 (3,3%) 43,878 (19,0%) 0,17 (0,06) 1.35 (1,22) 1,00 (1,22)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 6.492 (2.2%) 0.433 (25.8%) 0.49 (0.66) 0.18 (0.06) 1.28 (1.18) 1.00 (1.18)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.02 -0.01 0.05 0.01 -0.14 -0.17 0.06 0.00
HU - Bone mineral density: n (%) HU - Occurrence of readinine tests ordered ; n (%) HU - Number of D-dimer tests median [IQR] HU - Number of CRP, high-sensitivity CRP tests median [IQR] HU - Colonoscopy: n (%) HU - Colonoscopy: n (%) HU - Manmogram. n (%) HU - Manmogram. n (%) HU - Pap smear; n (%) HU - Pap smear; n (%) HU - Pneumonia vaccine; n (%) HU - Pap smear; n (%) HU - Pap smear; n (%) HU - Status developmentation (CD-10) V2 mean (sd) mean (sd)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 (0.00, 0.00] 0.07 (0.38) 0.00 (0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,667 (14.3%) 647 (16%) 7,329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1.41 (124) 1.00 (0.00, 2.00] 0.27 (0.54)	2,785 (3.9%) 3,859 (5.1%) 0.04 (0.22) 0.00 (0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,815 (3.6%) 12,910 (17.9%) 6,653 (8.1%) 8,844 (11.7%) 1,135 (1.6%) 16,159 (22.4%) 0.19 (0.06) 0.18 (0.15, 0.22) 1.53 (1.29) 1.00 (1.00, 2.00] 0.36 (0.62)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1.806 (4.3%) 2.525 (6.0%) 5.233 (12.5%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00] 0.29 (0.50)	804 (1.8%) 2,056 (4.2%) 0.04 (0.23) 0.00 (0.00, 0.00] 0.05 (0.30) 0.00 (0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 5,439 (11.0%) 1,180 (2.4%) 6,392 (12.9%) 0.17 (0.05) 0.16 (0.14, 0.19] 1.23 (1.24) 1.00 (1.00, 2.00] 0.31 (0.51)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00 -0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.09 (0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 15,435 (10.4%) 15,435 (10.4%) 15,435 (10.4%) 15,435 (10.4%) 13,27,67 (22.0%) 0.19 (0.06) 0.17 (0.14, 0.21] 1.37 (1.22) 1.00 [1.00, 2.00] 0.37 (0.62)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.09 (0.00, 0.00] 0.09 (0.42) 0.00 [0.00, 0.00] 6,707 (3.8%) 19,785 (11.2%) 19,785 (11.2%) 51,792 (29.3%) 0.19 (0.06) 0.18 (0.15, 0.22] 1.19 (1.12) 1.00 [0.00, 0.200] 0.42 (0.66)	-0.01 0.00	9,408 (4.1%) 8,184 (3.6%) 13,996 (6.1%) 0.04 (0.21) 0.00 (0.21) 0.08 (0.40) 0.00 (0.40) 9,466 (4.1%) 20,957 (13.0%) 29,977 (13.0%) 29,977 (13.0%) 43,878 (19.0%) 0.18 (0.06) 0.17 (0.06) 1.35 (1.22) 1.00 (1.22) 0.34 (0.59)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 28,207 (9.5%) 33,672 (11.3%) 6,492 (2.2%) 74,343 (24.9%) 0.19 (0.06) 0.18 (0.06) 1.28 (1.18) 1.00 (1.18) 0.39 (0.63)	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.00 0.02 0.02 0.01 0.14 -0.17 -0.17 0.06 0.00 -0.08
HU - Bone mineral density: n (%) HU - Cocurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain [UR] HU - Number of CRP, high-sensitivity CRP tests mean (sd) meadian [UR] HU - Colonescopy: n (%) HU - Flu vaccine; n (%) HU - Flu vaccine; n (%) HU - Pap smart, n (%) HU - Pap smart, n (%) HU - Pap smart, n (%) Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) V2 mean (sd) meadian [UR] HU - Number of Hospitalizations mean (tol) mean (tol]	1.333 (3.4%) 1.408 (3.6%) 1.968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1.530 (3.9%) 7.287 (18.4%) 3.466 (8.8%) 5.687 (14.3%) 647 (1.6%) 7.329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1.41 (1.24) 1.00 [0.00, 2.00]	2,755 (39%) 3,656 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 8,748 (11.7%) 1,135 (1.6%) 16,159 (22.4%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.53 (1.29) 1.00 [1.00, 2.00]	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.17 -0.09 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 (0.00, 0.00) 0.05 (0.29) 0.00 (0.00, 0.00] 1.806 (4.3%) 2.525 (6.0%) 5.233 (12.52 (6.0%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00]	804 (1.8%) 2,056 (4.2%) 0.04 (0.23) 0.00 (0.00, 0.00] 0.05 (0.30) 0.00 (0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 5,439 (11.0%) 1,180 (2.4%) 6,392 (12.9%) 0.17 (0.05) 0.16 (0.14, 0.19] 1.23 (1.24) 1.00 (1.00, 2.00] 0.31 (0.51)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6.141 (4.1%) 10.228 (6.9%) 0.04 (0.21) 0.09 (0.00, 0.00) 6.130 (4.1%) 15.435 (10.4%) 15.435 (10.4%) 13.635 (12.4%) 3.636 (2.4%) 3.636 (2.4%) 3.636 (2.4%) 0.19 (0.06) 0.17 (0.14, 0.21] 1.37 (1.22) 1.00 [1.00, 2.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.09 (0.00, 0.00] 6,707 (3.8%) 18,530 (10.5%) 19,785 (11.2%) 4,177 (2.4%) 51,792 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12) 1.00 [0.00, 2.00]	-0.01 0.00	9,408 (4,1%) 8,184 (3.6%) 13,996 (6,1%) 13,996 (6,1%) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 0,08 (0,40) 0,00 (0,40) 9,466 (4,1%) 60,935 (22,5%) 21,426 (9,3%) 23,426 (3,3%) 43,878 (19,0%) 0,17 (0,06) 1.35 (1,22) 1,00 (1,22)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 6.492 (2.2%) 0.433 (25.8%) 0.49 (0.66) 0.18 (0.06) 1.28 (1.18) 1.00 (1.18)	0.02 -0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.02 -0.01 0.05 0.01 -0.14 -0.17 0.06 0.00
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (IGR) HU - Number of CRP, high-sensitivity CRP tests meain (IGR) HU - Colonoscopy: n (%) HU - Colonoscopy: n (%) HU - Valum colon: n (%) HU - Pap smear: n (%) HU - Pap smear: n (%) HU - Pap smear: n (%) Fraitry Score: Empirical Version 365 days (ICD-9 and ICD-10) V2 meain (IGR) median (IGR) HU - Naminer of Hospitalizations meain (sd) meain (sd) meain (sd) meain (sd) meain (sd) meain (ICR) HU - Number of Hospitalizations meain (ICR) HU - Number of Hospitalizations	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 (0.00, 0.00] 0.07 (0.38) 0.00 (0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 7,329 (18.5%) 0.18 (0.06) 0.17 (0.14, 0.20] 1,41 (1.24) 1,00 (0.00, 2.00] 0,27 (0.54) 0.00 (0.00, 0.00]	2,765 (3.9%) 3,859 (5.1%) 0.04 (0.22) 0.00 (0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,815 (3.6%) 12,910 (17.9%) 6,563 (9.1%) 8,844 (11.7%) 14,159 (12.6%) 16,159 (22.4%) 0.19 (0.06) 0.18 (0.15, 0.22] 1.53 (1.29) 1.00 [1.00, 2.00] 0.36 (0.62) 0.00 [0.00, 1.00]	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1.806 (4.3%) 2.525 (6.0%) 5.233 (12.5%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00] 0.29 (0.50) 0.00 [0.00, 1.00]	804 (1.8%) 2,056 (4.2%) 0.04 (0.23) 0.00 (0.00, 0.00] 2,085 (4.2%) 0.00 (0.00, 0.00] 2,085 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,5439 (11.0%) 1,180 (2.4%) 6,392 (12.2%) 0.17 (0.05) 0.16 (0.14, 0.19] 1.23 (1.24) 1.00 (0.00, 2.00] 0.31 (0.51) 0.00 (0.00, 1.00]	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.09 (0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 19,4520 (32.6%) 15,435 (10.4%) 19,077 (12.8%) 3,636 (2.4%) 32,767 (22.0%) 0.19 (0.06) 0.17 [0.14, 0.21] 1.37 (122) 1.00 [1.00, 2.00] 0.37 (0.62) 0.00 [0.00, 1.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.09 (0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 19,785 (12.5%) 51,782 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12) 1.100 [0.00, 2.00] 0.42 (0.66) 0.000 [0.00, 1.00]	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 -0.05 0.00 -0.05 0.00 -0.02 -0.02 -0.02 -0.02 -0.02 -0.02 -0.08 0.00	9,408 (4,1%) 8,184 (3,6%) 13,996 (6,1%) 0,04 (0,21) 0,00 (0,21) 0,08 (0,40) 0,00 (0,40) 9,466 (4,1%) 60,955 (25,5%) 21,426 (9,3%) 5,305 (2,3%) 43,878 (19,0%) 0,18 (0,06) 0,17 (0,06) 1,35 (1,22) 1,00 (1,22) 0,34 (0,59) 0,00 (0,59)	$\begin{array}{c} 36,857(12.4\%)\\ 11,428(3.8\%)\\ 11,428(3.8\%)\\ 11,054(3.7\%)\\ 18,160(6.1\%)\\ 0.00(0.22)\\ 0.00(0.22)\\ 0.08(0.40)\\ 0.00(0.40)\\ 11,405(3.8\%)\\ 28,207(9.25\%)\\ 33,672(11.3\%)\\ 28,207(9.5\%)\\ 33,672(1.3\%)\\ 6,492(2.2\%)\\ 74,343(24.9\%)\\ 0.19(0.06)\\ 0.18(0.06)\\ 1.28(1.18)\\ 1.00(1.18)\\ 0.39(0.63)\\ 0.00(0.63)\\ \end{array}$	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.01 0.14 -0.17 0.06 0.00 -0.08 0.00
HU - Bone mineral density: n (%) HU - Cocumence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (sd) meain [IQR] HU - Number of CRP, high-sensitivity CRP tests mean (sd) meadian [IQR] HU - Solitone coopy: n (%) HU - Flu vaccine: n (%) HU - Plu vaccine: n (%) HU - Pap smart, n (%) HU - Pap smart, n (%) Frailty Score: Empiral Version 385 days (ICD-9 and ICD-10) V2 mean (sd) meain (sd) meain (sd) meain (sd) meain (sd) meain (sd) meain (IQR] HU - Number of Hospitalizations meain (sd) meain (sd)	1.333 (3.4%) 1.408 (3.6%) 1.968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1.530 (3.9%) 7.287 (18.4%) 3.666 (8.5%) 5.687 (14.3%) 647 (16.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1.41 (1.24) 1.00 [0.00, 2.00] 0.27 (0.54) 0.00 [0.00, 0.00] 1.40 (4.22)	2,756 (39%) 3,559 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,658 (31%) 8,448 (17.7%) 16,159 (22.4%) 0.19 (0.06) 0.19 (0.06) 0.19 (0.06) 0.19 (0.06) 0.38 (0.62) 0.00 [0.00, 1.00] 2.11 (5.65)	-0.02 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.17 -0.09 0.00 -0.15 0.00 -0.14	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.01 (0.00, 0.00] 1.806 (4.3%) 5.148 (12.3%) 5.148 (12.3%) 5.252 (6.0%) 5.233 (12.5%) 1.022 (2.4%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00] 0.29 (0.50) 0.00 [0.00, 1.00] 1.25 (3.19)	804 (1.8%) 2.056 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 2.083 (4.2%) 6.004 (12.1%) 5.438 (10.3%) 5.438 (10.3%) 1.180 (2.4%) 6.392 (12.9%) 0.17 (0.05) 0.17 (0.05) 0.17 (0.05) 0.17 (0.05) 0.31 (0.51) 0.30 (0.00, 1.00] 1.47 (3.68)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 14,525 (10.4%) 15,435 (10.4%) 15,435 (10.4%) 32,767 (22.0%) 0.19 (0.06) 0.17 [0.14, 0.21] 1.37 (1.22) 1.00 [1.00, 2.00] 0.37 (0.62) 0.00 [0.00, 1.00] 1.97 (5.34)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 [0.00, 0.00] 6,707 (3.8%) 18,530 (10.5%) 19,785 (11.2%) 4,177 (2.4%) 4,177 (2.4%) 4,177 (2.4%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.09 [1.2] 1.00 [0.00, 2.00] 0.42 (0.66) 0.42 (0.66) 0.42 (0.61)	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.05 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 0.00	9,408 (4, 1%) 8,184 (3.6%) 13,996 (6, 1%) 0.04 (0.21) 0.08 (0.40) 0.00 (0.21) 10,08 (0.40) 0.00 (0.21) 10,08 (0.40) 0,469 (4, 1%) 60,955 (26,3%) 21,426 (9,3%) 29,977 (13,0%) 5,305 (2,3%) 21,426 (9,3%) 29,977 (13,0%) 5,305 (2,3%) 21,426 (9,3%) 1,35 (12,2) 1,00 (1,22) 0.34 (0.59) 0,00 (0,59) 1,74 (4,83)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 6,492 (2.2%) 74,343 (24.9%) 0.19 (0.06) 0.18 (0.06) 1.28 (1.18) 1.00 (1.18) 0.09 (0.63) 0.01 (0.63) 2.11 (5.16)	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.05 0.01 0.05 0.01 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.05 0.04 0.05 0.04 0.05 0.04 0.05 0.06 0.00 0.00 0.02 0.04 0.04 0.04 0.06 0.00 0.00 0.00 0.04 0.04 0.00 0.00 0.02 0.04 0.04 0.00 0.00 0.00 0.04 0.00
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (IGR) HU - Number of CRP, high-sensitivity CRP tests meain (IGR) HU - Colonoscopy: n (%) HU - Colonoscopy: n (%) HU - Colonoscopy: n (%) HU - Nammogram: n (%) HU - Pag smear: n (%) HU - Pag smear: n (%) Fraity Score: Empirical Version 365 days (ICD-9 and ICD-10) V2 meain (IGR) median (IGR) HU - Nammodia Version 365 days (ICD-9 and ICD-10) V2 meain (IGR) meadian (IGR) HU - Number of Hospitalizations meain (ed) meain (HOR) HU - Number of Hospitali days mean (IGR)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 (0.00, 0.00] 0.07 (0.38) 0.00 (0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 7,329 (18.5%) 0.18 (0.06) 0.17 (0.14, 0.20] 1,41 (1.24) 1,00 (0.00, 2.00] 0,27 (0.54) 0.00 (0.00, 0.00]	2,765 (3.9%) 3,859 (5.1%) 0.04 (0.22) 0.00 (0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,815 (3.6%) 12,910 (17.9%) 6,563 (9.1%) 8,844 (11.7%) 14,159 (12.6%) 16,159 (22.4%) 0.19 (0.06) 0.18 (0.15, 0.22] 1.53 (1.29) 1.00 [1.00, 2.00] 0.36 (0.62) 0.00 [0.00, 1.00]	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.00 [0.00, 0.00] 1.806 (4.3%) 2.525 (6.0%) 5.233 (12.5%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00] 0.29 (0.50) 0.00 [0.00, 1.00]	804 (1.8%) 2,056 (4.2%) 0.04 (0.23) 0.00 (0.00, 0.00] 2,085 (4.2%) 0.00 (0.00, 0.00] 2,085 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,5439 (11.0%) 1,180 (2.4%) 6,392 (12.2%) 0.17 (0.05) 0.16 (0.14, 0.19] 1.23 (1.24) 1.00 (0.00, 2.00] 0.31 (0.51) 0.00 (0.00, 1.00]	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.09 (0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 19,4520 (32.6%) 15,435 (10.4%) 19,077 (12.8%) 3,636 (2.4%) 32,767 (22.0%) 0.19 (0.06) 0.17 [0.14, 0.21] 1.37 (122) 1.00 [1.00, 2.00] 0.37 (0.62) 0.00 [0.00, 1.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.09 (0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 19,785 (12.5%) 51,782 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12) 1.100 [0.00, 2.00] 0.42 (0.66) 0.000 [0.00, 1.00]	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.05 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 0.00	9,408 (4,1%) 8,184 (3,6%) 13,996 (6,1%) 0,04 (0,21) 0,00 (0,21) 0,08 (0,40) 0,00 (0,40) 9,466 (4,1%) 60,955 (25,5%) 21,426 (9,3%) 5,305 (2,3%) 43,878 (19,0%) 0,18 (0,06) 0,17 (0,06) 1,35 (1,22) 1,00 (1,22) 0,34 (0,59) 0,00 (0,59)	$\begin{array}{c} 36,857(12.4\%)\\ 11,428(3.8\%)\\ 11,428(3.8\%)\\ 11,054(3.7\%)\\ 18,160(6.1\%)\\ 0.00(0.22)\\ 0.00(0.22)\\ 0.08(0.40)\\ 0.00(0.40)\\ 11,405(3.8\%)\\ 28,207(9.25\%)\\ 33,672(11.3\%)\\ 28,207(9.5\%)\\ 33,672(1.3\%)\\ 6,492(2.2\%)\\ 74,343(24.9\%)\\ 0.19(0.06)\\ 0.18(0.06)\\ 1.28(1.18)\\ 1.00(1.18)\\ 0.39(0.63)\\ 0.00(0.63)\\ \end{array}$	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.01 0.14 -0.17 0.06 0.00 -0.08 0.00
HU - Bone mineral density: n (%) HU - Documence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests median (IGR) HU - Number of CRP, high-sensitivity CRP tests median (IGR) HU - Number of CRP, high-sensitivity CRP tests median (IGR) HU - Flu vaccine: n (%) HU - Flu vaccine: n (%) HU - Plu vaccine: n (%) HU - Pag smar, n (%) HI - Pag smar, n (%) HU - Number of hospitalizations medain (IGR) HU - Number of Hospital days median (IGR) HU - Number of Emergency Department (ED) visits	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,687 (14.3%) 647 (1.6%) 7,329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1,41 (1.24) 1,00 [0.00, 2.00] 0,27 (0.54) 0.00 [0.00, 0.00] 1,40 (4.22) 0,00 [0.00, 0.00]	2,78 (39%) 3,559 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,656 (31%) 8,446 (17.%) 16,159 (22.4%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.53 (129) 1.00 [1.00, 2.00] 0.36 (0.62) 0.00 [0.00, 1.00] 2,11 (5.65) 0.00 [0.00, 3.00]	-0.02 -0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.09 0.00 -0.15 0.00 -0.14 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.01 (0.00, 0.00] 1.806 (4.3%) 5.148 (12.3%) 5.148 (12.3%) 5.148 (12.3%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00] 0.29 (0.50) 0.00 [0.00, 1.00] 1.25 (3.19) 0.00 [0.00, 2.00]	804 (1.6%) 20,56 (4.2%) 0.04 (0.23) 0.00 (0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 5,439 (11.0%) 1,180 (2.4%) 6,392 (12.9%) 0.17 (0.05) 0.17	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00 -0.13 0.00 0.00 0.00 0.00 0.00 -0.13 0.00 0.	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 18,435 (104.%) 19,077 (12.2%) 32,767 (22.0%) 0.19 (0.06) 0.77 [0.14, 0.21] 1.37 (122) 1.00 [1.00, 2.00] 0.37 (0.62) 0.00 [0.00, 1.00] 1.97 (5.34) 0.00 [0.00, 3.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 [0.00, 0.00] 6,707 (3.8%) 18,530 (10.5%) 19,785 (11.2%) 51,792 (29.3%) 0.18 [0.15, 0.22] 1.19 (1.2) 1.00 [0.00, 2.00] 0.42 (0.66) 0.00 [0.00, 1.00] 2.29 (5.31) 0.00 [0.00, 3.00]	-0.01 0.00 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 -0.08 0.00 0.00	9,408 (4, 1%) 8,184 (3,6%) 13,996 (6, 1%) 0,04 (0,21) 0,08 (0,40) 0,00 (0,21) 10,08 (0,40) 0,00 (0,21) 10,08 (0,40) 0,08 (0,40) 0,08 (0,40) 0,09 (0,21) 14,28 (9,3%) 29,977 (13,0%) 5,308 (2,3%) 29,977 (13,0%) 5,308 (2,3%) 29,977 (13,0%) 5,308 (2,3%) 29,977 (13,0%) 5,308 (2,3%) 24,3878 (19,0%) 0,18 (0,06) 0,17 (0,06) 1,35 (1,22) 1,00 (1,22) 0,34 (0,59) 1,74 (4,83) 0,00 (4,83)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 28,207 (9.5%) 33,672 (11.3%) 0.19 (0.06) 0.18 (0.06) 1.28 (1.18) 1.00 (1.18) 0.39 (0.63) 0.00 (0.63) 2.11 (5.16) 0.00 (5.16)	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.03 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.05 0.00 0.02 0.04 0.04 0.04 0.06 0.00 0.00 0.02 0.04 0.04 0.06 0.00 0.00 0.00 0.04 0.06 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00
HU - Bone mineral density: n (%) HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meain (tid) median [IQR] HU - Number of CRP, high-sensitivity CRP tests mean (a) median [IQR] HU - Golonescopy: n (%) HU - Golonescopy: n (%) HU - Marimogram, n (%) HU - Pag smear: n (%) HU - Pag smear: n (%) HU - Pag smear: n (%) Frailly Score: Empirical Version 365 days (ICD-9 and ICD-10) V2 mean (ad) median [IQR] UR - Marimogram, n (%) HU - Number of Hospitalizations mean (sd) mean (sd)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,687 (14.3%) 647 (1.6%) 7,329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1,41 (1.24) 1,00 [0.00, 2.00] 0,27 (0.54) 0.00 [0.00, 0.00] 1,40 (4.22) 0,00 [0.00, 0.00] 0,77 (1.45)	2,756 (1,95) 2,756 (1,95) 0,04 (0,22) 0,00 (0,00,0,00] 2,61 (3,68) 12,910 (17,98) 6,653 (0,15) 16,159 (22,4%) 16,159 (22,4%) 16,159 (22,4%) 10,18 (0,15,0,22) 1,53 (1,29) 1,00 (1,00,2,00] 0,38 (0,62) 0,00 (0,00,3,00] 0,91 (1,55)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.17 -0.17 -0.19 0.00 -0.15 0.00 -0.14 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 (0.00, 0.00] 1.800 (4.3%) 0.05 (0.29) 0.05 (0.29) 0.05 (0.29) 0.05 (0.29) 1.806 (4.3%) 2.525 (6.0%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.20) 0.00 [0.00, 1.00] 0.00 [0.00, 2.00] 0.57 (2.15)	0.4 (1.8%) 2,056 (4.2%) 0.04 (0.23) 0.09 (0.00, 0.00] 0.05 (0.30) 0.00 (0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,439 (11.0%) 1,180 (2.4%) 6,392 (12.9%) 0.17 (0.05) 0.16 [0.14, 0.19] 1.23 (1.24) 1.00 [0.00, 1.00] 1.47 (3.88) 0.00 (0.00, 2.00] 0.73 (2.43)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00 -0.13 0.00 0.0	6,141 (4.1%) 10,228 (6.9%) 0,04 (0.21) 0,09 (0.03),0.00] 0,09 (0.43) 0,00 [0,00, 0,00] 6,130 (4.1%) 14,520 (32.6%) 15,435 (10.4%) 13,636 (2.4%) 3,636 (2.4%) 3,636 (2.4%) 3,777 (122) 1,00 [1,00, 2,00] 0,37 (0.62) 0,00 [0,00, 1,00] 1,97 (5.34) 0,00 [0,00, 3,00] 0,98 (1.68)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 (0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 4,177 (2.4%) 51,782 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12) 1.00 [0.00, 2.00] 0.42 (0.66) 0.00 [0.00, 1.00] 2.29 (5.31) 0.00 [0.00, 0.00, 1.00] 1.03 (1.66)	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.02 -0.01 0.05 0.00 -0.02 0.05 0.00 -0.02 0.05 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.00 0.00	9,408 (4, 1%) 8,184 (3.6%) 13,996 (6, 1%) 13,996 (6, 1%) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 1,00 (0,21) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,00 (1,2) 1,74 (4,83) 0,00 (4,83) 0,86 (1,74)	36,857 (12.4%) 11,428 (3.8%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 74,343 (24.9%) 0.19 (0.06) 1.28 (1.18) 1.00 (1.18) 0.39 (0.63) 0.00 (5.16) 0.95 (1.79)	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.02 -0.01 0.02 0.02 -0.01 0.05 0.01 0.14 -0.17 0.06 0.00 -0.06 0.00 -0.06 0.00 -0.06 0.00 -0.07 -0.05
HU - Bone mineral density: n (%) HU - Documence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meainn (bd) HU - Number of CRP, high-sensitivity CRP tests mean (a) median (IQR) HU - Colonescopy: n (%) HU - Flu vaccine: n (%) HU - Flu vaccine: n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - Pag smaar, n (%) HU - Pag smaar, n (%) HU - Number of Hospitalizations mean (tol) median (IQR] HU - Number of Hospital days mean (tol) median (IQR) HU - Number of Emergency Department (ED) visits mean (tol)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,687 (14.3%) 647 (1.6%) 7,329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1,41 (1.24) 1,00 [0.00, 2.00] 0,27 (0.54) 0.00 [0.00, 0.00] 1,40 (4.22) 0,00 [0.00, 0.00]	2,78 (39%) 3,559 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 (0.00, 0.00] 2,615 (3.6%) 12,910 (17.9%) 6,656 (31%) 8,446 (17.%) 16,159 (22.4%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.53 (129) 1.00 [1.00, 2.00] 0.36 (0.62) 0.00 [0.00, 1.00] 2,11 (5.65) 0.00 [0.00, 3.00]	-0.02 -0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.09 0.00 -0.15 0.00 -0.14 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 [0.00, 0.00] 0.05 (0.29) 0.01 (0.00, 0.00] 1.806 (4.3%) 5.148 (12.3%) 5.148 (12.3%) 5.148 (12.3%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.00 [0.00, 2.00] 0.29 (0.50) 0.00 [0.00, 1.00] 1.25 (3.19) 0.00 [0.00, 2.00]	0.4 (1.8%) 2,056 (4.2%) 0.04 (0.23) 0.09 (0.00, 0.00] 0.05 (0.30) 0.00 (0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,439 (11.0%) 1,180 (2.4%) 6,392 (12.9%) 0.17 (0.05) 0.16 [0.14, 0.19] 1.23 (1.24) 1.00 [0.00, 1.00] 1.47 (3.88) 0.00 (0.00, 2.00] 0.73 (2.43)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00 -0.13 0.00 0.00 0.00 0.00 0.00 -0.13 0.00 0.	6,141 (4.1%) 10,228 (6.9%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 (0.43) 0.00 [0.00, 0.00] 6,130 (4.1%) 18,435 (104.%) 19,077 (12.2%) 32,767 (22.0%) 0.19 (0.06) 0.77 [0.14, 0.21] 1.37 (122) 1.00 [1.00, 2.00] 0.37 (0.62) 0.00 [0.00, 1.00] 1.97 (5.34) 0.00 [0.00, 3.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.09 [0.00, 0.00] 6,707 (3.8%) 18,530 (10.5%) 19,785 (11.2%) 51,792 (29.3%) 0.18 [0.15, 0.22] 1.19 (1.2) 1.00 [0.00, 2.00] 0.42 (0.66) 0.00 [0.00, 1.00] 2.29 (5.31) 0.00 [0.00, 3.00]	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.02 -0.01 0.05 0.00 -0.02 0.05 0.00 -0.02 0.05 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.00 0.00	9,408 (4, 1%) 8,184 (3,6%) 13,996 (6, 1%) 0,04 (0,21) 0,08 (0,40) 0,00 (0,21) 10,08 (0,40) 0,00 (0,21) 10,08 (0,40) 0,08 (0,40) 0,09 (2,1) 10,08 (0,40) 14,28 (9,3%) 29,977 (13,0%) 5,308 (2,3%) 29,977 (13,0%) 5,308 (2,3%) 29,977 (13,0%) 5,308 (2,3%) 29,977 (13,0%) 5,308 (2,3%) 29,977 (13,0%) 5,308 (2,3%) 14,3878 (19,0%) 0,18 (0,06) 0,17 (0,06) 1,35 (1,22) 1,00 (1,22) 0,34 (0,59) 1,74 (4,83) 0,00 (4,83)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 28,207 (9.5%) 33,672 (11.3%) 0.19 (0.06) 0.18 (0.06) 1.28 (1.18) 1.00 (1.18) 0.39 (0.63) 0.00 (0.63) 2.11 (5.16) 0.00 (5.16)	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.03 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.05 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.05 0.00 0.02 0.04 0.04 0.04 0.05 0.00 0.00 0.04 0.04 0.06 0.00 0.00 0.00 0.04 0.06 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00
HU - Bone mineral density: n (%) HU - Number of D-dimer tests median [UR] HU - Number of CRP, high-sensitivity CRP tests meadian [UR] HU - Number of CRP, high-sensitivity CRP tests meadian [UR] HU - Golonescopy: n (%) HU - Flu vaccine: n (%) HU - Flu vaccine: n (%) HU - Pap smart, n (%) Frailty Score: Empirical Version 365 days (ICD-9 and ICD-10) V2 mean (sd) meadian [UR] HU - Number of Hospitalizations mean (sd) mean (sd) meadian [UR] HU - Number of Hospital days mean (sd) meadian [UR] HU - Number of Interpital days meadian [UR] HU - Number of Interpital days mean (sd) meadian [UR] HU - Number of Interpital days mean (sd) meadian [UR] HU - Number of Interpital days mean (sd) meadian [UR] HU - Number of Interpital days mean (sd) mean (sd)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0,04 (0.21) 0,00 (0.00, 0.00] 0,07 (0.38) 0,00 (0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,667 (14.3%) 647 (1.6%) 7,329 (18.5%) 0,18 (0.66) 0,17 (0.14, 0.20] 1,41 (1.24) 1,00 (0.00, 0.00] 1,40 (4.22) 0,00 (0.00, 0.00] 1,40 (4.22) 0,00 (0.00, 0.00] 0,77 (1.45) 0,00 (0.00, 1.00]	2,795 (39%) 3,559 (5.1%) 0.04 (0.22) 0.00 [0.00, 0.00] 0.07 (0.39) 0.00 [0.00, 0.00] 2,515 (36%) 12,910 (17.9%) 6,553 (31%) 8,444 (17.7%) 1.55 (32.4%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.53 (1.29) 1.00 [1.00, 2.00] 0.00 [0.00, 1.00] 2.11 (5.65) 0.00 [0.00, 3.00] 0.91 (1.55) 0.00 [0.00, 2.00]	-0.02 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 -0.01 -0.01 -0.10 -0.17 -0.09 0.00 -0.15 0.00 -0.14 0.00 -0.09 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 (0.00, 0.00) 1.800 (4.3%) 0.05 (0.29) 0.05 (0.29) 0.05 (0.29) 0.05 (0.0, 0.01) 1.806 (4.3%) 1.2525 (6.0%) 1.022 (2.4%) 3.782 (9.0%) 1.02 (2.4%) 3.782 (9.0%) 1.123 (1.19) 1.00 [0.00, 2.00] 0.26 (0.50) 0.00 (0.00, 1.00] 1.25 (3.19) 0.00 [0.00, 2.00] 0.57 (2.15) 0.00 [0.00, 0.0]	804 (1.6%) 20,56 (4.2%) 0.04 (0.23) 0.00 [0.00, 0.00] 20,030 (0.00, 0.00] 20,032 (4.2%) 6,004 (12.1%) 5,439 (11.0%) 1,180 (2.4%) 6,392 (12.9%) 0.17 (0.05) 0.16 [0.14, 0.19] 1.23 (1.24) 1.00 [0.00, 2.00] 0.31 (0.51) 0.00 [0.00, 1.00] 1.47 (3.68) 0.00 [0.00, 2.00] 0.73 (2.43) 0.00 [0.00, 0.00]	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.05 0.00 -0.13 0.00	6,141 (4.1%) 10,228 (6.9%) 0,04 (0.21) 0,00 (0.00, 0.00) 6,130 (4.1%) 45,520 (32.6%) 15,435 (10.4%) 3,636 (2.4%) 3,636 (2.4%) 3,636 (2.4%) 3,637 (12.2%) 10,017 (0.14, 0.21] 1.37 (1.22) 1.00 [1.00, 2.00] 0.37 (0.62) 0.00 (0.00, 1.00] 1.97 (5.34) 0.00 (0.00, 3.00] 0.96 (1.68) 0.00 [0.00, 2.00]	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 6,707 (3.8%) 18,530 (10.5%) 4,177 (2.4%) 51,792 (22.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12) 1.00 [0.00, 2.00] 0.42 (0.66) 0.00 [0.00, 3.00] 1.03 (1.66) 0.00 [0.00, 2.00]	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.00 0.00 -0.02 -0.01 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.08 0.00 -0.04 0.00	9,408 (4, 1%) 8,184 (3.6%) 13,996 (6, 1%) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 1,08 (0,40) 9,466 (4, 1%) 6,0955 (26,5%) 21,426 (9,3%) 12,426 (9,3%) 12,426 (9,3%) 12,426 (9,3%) 0,385 (26,5%) 11,35 (1,22) 1,00 (1,22) 1,00 (1,22) 1,34 (0,59) 1,74 (4,83) 0,00 (4,83) 0,866 (1,74) 0,000 (1,74)	36,857 (12.4%) 11,428 (3.8%) 11,054 (3.7%) 11,054 (3.7%) 0.04 (0.22) 0.00 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 33,672 (11.3%) 0.492 (2.2%) 74,343 (24.9%) 0.19 (0.06) 0.18 (0.06) 1.28 (1.18) 1.00 (1.18) 0.09 (0.63) 2.11 (5.16) 0.00 (6.516) 0.95 (1.79) 0.00 (1.79)	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.02 -0.01 0.05 0.01 0.17 0.06 0.00 -0.08 0.00 -0.08 0.00 -0.08 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05 0.00 -0.05
HU - Bone mineral density: n (%) HU - Documence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests meainn (bd) HU - Number of CRP, high-sensitivity CRP tests mean (a) median (IQR) HU - Colonescopy: n (%) HU - Flu vaccine: n (%) HU - Flu vaccine: n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - PSA test or Prostate exam for DRE; n (%) HU - Pag smaar, n (%) HU - Pag smaar, n (%) HU - Number of Hospitalizations mean (tol) median (IQR] HU - Number of Hospital days mean (tol) median (IQR) HU - Number of Emergency Department (ED) visits mean (tol)	1,333 (3.4%) 1,408 (3.6%) 1,968 (5.0%) 0.04 (0.21) 0.00 [0.00, 0.00] 0.07 (0.38) 0.00 [0.00, 0.00] 1,530 (3.9%) 7,287 (18.4%) 3,466 (8.8%) 5,687 (14.3%) 647 (1.6%) 7,329 (18.5%) 0.18 (0.06) 0.17 [0.14, 0.20] 1,41 (1.24) 1,00 [0.00, 2.00] 0,27 (0.54) 0.00 [0.00, 0.00] 1,40 (4.22) 0,00 [0.00, 0.00] 0,77 (1.45)	2,756 (1,95) 2,756 (1,95) 0,04 (0,22) 0,00 (0,00,0,00] 2,61 (3,68) 12,910 (17,98) 6,653 (0,15) 16,159 (22,4%) 16,159 (22,4%) 16,159 (22,4%) 10,18 (0,15,0,22) 1,53 (1,29) 1,00 (1,00,2,00] 0,38 (0,62) 0,00 (0,00,3,00] 0,91 (1,55)	-0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 -0.01 0.08 0.00 -0.10 -0.17 -0.17 -0.17 -0.19 0.00 -0.15 0.00 -0.14 0.00	635 (1.5%) 1.800 (4.3%) 0.04 (0.23) 0.00 (0.00, 0.00] 1.800 (4.3%) 0.05 (0.29) 0.05 (0.29) 0.05 (0.29) 0.05 (0.29) 1.806 (4.3%) 2.525 (6.0%) 1.022 (2.4%) 3.782 (9.0%) 0.17 (0.05) 0.16 [0.13, 0.19] 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.19) 1.23 (1.20) 0.00 [0.00, 1.00] 0.00 [0.00, 2.00] 0.57 (2.15)	0.4 (1.8%) 2,056 (4.2%) 0.04 (0.23) 0.09 (0.00, 0.00] 0.05 (0.30) 0.00 (0.00, 0.00] 2,083 (4.2%) 6,004 (12.1%) 3,114 (6.3%) 5,439 (11.0%) 1,180 (2.4%) 6,392 (12.9%) 0.17 (0.05) 0.16 [0.14, 0.19] 1.23 (1.24) 1.00 [0.00, 1.00] 1.47 (3.88) 0.00 (0.00, 2.00] 0.73 (2.43)	-0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -0.01 0.05 0.00 -0.13 0.00 0.0	6,141 (4.1%) 10,228 (6.9%) 0,04 (0.21) 0,09 (0.03),0.00] 0,09 (0.43) 0,00 [0,00, 0,00] 6,130 (4.1%) 14,520 (32.6%) 15,435 (10.4%) 13,636 (2.4%) 3,636 (2.4%) 3,636 (2.4%) 3,777 (122) 1,00 [1,00, 2,00] 0,37 (0.62) 0,00 [0,00, 1,00] 1,97 (5.34) 0,00 [0,00, 3,00] 0,98 (1.68)	7,455 (4.2%) 12,445 (7.0%) 0.04 (0.21) 0.00 (0.00, 0.00] 6,707 (3.8%) 58,029 (32.9%) 18,530 (10.5%) 4,177 (2.4%) 51,782 (29.3%) 0.19 (0.06) 0.18 [0.15, 0.22] 1.19 (1.12) 1.00 [0.00, 2.00] 0.42 (0.66) 0.00 [0.00, 1.00] 2.29 (5.31) 0.00 [0.00, 0.00, 1.00] 1.03 (1.66)	-0.01 0.00 0.00 0.00 0.00 0.02 -0.01 0.02 -0.01 0.05 0.00 -0.02 0.05 0.00 -0.02 0.05 0.00 -0.02 0.00 -0.02 0.00 -0.02 0.00 -0.00 0.00	9,408 (4, 1%) 8,184 (3.6%) 13,996 (6, 1%) 13,996 (6, 1%) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 0,08 (0,40) 0,00 (0,21) 1,00 (0,21) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (2,1) 1,00 (1,2) 1,00 (1,22) 1,00 (1,22) 1,00 (1,22) 1,00 (1,22) 1,00 (1,22) 1,00 (1,22) 1,00 (1,22) 1,00 (1,22) 1,74 (4,83) 0,00 (4,83) 0,86 (1,74)	36,857 (12.4%) 11,428 (3.8%) 11,428 (3.8%) 11,054 (3.7%) 18,160 (6.1%) 0.04 (0.22) 0.08 (0.40) 0.00 (0.40) 11,405 (3.8%) 76,943 (25.8%) 74,343 (24.9%) 0.19 (0.06) 1.28 (1.18) 1.00 (1.18) 0.39 (0.63) 0.00 (5.16) 0.95 (1.79)	0.02 -0.01 0.00 0.00 0.00 0.00 0.02 0.02 -0.01 0.02 0.02 -0.01 0.05 0.01 0.14 -0.17 0.06 0.00 -0.06 0.00 -0.06 0.00 -0.06 0.00 -0.07 -0.05

median [IQR]	5.00 [2.00, 11.00]	6.00 [2.00, 13.00]	-0.08	4.00 [1.00, 8.00]	4.00 [1.00, 8.00]	0.00	5.00 [2.00, 11.00]	5.00 [2.00, 11.00]	0.00	4.82 (10.02)	5.08 (10.70)	-0.03
HU - Number of different/distinct medication prescriptions mean (sd)	8.27 (4.49)	8.80 (4.57)	-0.12	7.93 (4.40)	8.28 (4.46)	-0.08	8.91 (4.39)	9.11 (4.38)	-0.05	8.62 (4.41)	8.90 (4.44)	-0.06
											,	
median [IQR] HU Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level	8.00 [5.00, 11.00]	8.00 [5.00, 11.00]	0.00	7.00 [5.00, 10.00]	8.00 [5.00, 11.00]	-0.23	8.00 [6.00, 11.00]	8.00 [6.00, 12.00]	0.00	7.82 (4.41)	8.00 (4.44)	-0.04
mean (sd)	8.26 (9.64)	11.99 (11.61)	-0.35	4.30 (6.67)	6.85 (8.07)	-0.34	8.17 (9.90)	11.04 (11.08)	-0.27	7.48 (9.35)	10.57 (10.78)	-0.31
					. ,		. ,	. ,			,	
median [IQR] HU - Number of Office visits	6.00 [0.00, 12.00]	9.00 [4.00, 17.00]	-0.28	1.00 [0.00, 6.00]	4.00 [0.00, 10.00]	-0.41	5.00 [0.00, 13.00]	9.00 [1.00, 17.00]	-0.38	4.44 (9.35)	8.17 (10.78)	-0.37
mean (sd)	5.05 (3.75)	5.15 (3.73)	-0.03	4.92 (3.80)	5.05 (3.82)	-0.03	12.51 (11.50)	12.74 (11.81)	-0.02	9.85 (9.51)	9.63 (9.40)	0.02
				. ,	. ,			10.00 [5.00,		. ,	. ,	
median [IQR] HU - Number of Cardiologist visits	4.00 [2.00, 7.00]	4.00 [3.00, 7.00]	0.00	4.00 [2.00, 7.00]	4.00 [2.00, 7.00]	0.00	10.00 [5.00, 16.00]	17.00]	0.00	7.88 (9.51)	7.55 (9.40)	0.03
mean (sd)	4.26 (5.03)	4.91 (5.46)	-0.12	3.11 (4.31)	3.40 (4.50)	-0.07	5.06 (6.08)	5.35 (6.10)	-0.05	4.57 (5.62)	4.92 (5.71)	-0.06
median [IQR]	3.00 [1.00, 6.00]	3.00 [1.00, 7.00]	0.00	2.00 [0.00, 4.00]	2.00 [0.00, 5.00]	0.00	3.00 [1.00, 7.00]	4.00 [1.00, 7.00]		2.82 (5.62)	3.43 (5.71)	-0.11
HU - Number electrocardiograms	2.14 (2.29)	0.04 (0.44)	-0.09	4.00.(4.00)	2.03 (2.01)	-0.05	2.27 (2.06)	2.44 (2.15)	-0.08	2.18 (2.09)	2.35 (2.19)	-0.08
mean (sd) median [IQR]	2.00 [1.00, 3.00]	2.34 (2.41) 2.00 [1.00, 3.00]	-0.09	1.92 (1.99) 1.00 [1.00, 3.00]	2.03 (2.01) 2.00 [1.00, 3.00]	-0.50	2.00 [1.00, 3.00]	2.00 [1.00, 3.00]	0.00	1.82 (2.09)		-0.08
HU - Number of echocardiograms		,					,					
mean (sd)	1.15 (3.20)	1.25 (3.37)	-0.03	0.86 (1.35)	0.96 (1.43)	-0.07	0.90 (1.24)	1.01 (1.28)	-0.09	0.94 (1.76)		-0.06
median [IQR] HU - Number of neurologist visits	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-0.30	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-0.72	1.00 [0.00, 1.00]	1.00 [0.00, 2.00]	0.00	0.65 (1.76)	1.00 (2.01)	-0.19
mean (sd)	0.32 (1.70)	0.42 (1.85)	-0.06	0.18 (1.09)	0.21 (1.16)	-0.03	0.36 (1.82)	0.44 (1.86)	-0.04	0.32 (1.69)	0.40 (1.76)	-0.05
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.69)		0.00
HU - Fecal occult blood (FOB) test; n (%) HU - Number of PT or aPTTt tests	1,505 (3.8%)	2,236 (3.1%)	0.04	1,223 (2.9%)	1,327 (2.7%)	0.01	4,622 (3.1%)	5,346 (3.0%)	0.01	7,350 (3.2%)	8,909 (3.0%)	0.04
mean (sd)	0.41 (1.20)	0.40 (1.14)	0.01	0.39 (1.13)	0.37 (1.10)	0.02	0.34 (1.08)	0.33 (0.99)	0.01	0.36 (1.11)	0.35 (1.05)	0.01
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.11)	0.00 (1.05)	0.00
N of days in database anytime prior				2.369.06								
mean (sd)	1,873.87 (1,373.15)	1,997.86 (1,480.21)	-0.09	(1,488.04)	2,555.93 (1,598.77)	-0.12	767.20 (508.76)	789.93 (494.30)	-0.05	1248.74 (945.52)	1375.59 (1048.57	-0.13
	1,493.00 [717.00,	1,564.00 [756.00,		2,168.00	2,395.00 [1,138.00,		61E 00 MEE 00	658.00 [497.00,				
median [IQR]	2,895.00]	3,051.00]	-0.05	[1,048.00, 3,668.75]	2,395.00 [1,138.00, 3,906.00]	-0.15	615.00 [465.00, 863.00]	909.00]	-0.09	1048.37 (945.52)	1165.71 (1048.57	-0.12
Socioeconomic Status Proxy Variables	_,,	-,,		-,,	-,,		,	,		()	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
SES - Mean Copay for per prescription cost (charges in U.S. \$)	04.07 (00.00)	00.04/07.54		45 40 (00 05)		0.05				00.00 (444.55)	74 50 (00 74)	
mean (sd)	21.67 (29.08)	20.24 (27.51)	0.05	15.18 (20.95) 10.21 [4.18,	14.15 (20.04)	0.05	115.27 (137.49) 90.00 (63.00,	113.78 (113.51) 90.72 [64.26,	0.01	80.98 (111.55)	74.59 (88.74)	0.06
median [IQR]	14.16 [6.00, 27.52]	12.92 [5.39, 25.50]	0.04	19.95]	0.00.00.07.00.001							
Missing; n (%) SES - Copay: pharmacy cost	1,786 (4.5%)					0.03	132.00]	131.13]	-0.01			0.04
		2,434 (3.4%)	0.06	3,963 (9.5%)	9.68 [3.97, 18.31] 6,979 (14.1%)	0.03 -0.14	132.00] 3,567 (2.4%)	131.13] 3,282 (1.9%)	-0.01 0.03	62.46 (111.55) 9,316 (4.0%)		0.04 -0.02
mean (sd)	203.92 (310.68)	2,434 (3.4%) 201.17 (313.71)	0.06									-0.02
mean (sd)	105.00 [30.00,	201.17 (313.71) 101.10 [30.00,	0.01	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12,	6,979 (14.1%) 119.00 (205.46)	-0.14 0.05	3,567 (2.4%) 159.63 (302.48) 51.43 [0.00,	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07,	-0.16	9,316 (4.0%) 161.72 (287.23)	12,695 (4.3%) 193.29 (324.65)	-0.02
mean (sd) median [IQR]		201.17 (313.71)		3,963 (9.5%) 129.33 (193.24)	6,979 (14.1%)	-0.14 0.05	3,567 (2.4%) 159.63 (302.48)	3,282 (1.9%) 210.89 (354.92)	0.03	9,316 (4.0%) 161.72 (287.23)	12,695 (4.3%)	-0.02
mean (sd)	105.00 [30.00,	201.17 (313.71) 101.10 [30.00,	0.01	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12,	6,979 (14.1%) 119.00 (205.46)	-0.14 0.05	3,567 (2.4%) 159.63 (302.48) 51.43 [0.00,	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07,	-0.16	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23)	12,695 (4.3%) 193.29 (324.65)	-0.02 -0.10 -0.09
mean (sd) median [IOR] SES - Business type: Commercial vs Medicare Commerical; n (%) Medicare; n (%)	105.00 [30.00, 267.78] 10,520 (26.6%) 29,054 (73.4%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%) 59,651 (82.5%)	0.01 0.01 0.22 -0.22	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12, 173.54] 20,919 (49.9%) 21,013 (50.1%)	6,979 (14.1%) 119.00 (205.46) 55.32 [0.00, 155.54] 22,834 (46.1%) 26,669 (53.9%)	-0.14 0.05 0.05 0.08 -0.08	3,567 (2.4%) 159.63 (302.48) 51.43 [0.00, 194.68] 0 (0.0%) 0 (0.0%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%)	0.03 -0.16 -0.14 0.00 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%)	-0.02 -0.10 -0.09 0.05 -0.17
mean (sd) median [OR] SES - Busiess type: Commercial vs Medicare Commerical; n (%) Medicare; n (%) SES - Low income indicator; n (%)	105.00 [30.00, 267.78] 10,520 (26.6%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%)	0.01 0.01 0.22	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12, 173.54] 20,919 (49.9%)	6,979 (14.1%) 119.00 (205.46) 55.32 [0.00, 155.54] 22,834 (46.1%)	-0.14 0.05 0.05 0.08	3,567 (2.4%) 159.63 (302.48) 51.43 [0.00, 194.68] 0 (0.0%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%)	0.03 -0.16 -0.14 0.00 0.00 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%)	-0.02 -0.10 -0.09 0.05
mean (sd) median [IOR] SES - Business type: Commercial vs Medicare Commerical; n (%) Medicare; n (%)	105.00 [30.00, 267.78] 10,520 (26.6%) 29,054 (73.4%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%) 59,651 (82.5%)	0.01 0.01 0.22 -0.22	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12, 173.54] 20,919 (49.9%) 21,013 (50.1%)	6,979 (14.1%) 119.00 (205.46) 55.32 [0.00, 155.54] 22,834 (46.1%) 26,669 (53.9%)	-0.14 0.05 0.05 0.08 -0.08	3,567 (2.4%) 159.63 (302.48) 51.43 [0.00, 194.68] 0 (0.0%) 0 (0.0%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%)	0.03 -0.16 -0.14 0.00 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%) 4,702 (2.0%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%)	-0.02 -0.10 -0.09 0.05 -0.17
meaina (isd) median (IQR) SES - Business type: Commercial vs Medicare Commercial n (%) Medicare: n (%) SES - Low income indicator; n (%) SES - Urban vs Rural (MSA variable) Urban; n (%) Rural; n (%)	105.00 [30.00, 267.78] 10.520 (26.6%) 29,054 (73.4%) 4,702 (11.9%) 0 (0.0%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%) 59,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%)	0.01 0.01 0.22 -0.25 0.00 0.00	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12, 173.54] 20,919 (49.9%) 21,013 (50.1%) 0 (0.0%) 29,285 (69.8%) 2,571 (6.1%)	6,979 (14.1%) 119.00 (205.46) 55.32 [0.00, 155.54] 22,834 (46.1%) 26,669 (53.9%) 0 (0.0%) 30,344 (61.3%) 5,127 (10.4%)	0.14 0.05 0.05 0.08 -0.08 0.00 0.18 -0.16	3,567 (2.4%) 159,63 (302.48) 51.43 [0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0.03 0.16 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%) 4,702 (2.0%) 29,285 (12.7%) 2,571 (1.1%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%) 30,344 (10.2%) 5,127 (1.7%)	-0.02 -0.09 -0.09 -0.17 -0.08 -0.08 -0.05
meain (sd) median (IQR) SES - Business type: Commercial vs Medicare Ormmericat, n (%) Medicare; n (%) SES - Low income indicator; n (%) SES - Urban s Rural (MSA variable) Urban; n (%) Unknown/Minsing; n (%)	105.00 [30.00, 267.78] 10.520 (26.6%) 29.054 (73.4%) 4.702 (11.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%) 59,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%)	0.01 0.22 -0.22 -0.05 0.00 0.00 0.00	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12, 173.54] 20,919 (49.9%) 21,013 (50.1%) 0 (0.0%) 29,285 (69.8%) 2,571 (6.1%) 10,076 (24.0%)	6,979 (14.1%) 119.00 (205.46) 55.32 [0.00, 155.54] 22,834 (46.1%) 26,669 (53.3%) 0 (0.0%) 30,344 (61.3%) 5,127 (10.4%) 14,032 (28.3%)	0.14 0.05 0.05 0.08 -0.08 0.00 0.00 0.18 -0.16 -0.10	3,567 (2.4%) 159.63 (302.48) 51.43 [0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0.03 -0.16 -0.14 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%) 4,702 (2.0%) 29,285 (12.7%) 2,571 (1.1%) 10,076 (4.4%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%) 30,344 (10.2%) 5,127 (1.7%) 14,032 (4.7%)	-0.02 -0.09 -0.09 -0.17 -0.08 0.08 0.08 -0.05 -0.01
meanian (IQR) SES - Business type: Commercial vs MedicareCommercial, n (%)Medicare; n (%) SES - Low noome indicator; n (%) SES - Urban vs Rural (MSA variable)Urba;n n (%)Urba;n n (%) SES - Just Status; n (%)	105.00 [30.00, 267.78] 10.520 (26.6%) 29,054 (73.4%) 4,702 (11.9%) 0 (0.0%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%) 59,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%)	0.01 0.01 0.22 -0.25 0.00 0.00	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12, 173.54] 20,919 (49.9%) 21,013 (50.1%) 0 (0.0%) 29,285 (69.8%) 2,571 (6.1%)	6,979 (14.1%) 119.00 (205.46) 55.32 [0.00, 155.54] 22,834 (46.1%) 26,669 (53.9%) 0 (0.0%) 30,344 (61.3%) 5,127 (10.4%)	0.14 0.05 0.05 0.08 -0.08 0.00 0.18 -0.16	3,567 (2.4%) 159,63 (302.48) 51.43 [0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0.03 0.16 0.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%) 4,702 (2.0%) 29,285 (12.7%) 2,571 (1.1%) 10,076 (4.4%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%) 30,344 (10.2%) 5,127 (1.7%) 14,032 (4.7%)	-0.02 -0.09 -0.09 -0.17 -0.08 -0.08 -0.05
meain (sd) median (IQR) SES - Business type: Commercial vs Medicare Ormmerical, n (%) Medicare; n (%) SES - Low income indicator; n (%) SES - Urban s Rural (MSA variable) Urban; n (%) Unknown/Minsing; n (%)	105.00 [30.00, 267.78] 10.520 (26.6%) 29.054 (73.4%) 4.702 (11.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%) 59,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%)	0.01 0.22 -0.22 -0.05 0.00 0.00 0.00	3,963 (9.5%) 129.33 (193.24) 66.00 [6.12, 173.54] 20,919 (49.9%) 21,013 (50.1%) 0 (0.0%) 29,285 (69.8%) 2,571 (6.1%) 10,076 (24.0%)	6,979 (14.1%) 119.00 (205.46) 55.32 [0.00, 155.54] 22,834 (46.1%) 26,669 (53.3%) 0 (0.0%) 30,344 (61.3%) 5,127 (10.4%) 14,032 (28.3%)	0.14 0.05 0.05 -0.08 -0.08 0.00 0.00 0.18 -0.16 -0.10	3,567 (2.4%) 159.63 (302.48) 51.43 [0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0.03 -0.16 -0.14 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%) 4,702 (2.0%) 29,285 (12.7%) 2,571 (1.1%) 10,076 (4.4%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%) 30,344 (10.2%) 5,127 (1.7%) 14,032 (4.7%) 25,715 (8.6%)	-0.02 -0.09 -0.09 -0.17 -0.08 0.08 0.08 -0.05 -0.01
meaina (icd)median (iQR) SES - Business type: Commercial vs MedicareCommercial n (%)Medicare: n (%) SES - Low income indicator: n (%) SES - Urban vs Rural (MSA variable)Urban; n (%)Urban; n (%)Unknown/Missing: n (%) SES - Dual Status; n (%) SES - Generic name prescription - unique valuemean (sd)	105.00 (30.00, 267.78) 10.520 (26.6%) 29.054 (73.4%) 4.702 (11.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8.27 (4.49)	201.17 (313.71) 101.10 (30.00, 257.34] 12.610 (17.5%) 56,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8.80 (4.57)	0.01 0.22 -0.22 -0.05 0.00 0.00 0.00 0.00 -0.12	3,963 (9,5%) 129,33 (193,24) 66,00 [6,12, 173,54] 20,919 (49,9%) 21,013 (50,1%) 0 (0,0%) 29,285 (69,8%) 2,571 (6,1%) 10,076 (24,0%) 0 (0,0%) 7,93 (4,40)	6,979 (14.1%) 119.00 (205.46) 55.32 (0.00, 155.54) 22,834 (46.1%) 26,669 (53.9%) 0 (0.0%) 30,344 (61.3%) 51,277 (10.4%) 14,032 (28.3%) 0 (0.0%) 8,28 (4.46)	0.14 0.05 0.05 0.08 -0.08 0.00 0.18 -0.16 -0.10 0.00 -0.08	3,567 (2.4%) 159,63 (302.48) 51.43 (0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 24,143 (16.2%) 8.91 (4.39)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 25,715 (14.6%) 9.11 (4.38)	0.03 0.16 0.14 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31.439 (13.6%) 50,067 (21.7%) 4,702 (20%) 29.285 (12.7%) 10,076 (4.4%) 24,143 (10.5%) 8.62 (4.41)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%) 30,344 (10.2%) 14,032 (4.7%) 25,715 (8.6%) 8.90 (4.44)	-0.02 -0.09 -0.09 -0.05 -0.17 -0.08 -0.05 -0.01 0.06 -0.06
mean (sd)median [IOR] SES - Business type: Commercial vs MedicareCommercial, n (%)Medicare; n (%) SES - Lowincome indicator; n (%) SES - Urban vs Rural (IVSA variable)Urban; n (%)Urban; n (%) SES - Dual Status; n (%) SES - Osal Status; n (%) SES - Generic name prescription - unique valuemean (sd)meal(n[QR]	105.00 (30.00, 267.78] 10,520 (26.6%) 29,054 (73.4%) 4,702 (11.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	201.17 (313.71) 101.10 [30.00, 257.34] 12,610 (17.5%) 59,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)	0.01 0.22 -0.22 -0.05 0.00 0.00 0.00 0.00	3,963 (9,5%) 129,33 (193,24) 66,00 [6,12, 173,54] 20,919 (49,9%) 21,013 (50,1%) 0 (0,0%) 29,285 (66,8%) 2,571 (6,1%) 10,076 (24,0%) 0 (0,0%)	6,979 (14.1%) 119.00 (205.46) 55.32 (0.00, 155.54) 22,834 (46.1%) 26,669 (53.9%) 0 (0.0%) 30,344 (61.3%) 51,277 (10.4%) 14,032 (28.3%) 0 (0.0%) 8,28 (4.46)	0.14 0.05 0.05 -0.08 -0.08 0.00 0.18 -0.16 -0.10 0.00	3,567 (2.4%) 159.63 (302.48) 51.43 (0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (0.0%) 2 (4,143 (16.2%)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 25,715 (14.6%)	0.03 0.16 0.14 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%) 92,926 (12.7%) 92,926 (12.7%) 92,926 (12.7%) 10,076 (4.4%) 24,143 (10.5%)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 9,719 (3.3%) 30,344 (10.2%) 5,127 (1.7%) 14,032 (4.7%) 25,715 (8.6%) 8.90 (4.44)	-0.02 -0.09 -0.09 -0.05 -0.17 -0.08 -0.08 -0.05 -0.05 -0.01 0.08
meaina (icd)median (iQR) SES - Business type: Commercial vs MedicareCommercial n (%)Medicare: n (%) SES - Low income indicator: n (%) SES - Urban vs Rural (MSA variable)Urban; n (%)Urban; n (%)Unknown/Missing: n (%) SES - Dual Status; n (%) SES - Generic name prescription - unique valuemean (sd)	105.00 (30.00, 267.78) 10.520 (26.6%) 29.054 (73.4%) 4.702 (11.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8.27 (4.49)	201.17 (313.71) 101.10 (30.00, 257.34] 12.610 (17.5%) 56,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8.80 (4.57)	0.01 0.22 -0.22 -0.05 0.00 0.00 0.00 0.00 -0.12	3,963 (9,5%) 129,33 (193,24) 66,00 [6,12, 173,54] 20,919 (49,9%) 21,013 (50,1%) 0 (0,0%) 29,285 (69,8%) 2,571 (6,1%) 10,076 (24,0%) 0 (0,0%) 7,93 (4,40)	6,979 (14.1%) 119.00 (205.46) 55.32 (0.00, 155.54) 22,834 (46.1%) 26,669 (53.9%) 0 (0.0%) 30,344 (61.3%) 51,277 (10.4%) 14,032 (28.3%) 0 (0.0%) 8,28 (4.46)	0.14 0.05 0.05 0.08 -0.08 0.00 0.18 -0.16 -0.10 0.00 -0.08	3,567 (2.4%) 159,63 (302.48) 51.43 (0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 24,143 (16.2%) 8.91 (4.39)	3,282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 25,715 (14.6%) 9.11 (4.38)	0.03 0.16 0.14 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31.439 (13.6%) 50,067 (21.7%) 4,702 (20%) 29.285 (12.7%) 10,076 (4.4%) 24,143 (10.5%) 8.62 (4.41)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%) 30,344 (10.2%) 5,127 (1.7%) 14,032 (4.7%) 25,715 (8.6%) 8.90 (4.44) 8.00 (4.44)	-0.02 -0.09 -0.09 -0.05 -0.17 -0.08 -0.05 -0.01 0.06 -0.06
median [IQR] SES - Business type: Commercial vs Medicare Commercial, n (%) Medicare; n (%) SES - Low income indicator; n (%) SES - Low income indicator; n (%) SES - Urban vs Rural (MSA variable) Urban; n (%) Rural; n (%) Rural; n (%) SES - Sual Status; n (%) SES - Genaric name prescription - unique value median [IQR] SES - Brand name prescription - unique value	105.00 (30.00, 267.78) 10,520 (26.6%) 29,054 (73.4%) 4,702 (11.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8.27 (4.49) 8.00 [5.00, 11.00]	201.17 (313.71) 101.10 (30.00, 257.34) 12,610 (17.5%) 59,651 (82.5%) 9,719 (13.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 8,800 (4.57) 8,00 (5.00, 11.00)	0.01 0.02 0.22 -0.05 0.00 0.00 0.00 0.00 -0.12 -0.18	3,963 (9.5%) 129,33 (193,24) 66,00 (6.12, 173,54] 20,919 (49.9%) 21,013 (50.1%) 0 (0.0%) 29,285 (69.8%) 2,571 (6.1%) 10,076 (24.0%) 0 (0.0%) 7,93 (4.40) 7,00 (5.00, 10.00]	6,979 (14.1%) 119.00 (205.46) 55.32 (0.00, 155.54] 22,834 (46.1%) 26,689 (53.9%) 0 (0.0%) 30,344 (61.3%) 51.27 (10.4%) 14,032 (28.3%) 0 (0.%) 8.28 (4.46) 8.00 (5.00, 11.00] 8.39 (4.55)	0.14 0.05 0.05 0.08 -0.08 0.00 0.00 0.18 -0.16 -0.10 0.00 -0.08 -0.23	3,567 (2.4%) 159,63 (302.48) 51.43 (0.00, 194.68] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 24,143 (16.2%) 8.91 (4.39) 8.00 (6.00, 11.00] 9.02 (4.48)	3.282 (1.9%) 210.89 (354.92) 97.00 [18.07, 264.50] 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 9.01 (4.6%) 9.11 (4.38) 8.00 [6.00, 12.00]	0.03 0.16 0.14 0.00	9,316 (4.0%) 161.72 (287.23) 63.28 (287.23) 31,439 (13.6%) 50,067 (21.7%) 4,702 (2.0%) 29,285 (12.7%) 24,571 (1.1%) 10,076 (4.4%) 24,143 (10.5%) 8.62 (4.41) 7.82 (4.41)	12,695 (4.3%) 193.29 (324.65) 91.08 (324.65) 35,444 (11.9%) 86,320 (28.9%) 9,719 (3.3%) 30,344 (10.2%) 5,127 (1.7%) 14,032 (4.7%) 25,715 (8.6%) 8.90 (4.44) 8.00 (4.44)	-0.02 -0.09 -0.05 -0.17 -0.08 -0.05 -0.01 -0.06 -0.06 -0.06 -0.06

			Matched									
		Optur	n		MarketScan			Medicare			Pooled	
ariable umber of patients	Rivaroxaban 34,067	Apixaban 34,06	St. Diff 7	Rivaroxaban 30,9	Apixaban 23 30,9	St. Diff 123	Rivaroxaban 119,11	Apixaban 7 119,1	St. Diff	Rivaroxaban 184,107	Apixaban 184,107	St. Diff
ge mean (sd)	72 20 (10 67)	72 15 (10 83)	0.004651034	66 74 (12 85)	66 58 (13 02)	0.012369273	76 50 (8 21)	76 51 (8 26)	-0.001214323	74.07 (9.61)	74 04 (9 71)	0.003105548
median [lQR] c categories		73.00 [66.00, 81.00]	0		0] 64.00 [58.00, 77.00]			)] 76.00 [70.00, 82.0		73.60 (9.61)	73.43 (9.71)	0.017598108
18 - 54; n (%)	2,227 (6.5%)	2,217 (6.5%)	0	4,719 (15.3%)	4,814 (15.6%)	-0.008300494	1,010 (0.8%)	987 (0.8%)	0	7,956 (4.3%)	8,018 (4.4%)	-0.004902461
55 - 64; n (%) 65 - 74; n (%)	4,694 (13.8%) 11,682 (34.3%)	4,717 (13.8%) 11,719 (34.4%)	0 -0.002105812	10,618 (34.3%) 6,320 (20.4%)	10,666 (34.5%) 6,291 (20.3%)	-0.004210172 0.002483849	3,145 (2.6%) 46,684 (39.2%)	3,146 (2.6%) 46,637 (39.2%)	0	18,457 (10.0%) 64,686 (35.1%)	18,529 (10.1%) 64,647 (35.1%)	-0.00332596
>=75; n (%)	15,464 (45.4%)	15,414 (45.2%)	0.004017798	9,266 (30.0%)	9,152 (29.6%)	0.008745557	68,278 (57.3%)	68,347 (57.4%)	-0.002021967	93,008 (50.5%)	92,913 (50.5%)	0
alendar Year (2014-2020) 2012-2013: n (%)	897 (2.6%)	867 (2.5%)	0.006343679	2.413 (7.8%)	2.364 (7.6%)		6.280 (5.3%)	6.172 (5.2%)				
2014; n (%)	2,798 (8.2%)	2,787 (8.2%)	0	5,492 (17.8%)	5,455 (17.6%)	0.005240165	21,548 (18.1%)	21,628 (18.2%)	-0.002594494	29,838 (16.2%)	29,870 (16.2%)	
2015; n (%) 2016; n (%)	3,811 (11.2%) 4.639 (13.6%)	3,804 (11.2%) 4,689 (13.8%)	0 -0.005816559	5,550 (17.9%) 5,931 (19.2%)	5,563 (18.0%) 5,973 (19.3%)	-0.002605727 -0.002536376	27,718 (23.3%) 29,239 (24.5%)	27,988 (23.5%) 29,110 (24.4%)	-0.004723989 0.002326717	37,079 (20.1%) 39,809 (21.6%)	37,355 (20.3%) 39,772 (21.6%)	
2017; n (%)	6,227 (18.3%)	6,247 (18.3%)	0	4,635 (15.0%)	4,716 (15.3%)	-0.008367444	34,332 (28.8%)	34,219 (28.7%)	0.002209474	45,194 (24.5%)	45,182 (24.5%)	0
2018; n (%) 2019; n (%)	6,937 (20.4%) 6,025 (17.7%)	6,984 (20.5%) 5,990 (17.6%)	-0.002479326 0.002622987	3,742 (12.1%) 3,160 (10.2%)	3,739 (12.1%) 3,113 (10.1%)	0 0.003311376	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0	10,679 (5.8%) 9,185 (5.0%)	10,723 (5.8%) 9,103 (4.9%)	0 0.004610229
020; n (%)	2,733 (8.0%)	2,699 (7.9%)	0.003696624	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	2,733 (1.5%)	2,699 (1.5%)	0
se /hite:n (%)	25.848 (75.9%)	25.812 (75.8%)	0.00233649	0 (0.0%)	0 (0.0%)	0	108 611 (91 2%)	108.678 (91.2%)	0	134 459 (73 0%)	134.490 (73.0%)	1.0
sian; n (%)	925 (2.7%)	948 (2.8%)	-0.006114921	0 (0.0%)	0 (0.0%)	0	1,701 (1.4%)	1,711 (1.4%)	0	2,626 (1.4%)	2,659 (1.4%)	0
Nack; n (%) Nack; n (%)		2,755 (8.1%) 2,919 (8.6%)	0	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0	4,521 (3.8%) 1.348 (1.1%)	4,509 (3.8%) 1.318 (1.1%)	0	7,268 (3.9%) 4,279 (2.3%)	7,264 (3.9%) 4,237 (2.3%)	0
North American Native; n (%)	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	335 (0.3%)	344 (0.3%)	0	335 (0.2%)	344 (0.2%)	0
hther; n (%) Inknown/Missing; n (%)	0 (0.0%) 1 616 (4 7%)	0 (0.0%) 1 633 (4 8%)	0	0 (0.0%) 0 (0.0%)	0 (0.0%)	0	1,333 (1.1%) 1,268 (1.1%)	1,330 (1.1%) 1,227 (1.0%)	0 0.009810761	1,330 (0.7%) 2,884 (1.6%)	1,330 (0.7%) 2,860 (1.6%)	0
nder	(1(((	.,		- ( //)	- ( //	0	.,=== (	., (,,	0.003010701		-, ()	0
ales; n (%) males; n (%)	18,512 (54.3%) 15,555 (45.7%)	18,548 (54.4%) 15,519 (45.6%)	-0.002007613 0.002007613	18,799 (60.8%) 12.124 (39.2%)	18,833 (60.9%) 12.090 (39.1%)	-0.002048821 0.002048821	54,420 (45.7%) 64.697 (54.3%)	54,409 (45.7%) 64,708 (54,3%)	0	91,731 (49.8%) 92,376 (50.2%)	91,790 (49.9%) 92.317 (50.1%)	-0.00200001
gion				, , , , , ,		3.002040021			•			
lortheast; n (%) iouth: n (%)	4,345 (12.8%) 13.622 (40.0%)	4,345 (12.8%)	0	6,750 (21.8%) 11.708 (37.9%)	6,748 (21.8%) 11,808 (38.2%)	0	23,184 (19.5%) 47,598 (40.0%)	23,389 (19.6%) 47,456 (39.8%)	-0.002521529 0.004084202	34,279 (18.6%) 72,928 (39.6%)	34,482 (18.7%) 72,973 (39.6%)	-0.002567333
lidwest; n (%)	7,027 (20.6%)	13,709 (40.2%) 7,052 (20.7%)	-0.002470397	8,193 (26.5%)	8,151 (26.4%)	0.002267233	26,441 (22.2%)	26,377 (22.1%)	0.002408153	41,661 (22.6%)	41,580 (22.6%)	0
/est; n (%) nknown+missing; n (%)	9,032 (26.5%) 41 (0.1%)	8,917 (26.2%) 44 (0.1%)	0.00681	4,114 (13.3%) 158 (0.5%)	4,065 (13.1%) 151 (0.5%)	0.005908606	21,776 (18.3%) 118 (0.1%)	21,778 (18.3%) 117 (0.1%)	0	34,922 (19.0%) 317 (0.2%)	34,760 (18.9%) 312 (0.2%)	0.002551639
mbined comorbidity score, 180 days			v			v			0			v
ean (sd) edian [IQR]	2.27 (2.15) 2.00 [1.00, 3.00]	2.25 (2.14) 2.00 [1.00, 3.00]	0.009323984	1.60 (1.63) 1.00 [0.00, 2.00]	1.60 (1.63) 1.00 [0.00, 2.00]	0	1.88 (1.84) 1.00 [0.00, 3.00]	1.88 (1.85) 1.00 [0.00, 3.00]	0	1.91 (1.87) 1.19 (1.87)	1.90 (1.87) 1.19 (1.87)	0.005347594
style Factors			0						0			-
estyle - Smoking ; n (%) estyle - Drug abuse or dependence; n (%)	6,621 (19.4%) 588 (1.7%)	6,611 (19.4%) 606 (1.8%)	0 -0.00762637	3,005 (9.7%) 248 (0.8%)	3,021 (9.8%) 252 (0.8%)	-0.003371124	26,041 (21.9%) 815 (0.7%)	26,032 (21.9%) 825 (0.7%)	0	35,667 (19.4%) 1,651 (0.9%)	35,664 (19.4%) 1,683 (0.9%)	0
style - Alcohol abuse or dependence; n (%)	820 (2.4%)	837 (2.5%)	-0.00646853	580 (1.9%)	588 (1.9%)	0	1,297 (1.1%)	1,301 (1.1%)	0	2,697 (1.5%)	2,726 (1.5%)	0
morbidities - Diabetic Retinopathy; n (%)	530 (1.6%)	543 (1.6%)	0	253 (0.8%)	261 (0.8%)	0	1.208 (1.0%)	1,193 (1.0%)	0	1.991 (1.1%)	1,997 (1.1%)	0
- Diabetic Neuropathy; n (%)	1,924 (5.6%)	1,921 (5.6%)	0	1,054 (3.4%)	1,085 (3.5%)	-0.005479185	4,403 (3.7%)	4,477 (3.8%)	-0.005263632	7,381 (4.0%)	7,483 (4.1%)	-0.005072843
- Diabetic Nephropathy; n (%) - Diabetes with peripheral circulatory disorders; n (%)	1,713 (5.0%) 168 (0.5%)	1,643 (4.8%) 149 (0.4%)	0.00926502 0.014941191	574 (1.9%) 159 (0.5%)	549 (1.8%) 157 (0.5%)	0.007421163	2,524 (2.1%) 753 (0.6%)	2,577 (2.2%) 767 (0.6%)	-0.006894503	4,811 (2.6%) 1,080 (0.6%)	4,769 (2.6%) 1.073 (0.6%)	0
- Diabetes with peripheral circulatory disorders and lower extremity amputation; n (%)	320 (0.9%)	299 (0.9%)	0	213 (0.7%)	213 (0.7%)	0	1,121 (0.9%)	1,129 (0.9%)	0	1,654 (0.9%)	1,641 (0.9%)	0
- Diabetes with unspecified complications; n (%) - Diabetes mellitus without mention of complications; n (%)	581 (1.7%) 7,987 (23.4%)	565 (1.7%) 7,960 (23.4%)	0	431 (1.4%) 6,409 (20.7%)	442 (1.4%) 6,433 (20.8%)	0 -0.002465992	1,218 (1.0%) 28,342 (23.8%)	1,240 (1.0%) 28,423 (23.9%)	0 -0.002346503	2,230 (1.2%) 42,738 (23.2%)	2,247 (1.2%) 42,816 (23.3%)	0 -0.00236728
- Diadetes mentas windut mentan of complications, in (%) - Hypertension; n (%)	26,217 (77.0%)	26,232 (77.0%)	0	21,209 (68.6%)	21,234 (68.7%)	-0.002465992	20,342 (23.0%) 100,576 (84.4%)	100,572 (84.4%)	0	42,738 (23.2%) 148,002 (80.4%)	42,010 (23.3%) 148,038 (80.4%	
- Hyperlipidemia; n (%)	19,147 (56.2%) 766 (2.2%)	19,028 (55.9%) 779 (2.3%)	0.006044439 -0.006742995	15,159 (49.0%) 647 (2.1%)	15,017 (48.6%) 639 (2.1%)	0.008002369	61,613 (51.7%) 2.681 (2.3%)	61,604 (51.7%) 2.693 (2.3%)	0	95,919 (52.1%) 4.094 (2.2%)	95,649 (52.0%) 4.111 (2.2%)	0.002001684
-Acute Mi; n (%) - ACS/unstable angina; n (%)	766 (2.2%) 771 (2.3%)	779 (2.3%) 751 (2.2%)	-0.006742995	621 (2.0%)	595 (1.9%)	0.007232055	2,681 (2.3%) 2,555 (2.1%)	2,693 (2.3%) 2,574 (2.2%)	-0.006894503	4,094 (2.2%) 3,947 (2.1%)	4,111 (2.2%) 3,920 (2.1%)	0
- Old MI; n (%)	1,430 (4.2%)	1,379 (4.0%)	0.010086356	606 (2.0%)	633 (2.0%)	0	4,808 (4.0%)	4,745 (4.0%)	0	6,844 (3.7%)	6,757 (3.7%)	0
- Stable angina; n (%) - Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)	1,478 (4.3%) 8.484 (24.9%)	1,501 (4.4%) 8.497 (24.9%)	-0.004902461 0	935 (3.0%) 6.205 (20.1%)	935 (3.0%) 6.178 (20.0%)	0.002497663	3,675 (3.1%) 29.809 (25.0%)	3,654 (3.1%) 29,653 (24,9%)	0.002310945	6,088 (3.3%) 44,498 (24,2%)	6,090 (3.3%) 44,328 (24.1%)	0
- Other atherosclerosis; n (%)	323 (0.9%)	319 (0.9%)	0	253 (0.8%)	234 (0.8%)	0	1,179 (1.0%)	1,172 (1.0%)	0	1,755 (1.0%)	1,725 (0.9%)	0.010309004
- Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA; n (%) - Ischemic stroke: n (%)	2,189 (6.4%) 3.524 (10.3%)	2,169 (6.4%) 3.518 (10.3%)	0	776 (2.5%) 2,627 (8.5%)	779 (2.5%) 2,602 (8.4%)	0	8,544 (7.2%) 13,171 (11.1%)	8,511 (7.1%) 13,113 (11.0%)	0.003881118 0.003189675	11,509 (6.3%) 19.322 (10.5%)	11,459 (6.2%) 19,233 (10.4%)	0.004131191 0.00326896
- Hemorrhagic stroke; n (%)	78 (0.2%)	73 (0.2%)	0	31 (0.1%)	26 (0.1%)	0	196 (0.2%)	205 (0.2%)	0	305 (0.2%)	304 (0.2%)	0
·TIA; n (%) - Other cerebrovascular disease; n (%)	1,291 (3.8%) 1,205 (3.5%)	1,264 (3.7%) 1,187 (3.5%)	0.005263632	1,087 (3.5%) 766 (2.5%)	1,085 (3.5%) 771 (2.5%)	0	4,630 (3.9%) 3,895 (3.3%)	4,670 (3.9%) 3,849 (3.2%)	0 0.005639422	7,008 (3.8%) 5,866 (3.2%)	7,019 (3.8%) 5,807 (3.2%)	0
Late effects of cerebrovascular disease; n (%)	989 (2.9%)	974 (2.9%)	0	504 (1.6%)	496 (1.6%)	ō	3,164 (2.7%)	3,157 (2.7%)	0	4,657 (2.5%)	4,627 (2.5%)	ō
- Heart failure (CHF); n (%) - Perioheral Vascular Disease (PVD) or PVD Surgery; n (%)	7,175 (21.1%) 2.650 (7.8%)	7,124 (20.9%) 2,666 (7.8%)	0.004910301	4,778 (15.5%) 1.330 (4.3%)	4,738 (15.3%) 1.323 (4.3%)	0.005540974	22,497 (18.9%) 7.895 (6.6%)	22,414 (18.8%) 7.884 (6.6%)	0.002556822	34,450 (18.7%) 11.875 (6.5%)	34,276 (18.6%) 11.873 (6.4%)	0.002567333
- Other cardiac dysrhythmia; n (%)	29,592 (86.9%)	29,680 (87.1%)	-0.005947037	22,573 (73.0%)	22,627 (73.2%)	-0.004510205	83,159 (69.8%)	83,157 (69.8%)	0	135,324 (73.5%)	135,464 (73.6%	) -0.002267233
- Cardiac conduction disorders; n (%) - Other CVD: n (%)	3,110 (9.1%) 11.779 (34.6%)	3,141 (9.2%) 11.695 (34.3%)	-0.003468388 0.006313097	2,216 (7.2%) 9,666 (31.3%)	2,206 (7.1%) 9.600 (31.0%)	0.003881118 0.006478024	9,015 (7.6%) 35.021 (29.4%)	8,944 (7.5%) 34.673 (29.1%)	0.003785069 0.006594737	14,341 (7.8%) 56.466 (30.7%)	14,291 (7.8%) 55.968 (30.4%)	0
Medications - ACE inhibitors; n (%)	10,342 (30.4%)	10,318 (30.3%)	0.002175005	9,033 (29.2%)	9,039 (29.2%)	0	37,734 (31.7%)	37,793 (31.7%)	0	57,109 (31.0%)	57,150 (31.0%)	0
Medications - ARBs; n (%) Medications - Alpha blockers; n (%)	7,534 (22.1%) 3,937 (11.6%)	7,581 (22.3%) 3,937 (11.6%)	-0.004812436	6,867 (22.2%) 2,825 (9.1%)	6,809 (22.0%) 2,855 (9.2%)	0.004820215	28,936 (24.3%) 14.595 (12.3%)	28,724 (24.1%) 14,663 (12.3%)	0.004669699	43,337 (23.5%) 21.357 (11.6%)	43,114 (23.4%) 21,455 (11,7%)	0.002360241
Medications - Beta blockers; n (%)	22,348 (65.6%)	22,416 (65.8%)	-0.004213095	20,697 (66.9%)	20.720 (67.0%)	-0.002125882	81,685 (68.6%)	81,727 (68.6%)	0	124,730 (67.7%)	124,863 (67.8%	) -0.002139345
Medications - Loop Diuretics; n (%) Medications - Other diuretics: n (%)	6,871 (20.2%) 1,520 (4,5%)	6,783 (19.9%) 1,532 (4,5%)	0.007493037	4,918 (15.9%) 1,206 (3.9%)	4,920 (15.9%) 1,219 (3,9%)	0	27,836 (23.4%) 5,513 (4.6%)	27,874 (23.4%) 5,482 (4.6%)	0	39,625 (21.5%) 8,239 (4.5%)	39,577 (21.5%) 8,233 (4.5%)	0
Medications - Use of nitrates: n (%)	1,576 (4.6%)	1,606 (4.7%)	-0.004749134	1,188 (3.8%)	1,207 (3.9%)	-0.005197523	7,347 (6.2%)	7,306 (6.1%)	0.004162423	10,111 (5.5%)	10,119 (5.5%)	ő
Medications - Use of statins; n (%) Medications - Use of other lipid-lowering drugs; n (%)	17,122 (50.3%) 1.232 (3.6%)	17,176 (50.4%) 1.231 (3.6%)	-0.00200005	14,087 (45.6%) 1.353 (4.4%)	14,047 (45.4%) 1.326 (4.3%)	0.004016307 0.004902461	63,600 (53.4%) 5.124 (4.3%)	63,607 (53.4%) 5,109 (4,3%)	0	94,809 (51.5%) 7.709 (4.2%)	94,830 (51.5%) 7.666 (4.2%)	0
Medications - calcium channel blockers; n (%)	12,788 (37.5%)	12,824 (37.6%)	-0.002065043	11,453 (37.0%)	11,469 (37.1%)	-0.002070657	46,948 (39.4%)	46,720 (39.2%)	0.004094872	71.189 (38.7%)	71,013 (38.6%)	0.002053611
er Comorbidity - Osteoporosis; n (%) er Comorbidity - Dementia; n (%)	2,752 (8.1%) 2,507 (7.4%)	2,723 (8.0%) 2,505 (7.4%)	0.003675589	1,291 (4.2%) 1,220 (3.9%)	1,266 (4.1%) 1,211 (3.9%)	0.005013965	11,020 (9.3%) 8,916 (7.5%)	10,950 (9.2%) 8,905 (7.5%)	0.003451489	15,063 (8.2%) 12,643 (6.9%)	14,939 (8.1%) 12.621 (6.9%)	0.003654958
er Comorbidity - Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland ; n (%)	7,094 (20.8%)	7,038 (20.7%)	0.002465992	4,914 (15.9%)	4,969 (16.1%)	-0.005455468	14,854 (12.5%)	14,982 (12.6%)	-0.003018552	26,862 (14.6%)	26,989 (14.7%)	-0.002828003
er Comorbidity - Edema; n (%) er Comorbidity - Depression; n (%)	3,550 (10.4%) 2.913 (8.6%)	3,521 (10.3%) 2,935 (8.6%)	0.003282882	2,259 (7.3%) 1,926 (6.2%)	2,290 (7.4%) 1,938 (6.3%)	-0.003832079 -0.004131191	9,467 (7.9%) 9,465 (7.9%)	9,467 (7.9%) 9,554 (8.0%)	0 -0.003696624	15,276 (8.3%) 14,304 (7.8%)	15,278 (8.3%) 14,427 (7.8%)	0
er Comorbidity - Anxiety; n (%)	3,874 (11.4%)	3,869 (11.4%)	0	2,613 (8.5%)	2,665 (8.6%)	-0.003576233	10,377 (8.7%)	10,419 (8.7%)	0	16,864 (9.2%)	16,953 (9.2%)	ő
ar Comorbidity - Pneumonia; n (%) ar Comorbidity - COPD; n (%)	2,186 (6.4%) 4,968 (14.6%)	2,163 (6.3%) 5,013 (14.7%)	0.00410072 -0.002828003	1,557 (5.0%) 2,812 (9.1%)	1,506 (4.9%) 2,783 (9.0%)	0.004610229 0.00348558	7,900 (6.6%) 16,610 (13.9%)	7,890 (6.6%) 16,533 (13.9%)	0	11,643 (6.3%) 24,390 (13.2%)	11,559 (6.3%) 24,329 (13.2%)	0
ar Comorbidity - COPD; n (%) ar Comorbidity - Asthma; n (%)	2,169 (6.4%)	2,178 (6.4%)	0	1,771 (5.7%)	2,783 (9.0%) 1,816 (5.9%)	-0.008556468	7,281 (6.1%)	7,253 (6.1%)	0	11,221 (6.1%)	11,247 (6.1%)	0
er Comorbidity - Acute renal disease; n (%)	1,700 (5.0%) 120 (0.4%)	1,706 (5.0%) 112 (0.3%)	0 0.01693335	1,002 (3.2%) 47 (0.2%)	993 (3.2%) 46 (0.1%)	0 0.025841432	5,417 (4.5%) 215 (0.2%)	5,506 (4.6%) 216 (0.2%)	-0.004798523 0	8,119 (4.4%) 382 (0.2%)	8,205 (4.5%) 374 (0.2%)	-0.0048496
er Comorbidity CKD Stage 1; n (%) er Comorbidity - CKD Stage 2; n (%)	781 (2.3%)	781 (2.3%)	0	237 (0.8%)	250 (0.8%)	0	1,262 (1.1%)	1,268 (1.1%)	õ	2,280 (1.2%)	2,299 (1.2%)	0
er Comorbidity - CKD Stage 3; n (%)	3,259 (9.6%) 1,622 (4.8%)	3,190 (9.4%) 1,627 (4.8%)	0.006820975	1,063 (3.4%) 691 (2.2%)	1,066 (3.4%) 691 (2.2%)	0	6,931 (5.8%) 4,903 (4.1%)	7,025 (5.9%) 4,977 (4.2%)	-0.004261013 -0.005013965	11,253 (6.1%) 7,216 (3.9%)	11,281 (6.1%) 7,295 (4.0%)	0 -0.00513398
er Comorbidity - Occurrence of chronic renal insufficiency w/o CKD ; n (%) er Comorbidity - Occurrence of miscellaneous renal insufficiency; n (%)	1,622 (4.8%) 1,895 (5.6%)	1,627 (4.8%) 1,886 (5.5%)	0 0.004367708	691 (2.2%) 1,098 (3.6%)	691 (2.2%) 1,131 (3.7%)	0 -0.00533248	4,903 (4.1%) 5,248 (4.4%)	4,977 (4.2%) 5,332 (4.5%)	-0.005013965 -0.0048496	7,216 (3.9%) 8,241 (4.5%)	7,295 (4.0%) 8,349 (4.5%)	-0.00513398 0
er Comorbidity - Hypertensive nephropathy; n (%)	2,673 (7.8%)	2,586 (7.6%)	0.007502169	978 (3.2%)	940 (3.0%)	0.011539699	7,114 (6.0%)	7,243 (6.1%)	-0.004194449	10.765 (5.8%)	10,769 (5.8%)	0
er Comorbidity - Obstructive sleep apnea; n (%) er Comorbidity - Osteoarthritis; n (%)	3,823 (11.2%) 7,142 (21.0%)	3,809 (11.2%) 7.114 (20.9%)	0 0.002457295	4,198 (13.6%) 4.883 (15.8%)	4,221 (13.7%) 4.861 (15.7%)	-0.002912748 0.002745207	7,739 (6.5%) 25,295 (21.2%)	7,701 (6.5%) 25.311 (21.2%)	0	15,760 (8.6%) 37,320 (20.3%)	15,731 (8.5%) 37,286 (20.3%)	0.003576233
er Comorbidity - Other arthritis, arthropathies and musculoskeletal pain; n (%)	13,179 (38.7%)	13,129 (38.5%)	0.004108214	10,699 (34.6%)	10,712 (34.6%)	0	43,434 (36.5%)	43,465 (36.5%)	0	67,312 (36.6%)	67,306 (36.6%)	
er Comorbidity - Dorsopathies; n (%) er Comorbidity - Fractures; n (%)	7,796 (22.9%) 1,609 (4.7%)	7,732 (22.7%) 1,603 (4.7%)	0.00476711	6,222 (20.1%) 1,056 (3.4%)	6,260 (20.2%) 1,090 (3.5%)	-0.002493018 -0.005479185	24,994 (21.0%) 5,648 (4.7%)	24,900 (20.9%) 5,751 (4.8%)	0.002457295	39,012 (21.2%) 8,313 (4.5%)	38,892 (21.1%) 8,444 (4.6%)	0.002448749
	2 104 (6 2%)	2,019 (5.9%)	0.012583567	720 (2.3%)	724 (2.3%)	0	2,511 (2.1%)	2,515 (2.1%)	0	5,335 (2.9%)	5,258 (2.9%)	0
ther Comorbidity - Falls; n (%) ther Comorbidity - Sleep Disorder; n (%) ther Comorbidity - Delirium; n (%)	1,567 (4.6%) 901 (2.6%)	1,567 (4.6%) 884 (2.6%)	0	2,121 (6.9%) 494 (1.6%)	2,093 (6.8%) 479 (1.5%)	0.003958805 0.008095242	5,615 (4.7%) 2,966 (2.5%)	5,611 (4.7%) 2.937 (2.5%)	0	9,303 (5.1%) 4,361 (2.4%)	9,271 (5.0%) 4,300 (2.3%)	0.004566758 0.006601343

Procedures Procedure - Hip Surgery; n (%)	198 (0.6%)	209 (0.6%)	0	92 (0.3%)	116 (0.4%)	-0.01693335	607 (0.5%)	640 (0.5%)	0	897 (0.5%)	965 (0.5%)	0
Medications			Ÿ.			0.01000000						-
DM Medications - Meglitinides; n (%) DM Medications - AGIs: n (%)	72 (0.2%) 20 (0.1%)	77 (0.2%) 24 (0.1%)	0	74 (0.2%) 14 (0.0%)	75 (0.2%) 17 (0.1%)	0 -0.044743737	345 (0.3%) 94 (0.1%)	347 (0.3%) 95 (0.1%)	0	491 (0.3%) 128 (0.1%)	499 (0.3%) 136 (0.1%)	0
DM Medications - AGIS; n (%) DM Medications - Insulin; n (%)	1,478 (4.3%)	1,479 (4.3%)	0	1,294 (4.2%)	1,306 (4.2%)	-0.044743737	4,175 (3.5%)	4,109 (3.4%)	0.005479185	6,947 (3.8%)	6,894 (3.7%)	0.005263632
DM Medications - Glitazones; n (%)	357 (1.0%)	374 (1.1%)	-0.009810761	353 (1.1%)	354 (1.1%)	0	1.266 (1.1%)	1,269 (1.1%)	0	1,976 (1.1%)	1,997 (1.1%)	0
DM Medications - 1st and 2nd Generation SUs ; n (%) DM Medications - DPP-4 Inhibitors; n (%)	2,118 (6.2%) 860 (2.5%)	2,081 (6.1%) 888 (2.6%)	0.004162423 -0.006343679	1,622 (5.2%) 978 (3.2%)	1,634 (5.3%) 979 (3.2%)	-0.004483651	7,542 (6.3%) 3,422 (2.9%)	7,589 (6.4%) 3,455 (2.9%)	-0.00410072	11,282 (6.1%) 5,260 (2.9%)	11,304 (6.1%) 5,322 (2.9%)	0
DM Medications - GLP-1 RA; n (%)	345 (1.0%)	349 (1.0%)	0	452 (1.5%)	454 (1.5%)	0	793 (0.7%)	774 (0.6%)	0.012444223	1,590 (0.9%)	1,577 (0.9%)	0
DM Medications - SGLT-2 Inhibitors ; n (%)	317 (0.9%)	317 (0.9%)	0	387 (1.3%)	384 (1.2%)	0.009000794	524 (0.4%)	519 (0.4%)	0	1,228 (0.7%)	1,220 (0.7%)	0
DM Medications - Metformin; n (%) Other Medications - Use of NSAIDs: n (%)	4,637 (13.6%) 4,170 (12.2%)	4,625 (13.6%) 4,141 (12.2%)	0	3,972 (12.8%) 4 177 (13.5%)	3,996 (12.9%) 4,205 (13.6%)	-0.002988238 -0.002921785	15,017 (12.6%) 15.933 (13.4%)	15,014 (12.6%) 15.888 (13.3%)	0 002940191	23,626 (12.8%) 24,280 (13.2%)	23,635 (12.8%) 24,234 (13.2%)	0
Other Medications - Use of other hypertension drugs; n (%)	2,254 (6.6%)	2,221 (6.5%)	0.004041947	1,668 (5.4%)	1,691 (5.5%)	-0.004405265	8,885 (7.5%)	8,941 (7.5%)	0	12,807 (7.0%)	12,853 (7.0%)	ō
Other Medications - Digoxin; n (%)	2,219 (6.5%)	2,219 (6.5%)	0	2,082 (6.7%)	2,078 (6.7%)	0	10,307 (8.7%)	10,355 (8.7%)	0	14,608 (7.9%)	14,652 (8.0%)	-0.003696624
Other Medications - Use of Anti-arrhythmics; n (%) Other Medications - Use of antipsychotics: n (%)	5,454 (16.0%) 632 (1.9%)	5,437 (16.0%) 603 (1.8%)	0 007421163	6,102 (19.7%) 409 (1.3%)	6,071 (19.6%) 407 (1.3%)	0.002516669	21,156 (17.8%) 3.028 (2.5%)	21,105 (17.7%) 3.074 (2.6%)	0.002617178	32,712 (17.8%) 4.069 (2.2%)	32,613 (17.7%) 4 084 (2.2%)	0.002617178
Other Medications - Use of dementia meds; n (%)	1,093 (3.2%)	1,091 (3.2%)	0	625 (2.0%)	634 (2.1%)	-0.007057056	5,249 (4.4%)	5,267 (4.4%)	0	6,967 (3.8%)	6,992 (3.8%)	0
Other Medications - Use of antiparkinsonian meds; n (%)	857 (2.5%)	861 (2.5%)	0	625 (2.0%)	631 (2.0%)	0	3,737 (3.1%)	3,654 (3.1%)	0	5,219 (2.8%)	5,146 (2.8%)	0
Other Medications - Use of anxiolytics/hypnotics; n (%) Other Medications - Use of anticonvulsants; n (%)	1,623 (4.8%) 3,791 (11.1%)	1,628 (4.8%) 3,820 (11.2%)	0 -0.003177126	1,745 (5.6%) 2,559 (8.3%)	1,763 (5.7%) 2,524 (8.2%)	-0.004331176 0.003634718	7,389 (6.2%) 13,875 (11.6%)	7,356 (6.2%) 13,931 (11.7%)	0 -0.003116982	10,757 (5.8%) 20,225 (11.0%)	10,747 (5.8%) 20,275 (11.0%)	0
Other Medications - Use of antidepressants; n (%)	6 889 (20 2%)	6,906 (20.3%)	-0.002488413	5.413 (17.5%)	5,378 (17.4%)	0.002634779	26,364 (22.1%)	26,349 (22.1%)	0	38,666 (21.0%)	38,633 (21.0%)	0
Other Medications - Use of lithium; n (%) Other Medications - Use of Benzos: n (%)	35 (0.1%) 3.954 (11.6%)	41 (0.1%) 4.018 (11.8%)	0 -0.006222413	29 (0.1%) 3.432 (11.1%)	26 (0.1%) 3.418 (11.1%)	0	124 (0.1%) 16.809 (14.1%)	119 (0.1%) 16.796 (14.1%)	0	188 (0.1%) 24.195 (13.1%)	186 (0.1%) 24.232 (13.2%)	0 -0.002959053
Other Medications - Use of Benzos; n (%) Other Medication - Use of CNS stimulants; n (%)	103 (0.3%)	4,018 (11.8%) 106 (0.3%)	0	160 (0.5%)	172 (0.6%)	-0.013521541	357 (0.3%)	360 (0.3%)	0	24,195 (13.1%) 620 (0.3%)	638 (0.3%)	-0.002959055
Other Medications - Use of opioids; n (%)	6,999 (20.5%)	6,990 (20.5%)	0	6,296 (20.4%)	6,393 (20.7%)	-0.007424571	28,924 (24.3%)	28,893 (24.3%)	0	42,219 (22.9%)	42,276 (23.0%)	-0.002378059
Other Medications - Use of COPD/asthma meds; n (%) Other Medications - Use of oral corticosteroids: n (%)	5,766 (16.9%) 6,493 (19.1%)	5,805 (17.0%) 6,450 (18.9%)	-0.002665298 0.005098144	5,002 (16.2%) 5,641 (18.2%)	5,008 (16.2%) 5,733 (18.5%)	0 -0.007750476	22,985 (19.3%) 25,623 (21.5%)	22,848 (19.2%) 25,580 (21.5%)	0.002536376	33,753 (18.3%) 37,757 (20.5%)	33,661 (18.3%) 37,763 (20.5%)	0
Other Medications - Use of Sympatomimetic agents; n (%)	167 (0.5%)	179 (0.5%)	0	281 (0.9%)	296 (1.0%)	-0.010309004	374 (0.3%)	375 (0.3%)	0	822 (0.4%)	850 (0.5%)	-0.014941191
Other Medications - Use of bisphosphonates; n (%)	1,107 (3.2%)	1,123 (3.3%)	-0.005639422	583 (1.9%)	568 (1.8%)	0.007421163	4,155 (3.5%)	4,096 (3.4%)	0.005479185	5,845 (3.2%)	5,787 (3.1%)	0.005725279
Other Medications - Use of thiazide; n (%) Other Medications - Use of estrogens, progestins, androgens; n (%)	3,766 (11.1%) 1.067 (3.1%)	3,761 (11.0%) 1.092 (3.2%)	0.003189675 -0.005725279	3,186 (10.3%) 1.536 (5.0%)	3,151 (10.2%) 1,560 (5.0%)	0.003297019	14,993 (12.6%) 4,507 (3.8%)	14,980 (12.6%) 4,549 (3.8%)	0	21,945 (11.9%) 7.110 (3.9%)	21,892 (11.9%) 7.201 (3.9%)	U 0
Healthcare Utilization			0.000,20210			•			•		,	
HU - Bone mineral density; n (%)	1,247 (3.7%)	1,253 (3.7%)	0	481 (1.6%)	487 (1.6%)	0	4,954 (4.2%)	4,933 (4.1%)	0.005013965	6,682 (3.6%)	6,673 (3.6%)	0
HU - Occurrence of creatinine tests ordered ; n (%) HU - Number of D-dimer tests	1,673 (4.9%)	1,669 (4.9%)	U	1,312 (4.2%)	1,307 (4.2%)	U	8,163 (6.9%)	8,199 (6.9%)	U	11,148 (6.1%)	7,909 (4.3%)	0.081137899
mean (sd)	0.04 (0.22)	0.04 (0.20)	0	0.04 (0.24)	0.04 (0.23)	0	0.04 (0.21)	0.04 (0.21)	0	0.04 (0.22)	0.04 (0.21)	0
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 (0.22)	0.00 (0.21)	0
HU - Number of CRP, high-sensitivity CRP tests mean (sd)	0.07 (0.39)	0.07 (0.40)	0	0.05 (0.28)	0.05 (0.29)	0	0.09 (0.43)	0.09 (0.42)	0	0.08 (0.68)	0.08 (0.40)	0
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 (0.68)	0.00 (0.40)	0
HU - Colonoscopy; n (%) HU - Flu vaccine: n (%)	1,320 (3.9%) 6,264 (18,4%)	1,259 (3.7%) 6.278 (18.4%)	0.0104606	1,336 (4.3%) 3.830 (12.4%)	1,346 (4.4%) 3,779 (12.2%)	-0.004902461	4,808 (4.0%) 38,751 (32.5%)	4,900 (4.1%) 38.699 (32.5%)	-0.005072843	7,464 (4.1%) 48.845 (26.5%)	7,505 (4.1%) 48.756 (26.5%)	0
HU - Mammogram, n (%)	3,020 (8.9%)	3,010 (8.8%)	0.003520876	1,914 (6.2%)	1,943 (6.3%)	-0.004131191	12,335 (10.4%)	12,404 (10.4%)	0	17.269 (9.4%)	17,357 (9.4%)	0
HU - PSA test or Prostate exam for DRE; n (%)	4,669 (13.7%)	4,706 (13.8%)	-0.002903819	3,774 (12.2%)	3,742 (12.1%)	0.003060846	14,754 (12.4%)	14,815 (12.4%)	0	23,197 (12.6%)	23,263 (12.6%)	0
HU - Pap smear; n (%) HU - Pneumonia vaccine: n (%)	549 (1.6%) 7.071 (20.8%)	509 (1.5%) 7 077 (20.8%)	0.008095242	744 (2.4%) 3.494 (11.3%)	757 (2.4%) 3.528 (11.4%)	0	2,839 (2.4%) 30.996 (26.0%)	2,838 (2.4%) 30.949 (26.0%)	0	4,132 (2.2%) 41.561 (22.6%)	4,104 (2.2%) 41.554 (22.6%)	0
Frailty Score: Empirical Version 365 days	7,071 (20.0%)	7,077 (20.6%)	0	3,484 (11.3%)	3,328 (11.4%)	-0.003152559	30,996 (20.0%)	30,949 (20.0%)	0	41,301 (22.0%)	41,334 (22.0%)	0
mean (sd)	0.18 (0.06)	0.18 (0.06)	0	0.17 (0.05)	0.17 (0.05)	0	0.19 (0.06)	0.19 (0.06)	0	0.18 (0.06)	0.18 (0.06)	0
median [IQR] CHADS2 score. 180 days	0.17 [0.14, 0.20]	0.17 [0.14, 0.21]	0	0.16 [0.14, 0.19]	0.16 [0.14, 0.19]	0	0.17 [0.14, 0.21]	0.17 [0.14, 0.21]	0	0.17 (0.06)	0.17 (0.06)	0
mean (sd)	1.38 (1.24)	1.37 (1.24)	0.008064516	1.19 (1.21)	1.19 (1.20)	0	1.24 (1.18)	1.25 (1.18)	-0.008474576	1.26 (1.20)	1.26 (1.19)	0
median [IQR]	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0	1.00 (1.20)	1.00 (1.19)	0
HU - Number of Hospitalizations mean (sd)	0.27 (0.55)	0.26 (0.52)	0.018684246	0.28 (0.50)	0.28 (0.49)	0	0.37 (0.63)	0.37 (0.62)	0	0.34 (0.60)	0.33 (0.58)	0.016946719
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0	0.00 (0.60)	0.00 (0.58)	0
HU - Number of hospital days	1.44 (4.38)	1.41 (4.34)	0.006880662	1.26 (3.31)	1.26 (3.39)		1.98 (5.21)	1.98 (5.14)		1.76 (4.79)	1.75 (4.74)	0.002098607
mean (sd) median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0	0.00 [0.00, 3.00]	0.00 [0.00, 3.00]	0	0.00 (4.79)	0.00 (4.74)	0.002098807
HU - Number of Emergency Department (ED) visits												
mean (sd) median [IQR]	0.79 (1.49) 0.00 [0.00, 1.00]	0.79 (1.42) 0.00 [0.00, 1.00]	0	0.60 (2.29) 0.00 (0.00, 0.00)	0.60 (2.09) 0.00 (0.00, 0.00)	0	0.98 (1.66) 0.00 [0.00, 2.00]	0.98 (1.65) 0.00 [0.00, 2.00]	0	0.88 (2.95) 0.00 (2.95)	0.88 (1.69) 0.00 (1.69)	0
HU - Number of internal medicine/family medicine visits			0	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	U	0.00 [0.00, 2.00]	0.00 [0.00, 2.00]	0			0
mean (sd)	9.03 (12.31)	8.97 (12.19)	0.0048979	6.28 (9.23)	6.34 (9.57)	-0.006381935	7.88 (9.58)	7.86 (9.63)	0.002082242	7.82 (16.98)	7.81 (10.14)	0.000715071
median [IQR] HU - Number of different/distinct medication prescriptions	5.00 [2.00, 12.00]	5.00 [2.00, 11.00]	U	4.00 [1.00, 8.00]	4.00 [1.00, 8.00]	U	5.00 [2.00, 11.00]	5.00 [2.00, 11.00]	U	4.83 (16.98)	4.83 (10.14)	U
mean (sd)	8.36 (4.50)	8.36 (4.48)	0	8.01 (4.42)	8.03 (4.39)	-0.004540269	8.93 (4.38)	8.92 (4.37)	0.002285713	8.67 (7.42)	8.67 (4.39)	0
median (IQR) HU - Number of Office visits	8.00 [5.00, 11.00]	8.00 [5.00, 11.00]	0	7.00 [5.00, 10.00]	7.00 [5.00, 10.00]	0	8.00 [6.00, 11.00]	8.00 [6.00, 11.00]	0	7.83 (7.42)	7.83 (4.39)	0
mean (sd)	5.06 (3.74)	5.08 (3.67)	-0.00539787	4.95 (3.80)	4.95 (3.73)	0	12.49 (11.61)	12.47 (11.44)	0.001735311	9.85 (16.16)	9.84 (9.46)	0.000755242
median [lQR]	4.00 [2.00, 7.00]	4.00 [2.00, 7.00]	0	4.00 [2.00, 7.00]	4.00 [2.00, 7.00]	0	9.00 [5.00, 16.00]	10.00 [5.00, 16.00	-0.120883684	7.23 (16.16)	7.88 (9.46)	-0.049090715
HU - Number of Cardiologist visits mean (sd)	4.28 (5.12)	4.34 (4.74)	-0.012161357	3.24 (4.47)	3.25 (4.26)	-0.002290288	5.00 (6.19)	5.02 (5.68)	-0.003366734	4.57 (9.67)	4.60 (5.30)	-0.003847436
median [lQR]	3.00 [1.00, 6.00]	3.00 [1.00, 6.00]	0	2.00 [0.00, 5.00]	2.00 [0.00, 5.00]	0		3.00 [1.00, 7.00]	0	2.83 (9.67)	2.83 (5.30)	0
HU - Number electrocardiograms	2.15 (2.34)	2.14 (2.14)	0.004459844	1.97 (2.07)	1.98 (1.94)	-0.004984912	2.29 (2.09)	2.29 (2.02)		2.21 (3.59)	2.21 (2.03)	
mean (sd) median [IQR]	2.15 (2.34) 2.00 [1.00, 3.00]	2.14 (2.14) 2.00 [1.00, 3.00]	0.00+439044	1.97 (2.07) 1.00 [1.00, 3.00]	1.98 (1.94) 1.00 [1.00, 3.00]	-0.004984912 0		2.29 (2.02) 2.00 [1.00, 3.00]	0	2.21 (3.59) 1.83 (3.59)	2.21 (2.03) 1.83 (2.03)	0
HU - Number of echocardiograms												
mean (sd) median (IOR)	1.10 (3.08) 0.00 [0.00, 1.00]	1.09 (2.86) 0.00 [0.00, 1.00]	0.003364696	0.89 (1.40) 1.00 [0.00, 1.00]	0.90 (1.34) 1.00 [0.00, 1.00]	-0.007297521 0	0.92 (1.26) 1.00 [0.00, 1.00]	0.92 (1.20) 1.00 [0.00, 1.00]	0	0.95 (2.97) 0.81 (2.97)	0.95 (1.66) 0.81 (1.66)	0
HU - Number of neurologist visits			-			-			-			-
mean (sd) median (IQR)	0.33 (1.74)	0.33 (1.52) 0.00 (0.00, 0.00)	0	0.19 (1.06) 0.00 (0.00, 0.001	0.19 (1.15) 0.00 (0.00, 0.00)	0	0.37 (1.90) 0.00 (0.00, 0.00)	0.37 (1.60) 0.00 [0.00, 0.00]	0	0.33 (2.96)	0.33 (1.52)	0
median [IQR] HU - Fecal occult blood (FOB) test: n (%)	0.00 [0.00, 0.00] 1,205 (3.5%)	0.00 [0.00, 0.00] 1.192 (3.5%)	0 -0.26526667	0.00 [0.00, 0.00] 891 (2.9%)	0.00 [0.00, 0.00] 873 (2.8%)	0 0.006009774		0.00 [0.00, 0.00] 3.648 (3.1%)	0 -0.005815379	0.00 (2.96) 5.699 (3.1%)	0.00 (1.52) 5.713 (3.1%)	0 0.030052126
HU - Number of PT or aPTTt tests		,									., ,	
mean (sd) median (IOR)	0.39 (1.11) 0.00 [0.00, 0.00]	0.40 (1.18) 0.00 [0.00, 0.00]	-0.008729547	0.38 (1.09) 0.00 [0.00, 0.00]	0.39 (1.18) 0.00 [0.00, 0.00]	-0.008803656	0.33 (1.01) 0.00 [0.00, 0.00]	0.33 (1.06) 0.00 [0.00, 0.00]	0	0.35 (1.76) 0.00 (1.76)	0.35 (1.10) 0.00 (1.10)	0
Socioeconomic Status Proxy Variables	0.00 [0.00, 0.00]	5.00 [0.00, 0.00]	č	5.00 [0.00, 0.00]	5.55 [0.00, 0.00]	•	5.00 [0.00, 0.00]	0.00 [0.00, 0.00]	•	0.00 (1.70)	0.00 (1.10)	
SES - Mean Copay for per prescription cost (charges in U.S. \$)	21.17 (29.07)	21.30 (29.55)	-0 004435198	14.41 (21.23)	14.37 (20.17)	0.001931734	115 29 (139 28)	115.21 (121.85)	0.000611261	80.93 (190.30)	80.90 (99.18)	0 000197705
mean (sd) median [IQR]	21.17 (29.07) 13.65 [5.74, 26.67]	21.30 (29.55) 13.44 [5.62, 26.67]	-0.004435198 0.00716455	14.41 (21.23) 9.79 [3.69, 18.75]		-0.003380535	115.29 (139.28) 90.50 [63.50, 132.09	91.00 [64.22, 132.		80.93 (190.30) 62.72 (190.30)		-0.001977051
Missing; n (%)	1,440 (4.2%)	1,415 (4.2%)	0	3,256 (10.5%)	3,225 (10.4%)	0.00326896	2,615 (2.2%)	2,654 (2.2%)	0	7,311 (4.0%)	7,294 (4.0%)	
SES - Copay: pharmacy cost mean (sd)	200.41 (308.17)	202.34 (320.10)	-0.006142748	123.97 (196.24)	123.68 (197.22)	0.001474097	186.85 (323.76)	187.35 (341.03)	-0.001503727	178.80 (510.13)	179.43 (317.40)	-0.001482917
median [lQR]		202.34 (320.10) 2] 101.76 [29.70, 260.02]			123.68 (197.22) ] 60.00 [2.43, 165.00]	0	78.74 [9.00, 234.36]			79.89 (510.13)		0.005790437
SES - Business type: Commercial vs Medicare												
Commerical; n (%) Medicare; n (%)	8,158 (23.9%) 25,909 (76.1%)	8,126 (23.9%) 25,941 (76.1%)	0	15,370 (49.7%) 15,553 (50.3%)	15,482 (50.1%) 15,441 (49.9%)	-0.00800008 0.00800008	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	U 0	23,528 (12.8%) 41,462 (22.5%)	23,608 (12.8%) 41.382 (22.5%)	
SES - Low income indicator; n (%)	4,230 (12.4%)	4,250 (12.5%)	-0.00302892	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	4,230 (2.3%)	41,382 (22.5%) 4,250 (2.3%)	0
SES - Urban vs Rural (MSA variable)						-0.008468572						0.002477400
Urban; n (%) Rural; n (%)	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0	20,469 (66.2%) 2,559 (8.3%)	20,580 (66.6%) 2,532 (8.2%)	-0.008468572 0.003634718	0 (0.0%) 0 (0.0%)	0 (0.0%) 0 (0.0%)	0	20,469 (11.1%) 2,559 (1.4%)	20,580 (11.2%) 2,532 (1.4%)	-0.003177126 0
Unknown/Missing: n (%)	0 (0.0%)	0 (0.0%)	0	7,895 (25.5%)	7,811 (25.3%)	0.00459457	0 (0.0%)	0 (0.0%)	0	7,895 (4.3%)	7,811 (4.2%)	0.004957212
SES - Dual Status; n (%) SES - Generic name prescription - unique value	0 (0.0%)	0 (0.0%)	0	0 (0.0%)	0 (0.0%)	0	18,556 (15.6%)	18,490 (15.5%)		18,556 (10.1%)	18,490 (10.0%)	0.00332596
SES - Generic name prescription - unique value mean (sd)	8.36 (4.50)	8.36 (4.48)	0	8.01 (4.42)	8.03 (4.39)	-0.004540269	8.93 (4.38)	8.92 (4.37)	0.002285713	8.67 (7.42)	8.67 (4.39)	0
median [IQR]	8.00 [5.00, 11.00]	8.00 [5.00, 11.00]	0	7.00 [5.00, 10.00]	7.00 [5.00, 10.00]	0		8.00 [6.00, 11.00]	0	7.83 (7.42)	7.83 (4.39)	ō
SES - Brand name prescription - unique value mean (sd)	8.45 (4.59)	8.45 (4.56)	0	8.12 (4.52)	8.14 (4.49)	-0.004439487	9.03 (4.47)	9.03 (4.46)	0	8.77 (7.58)	8.77 (4.48)	0
	0.40 (4.00)	0.40 (4.00)	~	0.12 (4.02)	0.14 (4.40)	0.00-400407	0.00 (4.47)	0.00 (4.40)		5.77 (1.50)	0.77 (4.40)	-







The c-statistics for the propensity score model, pre-matching was 0.687. The post-matching c-statistic was 0.514

The c-statistics for the propensity score model, pre-matching was 0.707. The post-matching c-statistic was 0.513

The c-statistics for the propensity score model, pre-matching was 0.668. The post-matching c-statistic was 0.506